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Abstract 
The drug discovery and development subsector lies at the heart of the pharmaceutical and 
biotechnology industry. However, previous studies have not distinguished this subsector from the 
industry as a whole. Little detailed analysis has looked at the fIrms that discover and develop new 
therapies. From a perspective of the Sectoral Systems of Innovation, this thesis aims to address this 
important gap in knowledge by looking at the structure, clustering, knowledge production and 
networking in the drug discovery and development subsector, and to stress the relevant policy 
implications. 
This study intends to objectively examine the best available indicators for the knowledge produced 
by this subsector and industry dynamics, therefore a broad design of methodology was chosen. 
Data was collected from government databases, scientific databases, commercial databases, 
industry associations and companies' websites, concerning the subsector's structure, clustering and 
concentration, research and development (R&D) investments, product pipelines, scientifIc 
publications and citations, patent publications, and alliance agreements. 
This study indicates that the drug discovery and development subsector was geographically 
clustered. The finding further reveals this subsector's hierarchical structure and divergence in 
strategy development. This thesis also suggests that the focuses of knowledge production in this 
subsector were changed when partners changed. Moreover, in arguing that this subsector featured 
massive knowledge production and expanding collaboration with other actors of the innovation 
systems, the analysis questioned the notion that domestic industry would benefit much from the 
2 
successful knowledge production of this subsector, because much of the knowledge produced by 
this sector was going abroad through commercial licensing, and through mergers and acquisitions 
(M&As). The data of this study also indicated that the strategies of companies are co-evolved with 
its position within the networking and industry structure. 
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Chapter One: Introduction 
The pharmaceutical industry has been seen by the UK government as a key part of the knowledge-
driven economy and an important source of economic growth: the UK not only has one of the 
largest pharmaceutical market of the world (Towse 1996), but it also has been a major exporter of 
pharmaceuticals (Earl-Slater 1998). In addition, the pharmaceutical and biotechnology industry is 
the largest research and development (R&D) investor ofthis country. 
Central to the pharmaceutical and biotechnology industry is the drug innovation process. The UK 
has already established the strongest research base of Europe (Cooke 2006). Public policies are 
directed to support drug innovation activities and to establish a virtuous circle of innovation (Reiss 
et al. 2004). However, there has been a lot of policy debate about how best to support this sector 
(Walley et al. 2000). 
From existing work in social science and innovation studies (see Literature Review Chapter) a 
number of key factors which influence the development of the drug discovery and development 
have been identified. However, most of these studies have not distinguished the drug discovery and 
development subsector from the industry as a whole. In particular, little detailed analysis has 
looked at the firms that lie at the heart of the industry - those involved in discovering and 
developing new therapies. This study aims to address this important gap in knowledge. 
This chapter aims to provide an introduction to this thesis: to begin with, the first section of this 
chapter will discuss the procedure of drug discovery and development, followed by the history of 
drug discovery and development, and a discussion of regulation. These two sections aim to provide 
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a historical background of how the phannaceutical industry has been using technology 
breakthroughs to improve drug discovery and development procedures, how regulation and 
legislation have changed to ensure drug safety, effectiveness and reasonable pricing, and outlines 
current policy debates on how to improve the efficacy and effectiveness of the regulatory agencies. 
This chapter will also introduce the research questions of this study, and the context where these 
questions were raised. From a historical and industry dynamical perspective, this study aims to 
understand the co-evolution of knowledge production, industry structure and networks in the drug 
discovery and development subsector, and to stress the policy implications of these developments. 
An outline ofthe thesis structure will be briefly sketched in the final section. 
1.1. Drugs: From Concepts to Markets 
It takes a long time to bring a drug from discovery and development to the market. Basically 
several stages are involved in this procedure: drug discovery, preclinical trials, clinical trials, 
manufacturing, and marketing application (Figure 1). The last four stages should fulfill relevant 
regulatory requirements in practice (Rick 2004). This procedure was also described as six phases 
leading from drug discovery and development to drug registration: drug discovery phase, 
preclinical phase, clinical phase I, clinical phase II, clinical phase III and registration (Warne 2003). 
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Figure 1 The stages from drug discovery to marketing approval 
(Rick 2004) 
Drug Di.;,cowry 
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There are also six steps of classic drug discovery phase: target generation, lead generation, lead 
optimization, candidate selection, candidate proposal and candidate acceptance (Warne 2003). The 
rest of the phases are regulated by different authorities in different countries. However, the tasks 
and procedures are similar. Take the U.S. for example, the Preclinical phase consists of testing 
drug candidates on animals, inspecting of the claims on intellectual property rights, and filing an 
Investigational New Drug Application (NDA) (Schryver & Assellbergh 2003). The NDA serves as 
a hurdle where the regulator decides if the compound can be tested upon healthy volunteers 
(Schryver & Assellbergh 2003). After the preclinical phase, there are three consecutive clinical 
phases: Phase I, Phase II and Phase III, followed by registration. 
Phase I: Is the new compound safe for healthy volunteers? 
Phase II: Is the compound both safe and effective for the patients? 
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Phase III: 
Registration: 
Are effectiveness and safety demonstrable for the population? And is 
there a significant socio-economic advantage for the society? 
Once a compound passes the clinical phase, a New Drug Application 
(NDA) has to be filed to convince the regulator of the safety, 
effectiveness and socio-economic benefit of the new compound. 
(Schryver & Asselbergh 2003) 
In the UK, drugs can be licensed in two ways, which will be discussed in detail later in this section, 
either through the European Medicines Evaluation Agency (EMEA) to apply an EU wide license 
or through the UK Medicines and Healthcare products Regulatory Agency (MHRA) to apply for a 
UK only license. 
1.2. History of Drug Discovery and Development 
1.2.1.Hlstory of drug discovery 
The pharmaceutical industry has experienced important changes in drug discovery during the last 
century. 
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" ... starting with the development and gradual acceptance of the germ theory of disease at the turn 
of the century and accelerating during the chemo-therapeutic revolution of the 1930s and I 940s. 
Synthetic organic chemistry and soil microbiology generated significant opportunities for 
pharmaceutical innovation ... In the 1940s and 1950s, advances in virology provided another set 
of new opportunities for entrepreneurship, followed shortly by a new wave of breakthroughs in 
microbial biochemistry and enzymology, breakthroughs that provided the basis for a new style of 
targeted pharmaceutical research and development ... The next, partially overlapping wave of 
innovation ... was grounded in recombinant DNA technology and molecular genetics, and is 
generally refe"ed to as the biotechnological or 'biotech' revolution. " (Galambos & Sturchio 1998: 
251-252) 
The history of the phannaceutical industry will be briefly reviewed according to these important 
innovations. 
Early 2'" century - World War I 
The development of colour-dye technology in Europe in the 19th century was a milestone in drug 
innovation. The main reason for this was that both drug innovation and dye research involved 
applications of organic chemistry (Bogner 1996;Thayer 2002). In 1883, one of Germany's leading 
dyestuff makers, Hoechst, decided to establish a separate scientific laboratory to investigate the 
"the possible link between synthetic dyes and biologically-active substance" (Goodman 2000:142). 
The first phannaceuticals emerging from the dye companies in Germany were antipyretics and 
analgesics (Goodman 2000). Antipyrin (1883), pyramidon (1896), and novocain (1905) were 
introduced to the market by Hoechst, and phenacetin (1887) and aspirin (1897) were introduced to 
the market by Bayer (Da Rin 1998). 
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The second milestone for drug innovation was the research in anti-infectants, which also emerged 
in Europe (Bogner 1996). Gerhard Domagk, the research director of the Hoechst laboratory, 
synthesized the red sulphonamide dye, Prontosil, which cured lethal streptococci infections, for 
which he won the 1939 Nobel Prize (Bogner 1996). 
World War I not only gave American pharmaceutical companies an opportunity to conduct drug 
innovation and development (Liebenau 1987), but also an opportunity to consolidate their positions 
and to plan long-term development (Liebenau 1990). From 1905, the strategy of German 
pharmaceutical companies to patent every chemical around marketable drugs in the US, was 
"successful in discouraging competition (from US drug companies) because there was little 
incentive to work through a development phase when patents were already held on every 
conceivable related products" (Liebenau 1987: 110). In the 1916 edition of New and Non-official 
Remedies, 228 drugs out of 592 drugs listed were imported from Germany (Liebenau 1987). 
During World War I the Adamson Bill authorized the President of the US to "license citizens to 
operate enemy patents" and this enabled the US pharmaceutical industry to synthesize and produce 
drugs patented by German companies, e.g., Salvarsan. 
British pharmaceutical companies in the 19th century were importers and retailers, relying on cartel, 
convention and licensing agreements with German and Swiss companies to offer new products 
(Liebenau 1990). Except for Burroughs Wellcome, who maintained a well established company 
laboratory, there were no other industrial laboratories doing product development (Liebenau 1984). 
The outbreak of World War I also caused a drug shortage in the UK, because of this dependence 
on German imports. In 1915, the British Medical Journal published a long list of products which 
were in shortage (Liebenau 1988). With the aid of its North American and Australian branches, 
Burroughs Wellcome not only developed a substitute for Salvarsan, but also manufactured Aspirin, 
Urotropine and vaccines (Corley 2003). 
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The Swiss industry also benefited from the market of the war, e.g. Hoffmann-La Roche, which 
grew from a medium-sized drug manufacturer to a European-wide pharmaceutical company 
(Liebenau 1990). 
Interwar perlod- World War" 
Major new products of the interwar period bolstered the industry, e.g. sulphonamides, insulin, and 
chemotherapeutics. However, it was still a very small industry (Liebenau 1990). Vitamins, which 
could be used both as nutritional supplements and drugs, were exploited by firms such as Glaxo in 
the UK (Liebenau 1990). 
The period during World War II was characterized by large scale technology development, and 
close collaboration of the industry, universities and government (Freeman 2003). In the UK, Boots, 
British Drug Houses, Wellcome, Glaxo and May & Baker founded the Therapeutic Research 
Corporation (TRC) in 1941 (Corley 2003). By the end of 1941, the anti-malaria drug Paludrine 
was developed through the collaboration of May & Baker, ICI and Boots (Corley 2003). The 
discovery of Penicillin in 1928 and the subsequent research at Oxford until the 1940s, before 
Penicillin research moved to the US, is strong evidence of the research competence of the UK 
academic institutes. However, the US companies benefited from the Penicillin research, and they 
created a new drug research industry based on antibiotics. Bogner suggested that the main reasons 
for this were "the lack of early government support in the UK, the movement of Penicillin research 
from Oxford to the US and the formation of the Midwest Group 1 for collaborative research" 
1 With the US government approval, several firms were brought together to collaborate on 
penicillin research and to share information (Merck did its own research, but agree to share 
information). The others-Squibb, Pfizer, Abbott, Eli Lilly, Parke-Davis, and Upjohn-all agreed to 
form a consortium, known as the "Midwest Group", to develop technology for the mass production 
of penicillin production through deep-tank fermentation (Bogner 1996). 
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(Bogner 1996: 65). However, the different roles of the UK and the US in World War II and the 
relatively scarce resources of the UK during that period were also major reasons. 
A survey of leading British companies in 1942 showed the variation in the research capacity of 
companies: between 1936 and 1941, May & Baker, which was the leading British company, held 
40 patent applications, published I I scholarly articles and 15 of their staff held doctorates; 
Burroughs Wellcome only had 6 patent applications, but they had published 220 articles and 24 of 
their staff held doctorates; Glaxo had only 6 staff who held doctorates, but they published 345 
articles and held 13 patent applications (Liebenau 1990). 
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Two new types of drugs stimulated the rapid growth of the industry after World War II: antibiotics 
and psychoactive drugs. The industry also began to have new international and transnational 
characters (Liebenau 1990). 
After the discovery of Penicillin and related substances, many companies established a 
microbiology and fermentation department (Drews 2000). This period was named the "antibiotic 
era" (Bogner 1996), mainly because of the major role played by antibiotics in drug innovation 
research and production. The US companies, in partiCUlar, played important roles in basic research. 
The development of antibiotic research was improved by the results of basic research across the 
industry, together with the knowledge of infections gained in the war (Bogner 1996). The 
combination of soil sample screening, observations and trial-and-error testing, was the core 
technology during this period. In Pfizer's research on Oxytetracycline, around 100,000 soil 
samples were examined (Bogner 1996). The major reason for maintaining large scale sample 
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screening and trial-and-error testing was the lack of understanding of the chemical structure of the 
antibiotics. This also limited further drug development (Bogner 1996). 
During the antibiotics era, many other new drugs were also developed by using the companies' 
microbiological capabilities, for example, Invermectin, a drug against tropical filariosis (Drews 
2000). Other non-antibiotic drugs were also developed, e.g. insulin by Lilly (Bogner 1996). 
Patent laws during this period were mainly concerned with the patentability of drugs. Patent law 
prohibited the patent of drugs which were naturally occurring substances, e.g. some antibiotics, and 
some countries even prohibited patenting of any drug products (Bogner 1996). To be patentable, 
any drug discovery should be patented within one year after it was created. However, some 
synthetic substances' effectiveness as drugs was only discovered a few years later, and those drugs 
were excluded from patents (Bogner 1996). In 1948, the patent law of the US allowed modified 
naturally occurring substances to be patented, because ''the modification of the naturally occurring 
products made it sufficiently nonnatural and product patents could be issued", and this change 
encouraged the development of more substitutes (Bogner 1996). 
Bogner argued that during this period, the US industry lacked the vertical integration from raw 
material through R&D to firm sales (Bogner 1996). In the US, firms were either chemical 
producers e.g. Merck and Pfizer, or sellers of brand drugs, e.g. Abbott and Upjohn (Bogner 1996). 
In the UK., however, the pharmaceutical industry had already established drug and raw material 
distribution systems during World War II, e.g. Boots maintained both manufacturing systems and 
the largest retailing systems (Corley 2003). 
1970s- The present 
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During the I 970s, the phannaceutical industry was "in the early stage of mastering drug 
development by design, applying across a broad front the molecular insights provided by microbial 
biochemistry and enzyme inhibition" (Galambos & Sturchio 1998:255), and recombinant DNA 
technology also become possible (Galambos & Sturchio 1998a). 
During the last two decades, the development of the phannaceutical industry has been influenced 
by many factors. One of them is the application of biotechnology. Biotechnology refers to the 
application of genomic and molecular biology to the health, food and agriculture sectors (powell & 
Owen-Smith 1998). Biotechnology products include antibacterials, antibodies, gene therapy, stem 
cells, proteins and peptides, therapeutic vaccines and other vaccines, immunology therapy, toxins, 
hormones and other biological molecules. The differences between biotechnology products and 
small molecules are shown in Table I. Both biotechnological and small molecule drugs will be 
examined in this study. 
Table I Differences between biotechnology products and small molecules 
(Ho & Gibaldi 2003) 
Biotechnology products Small molecules 
Sources Derived from living sources-human and Chemically synthesized 
animal tissues and cells and microorganisms 
Size Macromolecules Small molecules 
Purity Standard degree of purity High degree of purity 
Different from other industries, small companies play important roles in adopting new drug 
innovation technologies, and the large pharmaceutical companies have to develop new strategies in 
order to enter this field (Galambos & Sturchio 1998a). The big pharmaceutical companies needed 
''not merely scientists working with nucleic acids, but scientific leaders with diplomatic skills and 
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links to the relevant (molecular genetics) networks that would enable them to build the teams and 
productive programs necessary to sustain biotech R&D over the long-term" (Galambos & Sturchio 
1998: 261). 
In summary, the three decades after World War II could be divided into three periods. This first 
period is from World War II to the 1960s, when antibiotic drugs were the main products of the 
pharmaceutical industry and the main innovation process adopted was soil sample screening and 
trial-and-error testing. The second period was characterised by application of chemical drug design. 
Although chemical drug design had emerged in the 1950s, it was not adopted as a major innovation 
technology until the late 1960s, when more and more knowledge on the relationship between 
chemical structure and biological processes was accumulated. The third periods began with the 
emergence of recombinant DNA technology and monoclonal antibody technology in the late 1970s. 
Although Bogner argued that the biotechnology applied in the drug innovation process was another 
type of rational drug design, the biotechnology was based on a different knowledge base from 
chemical drug design (Bogner 1996). The representative technology in different eras did not totally 
take the place of other technologies; instead, the industry adopted a combined discovery process. 
1.2.2.Hlstory of drug development 
The history of drug development is not as long as drug discovery. Drug development is based on 
clinical pharmacology - today pharmacology could be described as ''the study of the properties of 
drugs and how they interact with/affect the body" (Walsh 2003, P69). It was only established as a 
science discipline in the US in the late 1950s, and was recognized by the World Health 
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Organization in 1970 (Malinowski & Westelinck 2004). In the last four decades, clinical 
pharmacology research has emphasized different aspects (Table 2) (Sjoqvist 1999): 
Table 2 Four decades of cUnical research (1960-2000) 
(Sjoqvist 1999) 
1960-1970 Controlled clinical trial, adverse drug effects, drug metabolism, clinical pharmacokinetics 
1970-1980 Drug interactions, pharmacogenetics, therapeutic drug monitoring, improved 
methods to assess drug response, improved drug evaluation (phase I and III) 
1980-1990 Pharmacoepidemiology, pharmacovigilance, individualization of drug dosage 
scheduling, drug information. 
Molecular pharmacogentics, pharmacokinetic-pharmacodynamic modeling, 
1990-2000 population-based dose evaluation, pharmacokinetic optimization of drug 
effects, eveidence-based pharmacotherapy, pharmacoeconomy. 
Current major animal tests undertaken in preclinical trials include pharmacokinetic profile, 
pharmacodynamic profile, bioequivalence and bioavailability, acute toxicity, chronic toxicity, 
reproductive toxicity and teratogenicity, mutagenicity, carcinogenicity, immunotoxicity, local 
tolerance (Walsh 2003). 
As discussed earlier in this chapter, the clinical trials included three phases: Phase I, Phase II, and 
Phase III. Some drugs are under post-marketing safety surveillance, which also refers to Phase VI. 
Table 3 is an example clinical trial for typical chemical based drugs. 
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Table 3 Clinical trial for typical chemical based drugs 
(Walsh 2003) 
Trial Evaluation undertaken Usual number of Average 
phase patients duration (year) 
I Safetv testing in health human volunteers 20-80 1 
II Efficacy and safety testing in small number 100-300 2 
of patients 
II Large scale efficacy and safety testing in 1000-3000 3 
substantial number of patients 
IV Post-marketing safety surveillance varies Several 
undertaken for some drugs that are 
administered over particular long period of 
time 
A typical new molecular entity (NME) has most likely been studied preclinically for 5-7 years and 
will be in clinical trials for 6-7 years (Health & Colburn, 2000). The average cost of bringing an 
NME to market is between 500-800 million dollars including the costs of lost opportunities and 
lead-compound failures (Health & Colburn, 2000). 
1.2.3.Regulatlon and legislation 
Liebenau suggestes the 'ethical' status of the industry should be maintained by its regulation. He 
argues that although the technical specification, coverage and administration of regulation are 
similar in different countries, the genesis in each country is different, revealing "much about the 
character of governmental attitudes towards regulation, about the state of the pharmaceutical 
industry, and about the perception of the role of law within the respective medical communities" 
(Liebenau 1990: 86). 
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The UK regulatory framework 
In the UK, there were a series of regulations and legislation regarding the registration and 
qualification of chemists and druggists from 1841, e.g. Act of 1868 for qualification examination 
(Corley 2003). The first list of drugs with information on how they should be prepared was the 
London Pharmacopoeia, published in 1618 (MCA 2005). However, except for the Food and Drug 
laws which prohibited adulteration, there was no practical regulation on drug production (Liebenau 
1988) until World War I. Germany, in contrast, passed the Act of 1902 regarding hygiene, 
packaging and labelling during drug production, as well as inspection of company premises. The 
first British legislation that included a form of licensing for medicinal products was the 1925 
Therapeutic Substances Act which applied to medical substances such as vaccines, sera, toxins, 
antitoxins, antigens, insulin, pituitary hormone and surgical sutures (MCA 2005). Inspection of 
manufacturing sites and record keeping are included in this Act and labelling requirements were 
also introduced in order to identify the manufacturer of each batch of material produced (MCA 
2(05). 
After the National Health Service (NHS) was established in 1948, the UK government paid much 
more attention to drug prices, safety and R&D (Corley 2003). Since 1957, the UK government 
and industry have collaborated on the regulation of drug price and reward system (Earl-Slater 
1998). A voluntary agreement, the Pharmaceutical Price Regulation Scheme (PPRS), was made 
between the Department of Health and the Association of the British Pharmaceutical Industry 
(ABPI) (Earl-Slater 1998). This agreement was not only applied to the members of the ABPI, but 
to all organizations who supplied drugs to the NHS (Earl-Slater 1997). One of the aims of the 
PPRS was to encourage R&D in this industry (Corley 2003;Earl-Slater 1998) and penalize firms 
if they were merely followers (Corley 2003). 
28 
After one of the biggest medical disasters, Tha/idomide2, which caused as many as 10,000 babies 
worldwide to be born with severe deformity during the 1950s and early 1960s, the UK government 
set up the Committee on Safety of Drugs (CSD) in 1964. The members of CSD were medical 
experts on behalf of the industry, and they introduced many standards which are still in use today 
(Corley 2(03). After the Medicines Act 1968, the CSD became an independent official body, the 
Committee on Safety of Medicines (CSM) (Corley 2003). Corley suggests that the industry was 
shaped by government policies during this period and the rate of change in the industry 
"accelerated markedly" (Corley 2003: 18). 
The Medicines Control Agency (MCA) was launched in 1989, and became an executive agency of 
the Department of Health in 1991. This agency aimed to reduce licensing times for medicines and 
to ensure that all medicines on the U.K. market had met "appropriate standards of safety, quality, 
and efficacy" (American Chemical Society 2008). In 2003, the MCA and the Medical Devices 
Agency (MDA) merged to form the Medicines and Healthcare products Regulatory Agency 
(MHRA). 
In 1999, the National Institution for Clinical Excellence3 (NICE) was established, and its main 
responsibility was to evaluate clinical cost-effectiveness of drugs entering the England and Wales 
market (McDonald 2000). However, there are different views about NICE. Besides the criticism 
from the pharmaceutical industry, it has also been described as a sign of direct government 
intervention in the market (McDonald 2000). On the other hand, many researchers argued that 
NICE was a key element of the national pharmaceutical policy framework and it should be 
supported by integrated pharmaceutical policies (Walley et al. 2000). 
2 Thalidomide, 2-(2, 6-dioxopiperidin-3-yl)-1 H-isoindole-I ,3(2H)-dione, is a sedative, hypnotic, 
and multiple myeloma medication. Thalidomide was mainly sold during the late 1950s and early 
1960s to pregnant women to combat morning sickness. More than 10,000 children in 46 countries 
were estimated to have been born with deformities as a consequence of thalidomide use (FDA 
2(01). 
3 In Scotland, the Scottish Health Technology Assessment Centre (SHT AC) plays a similar role. 
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The current regulatory framework in the UK is primarily the system of licensing and conditional 
exemptions from licensing laid down in the European Medicines Evaluation Agency (EMEA) 
(MCA 2005). In 1965, the European Commission (EC) issued its first Directive in order to reduce 
national differences in drug regulation, and in 1975, the EC established the Committee of 
Proprietary Medical Products (CPMP) which was authorized to review all the drugs applying for 
licences in EC members (Vogel 1998). In order to build a single European market, the European 
Medicines Agency (EMEA) was established in London in 1995 (Vogel 1998). London was chosen 
because of the leading role of the UK pharmaceutical industry in the EU and the experience of the 
UK government in pharmaceutical regulation (Vogel 1998). EMEA was mainly responsible for the 
evaluation and supervision of medicinal products throughout the European Union (EMEA 2005). 
In 2004, the EU Clinical Trials Directive (2001l201EC) was implemented in the UK as the 
Medicines for Human Use (Clinical Trials) Regulations 2004, and replaced the clinical trial 
provisions of the Medicines Act 1968 and its secondary legislation (MHRA 2004). The major 
changes included that Pharmacology studies in healthy human volunteers (Phase I) require 
authorization from the MHRA where previously they only needed a favourable opinion of an ethics 
committee (MHRA 2008). Other changes included that each trial must have an identified sponsor, 
investigational medicinal products (IMPs) must be manufactured to Good Manufacturing Practice 
(GMP) and the manufacturer must have a license (MHRA 2004). 
Drug approva/ln the UK 
In the UK., drugs can be licensed in two ways: either companies send applications directly to the 
UK MHRA to apply for a UK only license, which is assessed by CSM, or through EMEA to apply 
an EU wide license. There are two systems within the EMEA: 'Centralized system' which grants 
10 years exclusivity, was compulsory for biotechnology products, as well as new drugs on AIDS, 
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cancer, neurodegenerative diseases and diabetes (NHS 2003). Companies send their application to 
EMEA, and EMEA passes them to CPMP. Based on assessments of selected representatives from 
two member states, CPMP will make recommendations for or against an EU wide license. If 
CPMP makes a recommendation, a European Public Assessment Report (EPAR) and marketing 
authorisation will be issued (NHS 2003) (Figure 2). 
Figure 2 The European Union centralised system 
(NHS 2003) 
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Launch 
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In "decentralized system" (or "mutual recognition system"), one member state will assess the drug 
application and grant the license (8 years exclusivity). In the UK, MHRA is the agency to consider 
these applications. After the license is granted, other member states will mutually recognise or 
object to the decision (Figure 3). Under this system, CPMP only intervenes when there are 
disagreements between member states (NHS 2003). Because reviews in different countries may 
lead to different results, companies are inclining to choose the member states where approval is 
less doubtful and the procedure is faster (NHS 2003). 
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Figure 3 The European Union decentralised (or mutual recognition) system 
(NHS 2003) 
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Besides the Medicines for Human Use Regulations 2004, Medicines Act 1968 and revisions, the 
Pharmaceutical Price Regulation Scheme (PPRS), the existing regulations and legislation regarding 
the UK pharmaceutical industry also include the Intellectual property rights, advertising of drugs, 
prescription charges, profit controls, generic prescribing targets, commercial competition, trade and 
parallel imports, drug tariffs, the Consumer Protection Act, and the production liability directive 
(Walley, Earl-Slater, Haycox, & Bagust 2000). 
Walley et al. argued that the integrated policy should "go beyond the regulation of drugs, the 
industry and the prescribers, but it would combine all of these", and the aims of the integrated 
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policy should be "effective and safe drugs that are readily accessible at an affordable price-and it 
would support continuing research into areas ofunmet need" (Walley et al. 2000: 1525). 
Policies to promote drug Innovation 
The policies aimed at promoting overall UK innovation and technology performance, and the 
specific policies to promote biotechnology development both had positive impacts on the drug 
discovery and development subsector. The Biotechnology and Biological Sciences Research 
Council (BBSRC) was established in 1994 by incorporation of the former Agricultural and Food 
Research Council (AFRC) with the biotechnology and biological sciences programmes of the 
fonner Science and Engineering Research Council (SERC). The Industrial Biotechnology 
Innovation and Growth Team (IB-IGT) was fonned in November 2007 by Department for 
Business Enterprise & Regulatory Refonn (BERR), and it was divided into three groups: Policy 
Measures work group, Technology and Manufacturing work group, and Finance and Investment 
workgroup. 
Cleff et al. suggested that the most important tax incentives for biotechnology innovation are direct 
ways of support - grants and subsidies - followed by indirect ways of support - tax credits and 
R&D allowances (Cleff et a!. 2(08). These include generic policies and biotech-specific policies to 
promoting innovation (D'Este, Senker, & Costa 2007). This section will first discuss the grants and 
subsides, and then introduce tax credits and R&D allowances. 
As direct ways of support, government annual expenditure on bioscience research exceeds 
US$ 960 million (The UK government's inward investment agency 2001). These policies included 
enhancing networking, strengthening linkages between academic institutes and industry, 
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facilitating biotechnology commercialization, promoting business, helping increase manufacturing 
potential and improving industry competitiveness (Zechendorf2004). 
Programmes to facilitate biotechnology commercialization included Harnessing Genomics which 
was a £25 million programme to help businesses to take up and commercialize genomics science. 
One important part of this programme was the OTI Bioscience Beacons project, which aimed to 
help the universities to commercialize their research. These projects included Imperial College's 
"imaging changes in diseases" and "computer models to detect toxicity", also, University College 
London's project "computer models to predict drug action", University of Edinburgh's "new rapid 
approach to detecting diseases", University of Glasgow's project ''biochemistry 'in silico'" and 
University of Liverpool's project "development of a high-throughput platform for functional gene 
analysis". 
The Biotechnology Mentoring and Incubator (BMO Challenge was a competition to encourage the 
provision of incubators and specialist business mentoring services to young biotechnology 
companies. BMI provides funds of up to £500,000 for each project, and from its beginning to 2006, 
has funded II with two extensions. According to OTI Bioscience Unit, BMI has catalyzed 137 
new biotechnology companies that employ over 900 staff. Many companies studied in this thesis 
benefit from BMI, such as Vectura, Ark Therapeutics and ReNeuron. Bio-Wise was a £13 million 
programme which aimed to improve the competitiveness of UK industry through the use of 
biotechnology, and support the development of the UK biotechnology supplier industry. Up to and 
including 2006 Bio-Wise helpline took over 25,000 enquires and organized 92 events. 
The UK Biotechnology Finance Advisory Service was a free service sponsored by OTI. Its aim 
was to assist both existing biotechnology companies and new companies to access financial 
support. Small companies could get Small Firms Loan Guarantee Fund from Regional Venture 
Capital Funds and the UK High Technology Fund to finance business proposals. 
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The general government grants for R&D were administered by the nine English Regional 
Development Agencies. Four types of grants were available: up to £20,000 for Micro Projects 
lasting less than 12 months, up to £ 1 00,000 for Research Projects lasting six to 18 months, up to 
£250,000 for Development Projects lasting six to 36 months and up to £500,000 for Exceptional 
Development Projects lasting six to 36 months. A similar regionally based programme was the 
Biotechnology Exploitation Platform (BEP) Challenge launched in 1999, which aimed to promote 
technology transfer. This programme covered technologies such as therapeutics, medical devices, 
diagnostics, plant sciences and environmental sciences. According to the DTI Bioscience Unit, by 
May 2006, 2085 technologies were indentified with commercial potential in BEP, 958 projects 
were selected for commercialization, 415 patents were filed and 58 were granted 
In order to help small to medium sized companies improve their manufacturing potential, a two-
year initiative, 'Manufacturing for Biotechnology', was launched in 1999, which provided help in 
the form of workshops, information, management tools, training grants and grants for feasibility 
studies (UK Trade and Investment). 
Policies also facilitated clustering of biotechnology companies. Zechendorf suggested that clusters 
and incubators had been supported with £50 million annually from regional innovation funds since 
2001. In addition six Genetics Knowledge Parks were also built (Zechendorf2004). 
Besides encouragement of basic research and commercialization, there are also programmes to 
enhance the network and linkages of companies and academics. For example, the EU Fifth 
Framework Programme (FP5) for the period 1999-2002 was designed to enhance linkages between 
countries, and between industry and academia. Similar programmes included EUREKA, a pan-
European network for market-oriented industrial R&D, which aimed to enhance partnerships 
between companies and organizations in EUREKA member states. The UK LINK scheme aimed 
to strengthen linkage between academic institutes and industry via cooperation in various life 
science fields. The government departments and Research Councils provided up to 50% of the cost. 
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According to the DTI Bioscience Unit, the LINK Applied Genomics, from its launch in 2000 to 
2006, has supported 21 projects in healthcare with around £29 million investment. Successful 
examples include development of prototype biochips for human protein expression profiling and 
antibody selection, and development of novel automated protein expression systems to accelerate 
drug discovery. Collaboration between the UK and the US was also encouraged, for example, the 
UKlUS Texas Bioscience Collaboration Initiative aimed to bring together researchers from UK and 
US academia and industry. 
Besides the direct support, there are also indirect fiscal incentives. Cleft" et al. have summarised the 
UK R&D allowances and tax credits for innovative companies: 
R&D allowance: 
Small and medium-sized companies: 150% deduction of expenditures on R&D, if at least 
GBP 10,000 p.a. is spent (c. EUR 15,000); also applies in principle to R&D expenditure 
on contracted research; benefits and subsidies received reduce the tax base. Restriction: 
Income tax and social security payments must not exceed an additional 50% reduction in 
any year (capping). SMEs can benefit from the concessions for large companies (see 
below), if they are unable to take up the concessions for SMEs because of government 
benefits or subsidies; SMEs are defined in accordance with the EU subsidy regulation 
(e.g. turnover ofGBP 25M (c. EUR 37M) p.a. or less). 
Large Companies (all companies other than SMEs): 125% deduction of R&D expenditure; 
also usually valid for R&D expenditure on contracted research; Restriction: The 125% 
reduction in any year must not exceed the income tax and social security payments 
(capping); any benefits and subsidies may be offset. 
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SMEs and large companies may deduct an additional 50% on R&D expenditure to 
combat epidemics. 
Tax Credit 
SMEs that do not make a profit and therefore cannot use the 150% deduction of expenses 
can applyfor a rebate of 24% of R&D expenditure (cash costs) as a tax credit. 
(Cleff et a!. 2008, P86) 
Tax allowance enables firms to claim back R&D expenditure and tax credit allows firms to directly 
deduct part of their tax (Cleff et al. 2008). Compared with the direct grants from government, there 
are many advantages of indirect fiscal incentives: they require less administration costs for both 
companies and government, avoiding long term project management and monitoring; there are less 
barriers for small and medium sized companies to obtain support; moreover, they are more neutral 
on the process and content of the R&D project (CleiT et al. 2008, P53). Therefore, the tax 
allowances have impact on all industries, while most direct grants and subsides discussed in the 
earlier section are biopharmaceutical sector-specific. 
In short, the UK and EU government have made policies to directly and indirectly promote the 
development of biopharmaceuticals. These policies are characterized with wide coverage, 
including basic research, technology commercialization, networking and industry development, 
from small and medium sized firms to large companies. However, there are also debates on these 
policies, in particular arguments from diiTerent actors. In the next sub section, policy debates will 
be discussed from perspectives of different stockholders. 
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Policy debates 
The policy disputes of biopharmaceutical regulation arise from the conflict of interests between 
different actors. First of all, there are conflicts of interest between industry and government. The 
drug discovery and development process "has developed into an evolutionary struggle between 
manufacturers, who wish to maximise sales and profits, and regulators, who wish to ensure that 
new agents are safe and effective" (Gale 2001, P1870). One Sociological concern is the impact of 
drug developers on regulation. On the one hand, the delay of drug approval may cost the company 
as much as one milIion each day (Montaner, O'Shaughnessy, & Schechter 2001); on the other hand, 
only the company whose drug is first approved will win when there is competition to develop 
similar compounds (Gale 2001). Therefore, the drug developers are actively influence the 
regulatory body and the regulation process making them important "political players" (Abraham 
2002b). 
Abraham is one of the most important researchers in the field of pharmaceutical policy: he 
published a series of papers and books to discuss the regulation and policies relating to the 
pharmaceutical industry (Abraham 2002a;Abraham & Lewis 2000;Abraham 1995;Abraham 
2002b;Abraham 2007;Abraham & Davis 2005;Abraham & Davis 2007;Abraham & Lewis 
1999;Abraham & Sheppard 1997). He argued that when the interest of public health and drug 
developers diverge, the company may influence the regulatory body via "subtle ways" (Abraham 
2002b). For example, one method is described as the ''revolving door", that is that many regulatory 
officials started their careers in the pharmaceutical and biotechnology industry and frequently 
move back to the industry where they may be promoted to higher positions than before (Abraham 
2002b). Therefore, the policy making process is influenced by employee movement between 
industry and regulatory bodies. 
Another factor which may influence the policy making process is the financial linkages between 
industry and the regulatory body. Abraham describes this as "regulatory capture", and suggested 
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that the "regulators too often consistently award industry the benefit of scientific doubt when 
reviewing products", and one important reason is that part or all of the running costs of the 
regulatory agency are provided by industry (Abraham 1995;Abraham 2002b). In the US, FDA 
scientists have claimed that their recommendation of approval of a drug is more welcome than 
recommendation of non-approval (Abraham 2002b). Furthermore, the pharmaceutical and 
biotechnology industry also paid attention to the financial links with experts: in 1996 only a forth 
of expert advisers on Committee on Safety of Medicines (CSM) or the Medicines Commission did 
not have financial interests in the industry (Abraham 2002b). Therefore, the regulatory body needs 
financial dependence from industry, and regulatory agencies also need more representation from 
patients and public health (Abraham 2OO2b). 
The industry also has impact on the globalization of drug testing and assessment standards: in 
order to reduce the cost and time of drug development, the industry organized the International 
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH), and 17 countries' regulatory agencies also attended (Abraham 2002b). 
Abraham argued that the ICH adopted low scientific standards suggested by industry, for example, 
minimum clinical trial treatments in initial marketing applications were reduced from 12 months to 
6 months, although evidence showed that one forth of serious adverse drug reactions, and one 
eighth ofall reactions, occurred after 6 months treatment (Abraham 2002b). 
Besides the direct impacts from the industry, there are also problems of the regulatory bodies and 
regulatory systems. For example, Abraham & Lewis suggested that the mutual recognition system 
of EU drug approval procedure will result in a competition between agencies to shorten approval 
time to attract applications and thereby increase the regulatory body's income (Abraham & Lewis 
1999). However, shortened time of review process was likely compromising drug safety (Abraham 
& Davis 2005). 
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Although there was no direct evidence to claim that the current mutual recognition system of EU 
drug approval procedure would have negative impacts on drug safety, there is evidence indicating 
that the shortened approval time does have impacts on the rates of drugs withdrawn. Based on the 
fact that there were twice the number of new drugs withdrawn because of safety reasons in the UK 
than in the US between 1971 and 1992, Abraham & Davis suggest five hypotheses to explain the 
difference: I) the UK approved more new drugs than the US, 2) differences in firms' strategy, 3) 
UK regulatory agencies were more strict at post-marketing surveillance, 4) because the approval 
process in the US is slower than that in the UK, the US regulatory agency learns from and avoids 
safety problems that emerged in the UK or European market, 5) the US regulatory agencies were 
more strict and they approved fewer unsafe drugs (Abraham & Davis 2005). Their conclusion was 
that the main reason was that the US regulatory agency has a more strict approval review process, 
which takes longer and prevents safety problems that have emerged in the UK or European market 
(Abraham & Davis 2005). 
However, the patients groups who benefit from long and strict approval processes raise another 
issue: the cost of the review process. The US researchers argued that the US regulatory systems 
need to speed up the review process and reduce the cost sharing of patients (Cohen et al. 2006). 
From a perspective of patients, drug safety and administration cost are both important requisites for 
drug approval process. 
From a perspective of pharmaceutical and biotechnology industry, the strict regulation may cause 
them to relocate their companies to other countries, and further damage export and employment; in 
addition, the slow and ineffective approval process will influence the public health (Abraham 
2002b). The indications of pharmaceutical and biotechnology industry were also controversial: as 
found in this project, companies are reluctant to invest in diseases such as tropical disease and 
tuberculosis because the development processes are costly, risky and have a low return. In order to 
balance the drug pipelines, public-private partnership and incentive packages have been offered to 
encourage the drug development of neglected diseases (Trouiller et al. 2002). 
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From a perspective of government, they must both support drug innovation and ensure drug safety 
and efficacy. Therefore, the policies and regulations should embody both restrictions and drive 
drug innovation. The current policy comments focus on these two directions: more strict control 
on drug approval and encouragement of drug innovation. There are several important reports in 
these two streams: "The Influence of the Pharmaceutical Industry" published by House of 
Commons Health Committee in 2005 suggested more strict control; while the report of Bioscience 
Innovation and Growth Team published in 2003 and Cooksey's report "A review of UK health 
research funding" published in 2006 both suggested the reform of regulatory agencies to 
encourage the drug innovation. 
In the report The Influence of the Pharmaceutical Industry, recommendations are focused on how 
to improve industry and the regulatory agency (House of Commons Health Committee 2005). The 
report suggested that for industry research the register of clinical trials needs to be more 
transparent and the design of trials should be improved to more accurately predict the performance 
of drugs; for industry marketing, company promotion needs to be controlled more strictly. For the 
regulatory agencies, the report suggested data submitted by companies to MHRA should be 
accessible to patients and the public rather than kept in secrecy, furthermore, the MHRA also need 
to review the standards developed by JCH. It also suggested that the MHRA need to be reviewed 
in-depth. Several principles were outlined: ''the need for greater independence from government; 
the need for greater independence from the pharmaceutical industry; the need for policies of 
greater transparency and accountability in light of recent freedom of information legislation; the 
need to increase effectiveness of the post-licensing department and the need for the MHRA to 
become pro-active rather than re-active; scrutiny of the regulatory standards underpinning clinical 
and non-clinical new drug review and reporting and evaluation of adverse drug reactions; the 
prioritisation of new marketing applications; and inclusion of the public in policy-making and 
implementation" (House of Commons Health Committee 2005, PI06-107). Based on the data from 
telephone interviews, other research suggested that the UK regulation systems need to improve the 
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fairness of the process and "provide guidelines for implementing recommendations" (Mitton et al. 
2006, P208). 
There are also reports which give comments on policies and regulations to encourage drug 
innovation. The report of Bioscience Innovation and Growth Team, suggested creation of the 
National Clinical Trials Agency (NCT A) to support clinical trials, create a public and regulatory 
environment supportive of innovation, provide sufficient funding for bioscience companies, and 
attract and retain scientific and managerial employees (Bioscience Innovation and Growth Team 
2003). 
Cooksey suggested that there are two gaps in the translation of research: translating basic ideas and 
clinical research into new drugs or treatments, and implementing these new drugs and treatments 
into clinical practice, therefore, the UK government will increase the amount of R&D, from basic 
laboratory to clinical trials to new drug approval and evaluation (Cooksey 2006). The result of this 
report is to carry out potential reform ofregulatory systems, that is establish an Office for Strategic 
Coordination of Health Research (OSCHR) to "achieve better coordination of health research and 
more coherent funding arrangements to support translation" (Cooksey 2006, P4). Moreover, there 
were several schemes set up to facilitate the translation of basic research: Higher Education 
Innovation Fund (HEIF), Public Sector Research Exploitation Fund (PSRE Fund), Science 
Research Investment Fund (SRIF), OTI's Equity Investment Programmes, Small Business 
Research Initiative (SBRI), OTI Technology Programme, etc. Take OTI's Equity Investment 
Programmes for example, which included several schemes such as Regional Venture Capital Funds 
(RVCFs) which provide up to £500K risk capital to SMEs which have growth potential; the Early 
Growth Funding (EGF) which is designed to help start-up companies (136 companies have benefit 
from this scheme); The UK High Technology Fund (UKHTF) which was founded to invest venture 
capital firms and further invest in high technology companies; and The Enterprise Capital Fund 
(ECF) which was developed to provide equity funding to small business (Cooksey 2006). 
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To conclude, the current arguments over policy and regulations are focused on establishing a 
reliable and efficient framework, which can, at the same time, mediate the conflict of interests 
among different actors: ensuring the safety of patients and their access to the new drugs, while 
ensuring the healthy development of the pharmaceutical and biotechnology industry. 
In summary, this section has provided a historical background of how the pharmaceutical and 
biotechnology industry has been using technology breakthroughs to improve drug discovery and 
development procedures, how regulation and legislation has changed to ensure drug safety, 
effectiveness and reasonable price, how policy has been used to promote the growth of the 
biotechnology industry and how policy disputes have been addressed and analysed. The next 
section will discuss how the research questions of this study have been raised and developed. 
1.3. Research Questions 
There are two main reasons for choosing drug discovery and development companies: first, the 
pharmaceutical industry plays an important role in the British economy: it accounts for 0.6% of 
UK GDP, employs around 73,000 people and generates 250,000 jobs in related industries (DTI, 
2006). The importance of the pharmaceutical industry can also be shown in international trade: in 
2005 it exported £12.2 billion and created a trade surplus of £ 3.4 billion (DTI, 2006). The 
pharmaceutical industry has been seen by the UK government as a key part of the knowledge-
driven economy and an important source of economic growth. According to the Department of 
Trade and Industry (DTI) 1998 Competitiveness White Paper, the UK will only compete 
successfully in the global economy if it builds a knowledge-driven economy, based on knowledge, 
skills and creativity. Moreover, this industry also provides large social benefits, e.g. increased 
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longevity, enhanced quality of life and improved labour force participation (DiMasi, Hansen, & 
Grabowski 2003;Grabowski 2002). 
Second, central to the pharmaceutical industry is the drug discovery and innovation process. 
Innovation is critical to Britain's long-term competitiveness, because innovation is a determinant 
for productivity growth and social gain (HM Treasury 2002). The potential of scientific and 
technological discovery to benefit the economy and society will only occur through successful and 
effective conversion into innovation (HM Treasury 2002). Therefore, the drug discovery and 
development subs ector has the greatest potential for wealth and job creation of the pharmaceutical 
industry. Public policies are directed to support drug innovation activities (Reiss et al. 2004), and 
to establish a virtuous circle of innovation: e.g. the UK government launched the R&D Credits 
Scheme to encourage companies to invest in research and development (R&D) in the form of tax 
relief. 
From existing work in social science and innovation studies (see Literature Review Chapter) a 
number of key factors which influence drug discovery and development have been identified, e.g. 
policy and regulations, market, alliances, R&D and management skills. There is a large body of 
research on the pharmaceutical industry, a fraction of which focuses on British companies. These 
studies mainly address topics of policy and regulation (Abraham & Lewis 2000;Earl-Slater 
1997;McMeekin, Green, & Coombs 2002;Sally 1998;Smith 2005b;Walley, Earl-Slater, Haycox, & 
Bagust 2000), innovation (Casper & Matraves 2003;Walsh 2002), drug markets (Franco & 
Orsenigo 2002;Green 2002;McMeekin & Green 2002a), alliances (Simon & Martha 1996) and 
clustering (Peter & Martha 1996;Van Reenen 2002). 
There are many debates among researchers. One important reason for researching the innovation 
systems ofbiopharmaceuticals is based on the debates ofperformance of this sector (Patel, Paunov, 
& Arundel 2008). On one hand, the pharmaceutical and biotechnology sector is regarded as a key 
driving force of the knowledge economy by many researchers and policy makers (Earl-Slater 
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1998;Van Reenen 2004); on the other hand, many researchers argue that the performance of 
biotechnology does not meet people's expectations (Hopkins et al. 2007;Pisano 2006). 
For the UK biopharmaceutical sector, the arguments focus on comparisons of its performance with 
those of other countries. In terms of volume of activities of the biotechnology sector it is ranked 
top of Europe (Patel, Paunov, & Arundel 2008). However, considering the R&D expenditure as a 
ratio of GDP and output per million capita (PMC), the UK is under performing. Patel, Paunov, & 
Arundel have compared the performance of the biotechnology sector of different countries and 
suggest that Switzerland and Denmark have the best performance of biotechnology innovation, 
followed by Ireland, Sweden and Belgium; and these countries' performance is better than the 
countries which had the largest ''volume of biotechnology related activates"-UK, Germany and 
France (Patel, Paunov, & Arundel 2008, P3). Their research used 17 indicators of three areas of 
innovation: human resources and knowledge creation, commercialization and finance, and outputs 
and markets (Patel, Paunov, & Arundel 2008). These indicators included "post-graduates in life 
science PMC, biotech publication PMC, citations per publication in biotech, government 
biotechnology R&D as a ratio of GDP, biotech business sector R&D expenditures as a ratio of 
GDP, biotechnology patents PMC, employment in dedicated biotechnology firms PMC, number of 
biotech start-ups PMC, strategic alliances in biotechnology PMC, total venture capital for DBFs as 
a ratio of GDP, total finance available for DBFs as a ratio of GDP, revenues of OBFs as ratio of 
GDP, revenues per employee for OBFs, number of approved biopharmaceuticals as a ratio of GOP, 
number of clinical trials of biopharmaceuticals as a ratio of GDP, index of optimism in biotech", 
and a non biopharmaceutical related indicator-"genetically modified organism field trials as ratio 
of agriculture output" (patel, Paunov, & Arundel 2008, P7). The large majority of the data were 
about biopharmaceuticals which placed the overall performance of UK biotechnology sector in the 
third level (Patel, Paunov, & Arundel 2008). Results of a Biopolis Final Report indicated that the 
best performing countries were Switzerland, Denmark, Sweden and Finland, with the UK ranking 
as second level, together with Austria, Belgium, the Netherlands, Ireland, Norway, Germany and 
France (Enzing et al. 2007). 
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Therefore, the UK biopharmaceutical industry is still under pressure of competition from other 
countries. Policies and regulation which support the development of this sector are required, in 
particular for drug discovery and development companies which are core for biopharmaceutical 
innovation. However, without understanding the development and structure of this sector, it is very 
difficult to make policies for the drug innovation sector. 
One gap in the research is that the performance of the drug discovery and development sub-sector 
has not been evaluated separately: most of these studies have not distinguished the drug discovery 
and development subsector from the industry as a whole. Take Patel, Paunov, & Arundel's study 
for example: it did not map the biopharmaceutical sector separately, although biopharmaceuticals 
accounted for "the large majority of all biotechnology R&D, employment and revenues" (Patel, 
Paunov, & Arundel 200S, PIS). Obviously, the policies and regulations regarding the 
biopharmaceutical sector are different from those for agriculture and environment. In many other 
studies, the drug discovery and development companies were considered as part of the health care 
industry, and were studied together with reagents and equipments companies, contract service 
companies, and manufacturers etc. In short, the development and contributions of the drug 
discovery and development sector were not properly evaluated in these studies. 
This subsector is the key part of knowledge production of the pharmaceutical and biotechnology 
industry, and its major activity is drug innovation. As discussed in an earlier section, there are 
many government policies and regulations to promote the development of this sector, and 
comments from academics to enhance the efficiency of policy implementation, however, little is 
known about this subsector, e.g. How has this sector evolved and what factors have shaped its 
development? How does this subsector contribute to knowledge production within the 
pharmaceutical industry? Is it realistic to expect this subsector to make a significant economic 
contribution in future? Do policies which were designed to promote this sector achieve their goals? 
As this sector evolves, are new policies required to enhance its development? However, these 
questions are not answered by previous literature, because in most cases the drug discovery and 
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development sector was either discussed with the pharmaceutical industry as a whole, or analysed 
together with other biotechnology sectors (agricultural, environmental biotechnology etc.). 
As suggested by the Biopolis Final Report, in order to design successful policies, "a broad and up-
to-date information base and the inclusion of different perspectives are important prerequisites" 
(Enzing et al. 2007, PI7). 
Therefore, to answer these questions firstly requires a detailed analysis of the subsector and the key 
factors influencing its development. Besides analyzing the current structure of this subsector, e.g. 
number of companies, size, and age, it is also important to study the industry dynamics, i.e. how 
the industry knowledge production and networking had changed over time. What technologies 
have been involved in the alliances between drug innovation companies and other pharmaceutical 
companies? How successful are these technologies in developing new drugs? There are two main 
reasons for this. First, it often takes a long time for a technology invention to transfer to 
commercial innovation, and even longer for this to come into widespread use (Charles Edquist 
1997). Second, understanding the dynamics of this industry will also help us to understand the 
accumulation of the influences of different factors upon the development of the biotechnology 
industry. Previous studies have only drawn a rough picture of the network and alliances: more 
studies are needed to understand the networks of the UK drug innovation subsector and its 
alliances, e.g. how are these drug innovation companies allied with other companies? How 
successful are these alliances in drug innovation? 
This study aims to understand the co-evolution of company strategy and networks, and co-
evolution of company strategy and structure from a historical and industry dynamics perspective, 
and to analyse the policy implications of these developments. 
To facilitate the analysis, a conceptual framework of Sectoral Systems of innovation will be 
adopted in this thesis (details will be discussed in next chapter). As suggested by Malerba, a 
47 
sectoral system has a specific knowledge base, technologies, inputs and demand, and agents are 
individuals and organizations at various levels of aggregation (Malerba 2002). They interact 
through processes of communication, exchange, co-operation, competition and command, and 
these interactions are shaped by institutions (Malerba 2002). As discussed in the previous section, 
the knowledge base of the drug discovery and development sector has experienced long term 
development and accumulation, and currently several technologies co-exist. The input to this 
expansion included not only R&D investment, but also human and social capital. 
This study is focused on the knowledge base, technology domain and networks of the drug 
discovery and development companies. One important feature is that a sectoral system undergoes 
change and transformation through the co-evolution of its various elements (Malerba 2002). 
Therefore this project will focus on the dynamics and interlinkages of different elements. 
In order to meet these aims, the study will focus on the following research questions, and how 
these questions have been raised which is further discussed in the literature review chapter: 
1) Is there a divergence of strategies existing in the drug discovery and development 
subsector? If so, what are the key factors which determine the divergence of strategy? 
2) How does the divergence of strategy influence industry structure? 
These research questions reflect the core element of Sectoral Systems of Innovation: co-evolution. 
Using this conceptual framework, the research questions are firstly broken down into four issues, 
and then analyzed in a systematic way. 
1) The drug discovery and development subsector's structure, the size and age of firms their 
clustering and concentration; 
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2) The knowledge contribution of the drug discovery and development subsector and how 
this has developed over time; 
3) Their networking and collaboration with other actors and how this has changed over time; 
4) The development of different company strategies. 
Each issue is important in describing the drug discovery and development sector and its changes 
overtime. Central to the analysis of these key issues, is the understanding of the relationship 
between this subsector and other actors of the pharmaceutical industry. Rather than studying the 
companies involved in drug innovation separately, this study investigates the role of these 
companies in a network of innovations. 
1.4. Thesis Structure 
As introduced above, the first chapter of this thesis provides a historical background of how this 
industry has been using technology breakthroughs to improve drug discovery and development 
procedures, and how regulation and legislation has been changing to ensure drug safety, 
effectiveness and reasonable price. Research questions were also discussed in this chapter. 
The second chapter will be the literature review and conceptual framework. In particular it will 
introduce and define the Sectoral System of Innovation, and discuss pros and cons of this 
conceptual framework. Literature on the pharmaceutical and biotechnology industry will also be 
reviewed. It will pay attention to structure and dynamism, clustering, networking and alliances, 
firm strategies, and policies. 
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The third chapter will discuss the research design and methodology of this thesis. It will begin with 
an introduction of data sources, followed by discussion of measurements and indicators and criteria 
of data collection. It will address the practical issues that arose and how the research process was 
designed in response. Finally, the limitations of the methods and research design will be discussed. 
The first section of the fourth chapter will focus on mapping the current British pharmaceutical and 
biotechnology industry, giving more details about its activities, structures, and clustering. This 
section will present an industrial background of the drug discovery and development subsector. 
The second section of the second chapter will provide an overview of the drug discovery and 
development subsector, more precisely, the drug discovery and development companies which 
were established after the 1980s - when biotechnology first started to be applied to the drug 
innovation process. This group of companies is the focus of this study. An overview of their 
product pipelines and R&D expenditure will also be discussed in this chapter. 
The next two chapters will focus on the R&D output of this subsector: the fifth chapter will focus 
on scientific publications of this subsector, and the sixth chapter will analyse its patent publications. 
The seventh chapter will discuss alliances and networking of this subsector, followed by a chapter 
integrating the four data chapters. The final chapter will be a discussion and conclusion. 
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Chapter Two: Conceptual Framework and Literature Review 
This chapter aims to introduce the conceptual framework used in this study and briefly review 
literature related to the pharmaceutical and biotechnology industry. The first section will introduce 
and define the concept of Systems of Innovation and Sectoral Systems of Innovation, and the pros 
and cons of using this conceptual framework. 
The second section will outline how research questions have been developed from the existing 
literature. It will then introduce a broader context of research and review literatures related to the 
pharmaceutical and biotechnology industry: first, studies of the structure and dynamics of the 
pharmaceutical and biotechnology industry will be reviewed to give a background of this industry; 
second, literature on the clustering of new biotechnology firms will be reviewed, followed by a 
review of the impact of globalization; third, the literature regarding the formation and performance 
of alliances in the pharmaceutical and biotechnology industry will be reviewed. The following 
section will focus on companies' R&D activities: both internal R&D and outsourcing of R&D. The 
next section will review literature on firm strategy and management, followed by a section to 
review the literature on policy and regulations. Finally, there will be a discussion and summary of 
this chapter. 
2.1. Conceptual Framework 
2.1.1.Systems of Innovation 
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First of all, definition of Systems of Innovation will be introduced. Innovation, defined by Nelson 
and Rosenberg, as "encompassing the processes by which firms master and get into practice 
product designs and manufacturing processes that are new to them, if not to the universe or even to 
the nation" (Nelson & Rosenberg 1993, P4). According to this definition, there are two types of 
innovations: product innovations which refer to "new or better material goods as well as new 
intangible services", and process innovations which refer to "new ways of producing goods and 
services" (Edquist 2005, PI82). 
"System" is defined as "a set of institutional actors that, together, plays the major role in the 
influencing innovative performance" (Nelson & Rosenberg 1993, P4-5). Edquist describes the 
systems of innovation as "all important economic, social, political, organizational, institutional, 
and other factors that influence the development, diffusion and use of innovations" (Edquist 1997 , 
P14). 
There are several different perspectives on Systems of Innovation, e.g. national, regional and 
sectoral systems of innovation. In the National Innovation Systems and Instituted Processes (de la 
Mothe & Paquet 2000), de la Mothe & Paquet suggeste the core idea of National Systems of 
Innovation was taken from National System of Political Economy written by German economist 
Friedrich List in 1841, and became a conceptual framework in 1980s and 1990s through the 
analytic and empirical efforts of Freeman (Freeman 1987), Lundvall (Lundvall 1992), Nelson 
(Nelson ed. Nelson 1993), Niosi et al. (Niosi et al. 1993), the OECD (OECD 1994a;OECD 
1994b)and Edquist (Edquist 1997). This conceptual framework is based on two assumptions. First, 
that knowledge is the most fundamental resource in the modem economy and learning is the most 
important process; and second, that this process cannot be understood without taking into account 
the social context (Lundvall 1992). 
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Similarly, Regional Systems of Innovation also based on the idea of territory, which could be 
described as "the institutional infrastructure supporting innovation within the production structure 
of the region" (Asheim & Gertler 2005). 
In contrast to the territorial notion, a Sectoral Systems of Innovation is originally defined as a 
"group of firms active in developing and making a sector's product and in generating and utilizing 
a sector's technologies" (Breschi & Malerba 1997, Pl3I). The definition of Sectoral Systems of 
Innovation has been redefined and expanded later and includes more elements: 
A sectoral system of innovation and production is a set of new and established products 
for specific uses and the set of agents carrying out market and non-market interactions for 
the creation, production and sale of those products. A sectoral system has a knowledge 
base, technologies, inputs and an existing, emergent and potential demand. The agents 
composing the sectoral system are organizations and individuals (e.g. consumers, 
entrepreneurs, sCientists). Organizations may be firms (e.g. users, producers and input 
suppliers) and non-firm organizations (e.g. universities, financial institutions, government 
agencies, trade-unions, or technical associations), including sub-units of larger 
organizations (e.g. R&D or production departments) and groups of organizations (e.g. 
industry associations). 
(Malerba 2002, P250) 
The Sectoral Systems of Innovation is also different from technological systems: technology 
systems focus on single technology utilized across sectors, while Sectoral Systems of Innovation 
may utilize many technologies (Malerba 2005). 
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2.1.2.Sectoral Systems of Innovation 
The early study of the elements of Sectoral Systems of Innovation included products; agents (firms 
and non-firm organizations); knowledge and learning processes; basic technologies, inputs, 
demand, and the related links and complementarities; mechanisms of interactions both within firms 
and outside firms; processes of competition and selection; and institutions (Malerba 2002,P250-
251). Geels criticized this framework that there were too many "heterogeneous elements", and 
their linkages are not clear (Geels 2004). 
Malerba further improved this framework and suggested that a sectoral systems framework 
emphasis three dimensions: knowledge and technological domain, actors and networks, and 
institutions (Malerba 2005). 
Although the focus of this project will be the drug discovery and development sector, this does not 
mean that they are the only actors of this system. This system includes actors such as firms, 
governments, public research institutions, support companies and other relevant organizations. 
Therefore this basic sectoral system consists of various actors and numerous linkages. 
McKelvey & Orsenigo summarised eight features of systems of pharmaceutical innovation: first of 
all, the actors and linkages are not simply co-existing, but dynamically interact with each other 
(McKelvey & Orsenigo 200 I). At the same time, new actors are emerging and old actors may exit, 
therefore linkages are also changing at the same time. For example, in a sector system of 
innovation, a company may compete with companies in the same system, may also establish long 
or short term collaboration with other companies, furthermore, it is regulated by a government 
agency and may be awarded a research grant from an agency, it may also collaborate with a 
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university on a specific research project etc. The collective of linkages fonns the network where 
the company positioned. One important feature of this system is that it is changing overtime. 
McKelvey & Orsenigo further suggested that this set of relations or network is not considered as 
coherent and efficient (McKelvey & Orsenigo 2001). The previous discussion of policy debates 
illustrated the conflict of interest of actors within this system. The third feature is that "the nature 
and the fonn of these relationships may also look different when looked at from alternative levels 
of aggregation or scales of analysis" (McKelvey & Orsenigo 2001, P61). Studies which focus on 
large pharmaceutical companies will require a different analysis to studies which focus on small to 
medium sized companies, although both large pharmaceutical companies and small to medium 
sized companies are all considered in the same system of innovation. 
The forth feature is that the system of innovation in pharmaceuticals can be defined in different 
boundaries, as suggested in the previous subsection, e.g. national, sectoral etc., the fifth feature is 
that the system changes over time which may be caused by external or internal factors (McKelvey 
& Orsenigo 2001). 
The sixth feature is that "evolution and adaptation to (internally generated and exogenous) shocks 
implies processes of restructuring, division of labour, reconfiguration of complementarities" 
(MCKelvey & Orsenigo 2001, P64). McKelvey and Orsenigo provide the example of molecular 
biology: "the emergence of a new knowledge base (molecular biology) implied a new "problem", 
new ways and procedures of learning, a new technological regime. The adaptation to the new 
knowledge base (technological regime) implied a deep reconfiguration of the system: at the finn 
level, at the level of the patterns of division of labour and relationships among finns (through the 
appearance of new specialized biotechnology finns, the emergence of networks of collaborative 
relations but also through M&A), at the level of market structure" (McKelvey & Orsenigo 200 I, 
P64). The seventh feature suggested is analysis from a systematic and dynamic view. The eighth 
and final feature is that ''within the evolving system, the lack or the weakness of specific 
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competencies, agents or relations between agents decreases overall performance" (McKelvey & 
Orsenigo 200 I, P65). These eight features described and summarized the actors and linkages of an 
innovation system. 
Another set of elements are knowledge and technology. Knowledge accumulation and diffusion is 
central to innovation activities and there are three key dimensions of knowledge: accessibility, 
opportunity and cumulativeness (Malerba 2005). Greater accessibility of knowledge within the 
sector may lead to a higher level of imitation of product and process (Malerba 2005). The sources 
of technological opportunity to innovation may come from universities or from advances in 
equipment or from suppliers and users (Malerba 2005). Cumulativeness was affected by the 
learning processes, the firm's capability and feedback from the market, and high cumulativeness 
leads to high "appropriability of innovation" (Malerba 2005). The knowledge base and technology 
further influenced the boundaries of Sectoral Systems of Innovation, e.g. the development of 
molecular biology changed the structure of the pharmaceutical and biotechnology industry 
(Malerba 2005). 
Malerba suggested that a sector is composed of organizations and individuals: organizations 
included firms (e.g. users, producers, and suppliers), non-firms (e.g. universities, governments, 
financial institutions, trade unions, and technical associations); individuals included consumers, 
entrepreneurs, and scientists; and the key actors of Sectoral Systems of Innovation are firms 
(Malerba 2005). 
The definition of "institutions" is controversial. There are two types of interpretation: one 
definition is that institutions include norms, routines, common habits, established practices, rules, 
laws, standards, and so on (Edquist 1997;Lundvall I 992;Malerba 2005); institutions have also been 
defined as different players and organizations of the system (Nelson & Rosenberg 1993). In 
Susan's study National systems of innovation: complex interdependence in the globe systems, 
'institutions' are interpreted as interlinks of the elements (Susan 1997). In the DTI Comparative 
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Statistics for the UK, European and US Biotechnology Sectors for the years 2001,2003 and 2003, 
they adopted national and Sectoral Systems of Innovation to compare the performance of 
biotechnology in different countries. However, they interpreted 'institutions' as organizations 
rather than interlinks. Moreover, many other works do not even interpret this term at all. In the 
publication of Innovation Systems: analytical and methodological issues in 2002 Carlsson et al. 
avoided using 'institutions'. They interpreted 'systems' as component, relationships and attributes 
(Carlsson et al. 2002): components are the operating parts of a system, and relationships are the 
links between components, and attributes are the properties of the components and relationship 
between them Therefore, as Edquist suggested, Systems of innovation should be used as a 
conceptual framework (intermediate theory) rather than a theory (Edquist 2005). 
2.1.3.Why adopt Sectoral Systems of Innovation approach? 
The Systems of innovation approach has been applied in many different ways: sectoral, national 
and regional. The DTI report and EU Commission also adopted this approach to conduct 
comparative analysis of different countries. 
Edquist suggestes six advantages to using the systems of innovation framework: this approach 
''places innovation and learning processes at the centre of focus, adopts a holistic and 
interdisciplinary perspective, employs historical and evolutionary perspectives, emphasizes 
interdependence and non-linearity, compasses both product and process innovation, and 
emphasizes the role of institutions" (Edquist 2005, PISS). Drug innovation, from the birth to the 
development of drugs, is not dependant on one single innovation or several sciences; it is the 
product of the accumulation of knowledge combined with the long time development of the 
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education base, industry base, economics and politics, as well as different resources required and 
interactions of actors of the innovation network. Therefore, System of Innovation approach, which 
emphasises the historical and evolutionary context of the innovation, is an appropriate conceptual 
framework for this study. 
However, there are also problems with this conceptual framework: first problem is, as discussed 
above, the different interpretation of 'institutions'. Are they rules, laws and norms? Or are they 
organization? Moreover, as an intermediate theory, how to define the core elements of the system 
is another problem (Edquist 1997). 
Although there are limitations of systems of innovation, it has been adopted by many researchers. 
For example, the biotechnology industry was investigated from the perspective of regional 
(Asheim & Gertler 2005;Cooke 2002), national (Edwards et al. 2006), technological (Bergek et al. 
2008) and sectoral systems of innovation (Brusoni & Geuna 2003;McKelvey & Orsenigo 2001). 
Since globalization has blurred national boundaries, some researchers also adopt an international/ 
global sectoral perspective. Bartholomew argued that the particular characteristics of national 
systems of biotechnology innovation "form the basis for complex interdependence within the 
global system, through international technological cooperation and the cross-border adoption and 
adaptations of institutional forms and practices" (Bartholomew 1997, P241). Van Rooij et al. 
studied the foreign technologies imported into Dutch companies from a perspective of international 
-sectoral systems (Van Rooij et al. 2008), and Miyazaki & Islam also adopted a similar approach 
to investigate Sectoral Systems of Innovation in nanotechnology (Miyazaki & Islam 2007). A 
system-evolutionary perspective has also been used to describe the dynamics of the life science 
sector and its implications on regional innovation policy (Rosiello & Orsenigo 2008). 
Malerba suggested four key challenges that are required for a better understanding of the 
relationship between innovation and the evolution of industries: the analyses of demand, 
knowledge, networks and co-evolution (Malerba 2006). Considering the pharmaceutical and 
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biotechnology industry as a Sectoral Systems ofInnovation, this study will examine the emergence 
of new actors in this system of innovation - the drug discovery and development companies 
established after 1980s, when biotechnology first started to be applied to the drug innovation 
process. This study will investigate the knowledge, networks and co-evolution of the drug 
discovery and development subsector from a perspective of Sectoral Systems of Innovation. As 
discussed in Section 1.3, this study will focused on this subsectors' structure, their knowledge 
contribution, their networking and collaboration with other actors and how this has changed over 
time. 
2.2. Literature Review 
2.2.1 Development of Research Questions 
Pisano had observed a trend toward vertical integration of new biotechnology companies from 
R&D activities to manufacturing and marketing during the 1980s (Pisano 1991). The rationale for 
integration of manufacturing is mainly "the complexity of process development and scale-up, the 
problems of protecting intellectual property rights, and regulations which make it costly to 
switch manufacturers after conducting Stage III clinical trials" (Pisano 1991, P244), and the 
rationale for integration of distribution is the transaction cost occurred in penetrating a new market 
(Pisano 1991, P246). Pisano also suggested that the rate of integration of new biotechnology firms 
is constrained by the availability of capital (Pisano 1991). 
However, after 15 years development, other researchers observed a different trend in 
biotechnology governance. Kollmer and Dowling (Kollmer & Dowling 2004) collected data from a 
sample of 70 North American biopharrnaceutical firms from ReCap, combined with a 
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questionnaire survey of these companies. They suggested that ''being not-fully integrated is not a 
transitional state, but a sustainable business strategy" (Kollmer & Dowling 2004, PI148). 
It is important for biotechnology firms to know when to vertically integrate, when to license and 
when to collaborate (Pisano 1991). Pisano suggested that the biopharmaceutical companies may 
adopt different strategies because of their products. He suggested three types of companies: 
companies adopting novel research methods and tools, companies focusing on novel targets and 
mechanisms, and companies focusing on novel compounds, treatments and markets (Pisano 2006, 
PI67-172). He analyzed the degree of information asymmetry, the need for investments in 
specialized assets, the tacitness of the knowhow and the degree to which they held relevant 
intellectual property (Pisano 2006, PI65-166). Pisano suggested that companies developing novel 
research methods and tools may adopt a strategy of contract service, companies focusing on novel 
targets and mechanisms may develop long-term collaboration with large pharmaceutical companies, 
and companies focusing on novel compounds may further their aims by integration (Pisano 2006). 
Kollmer and Dowling's findings indicated that licensing is a commercialisation strategy for both 
fully and not-fully integrated firms: for not fully integrated firms, licensing accounted for 76 per 
cent of total revenues, and for integrated companies, licensing still contribute 38 per cent of the 
total revenues (Kollmer & Dowling 2004). This result is consistent with a cross sector study which 
indicated that firm size is the determinant of licensing (Gambardella, Giuri, & Luzzi 2007): 
" .. .licensing has become a well-established commercialisation strategy which is used to fully 
exploit a company's technology assets"(Kollmer & Dowling 2004, PI 148). The main reasons for 
fully -integrated companies to license out technology are generally strategic misfit and/or low 
perspective of return (Kollmer & Dowling 2004). Arora & Ceccagnoli found that when 
effectiveness of patent protection increased, firms are more likely to patent; compared with firms 
lacking specialized complementary assets, firms that have specialized complementary assets are 
more reluctant to license (Arora & Ceccagnoli 2006). 
60 
Comparing these studies discussed above, there are three major arguments and differences. First of 
all, whether being not-fully integrated is a sustainable stage of firms as suggested by Kollmer & 
Dowling, or vertical integration is a major aim of a company's development as suggested by 
Pisano. Pisano argued that the drug discovery and development companies are started with 
fragments of an innovation process and business practice, therefore, vertical integration is a major 
aim of a company's development, from project development to manufacturing and marketing 
(Pisano 2(06). Moreover, the capability of firms and their position within networks also connected 
with its strategy. Gulati, Nohria, & Zaheer suggested that "an understanding of the consequences 
of the Ubiquitous growth of strategic networks emphasizes that firms are more properly viewed as 
connected to each other in multiple networks of resource and other flows" (Gulati, Nohria, & 
Zaheer 20(0). What are the major factors influencing the strategy of companies: products and 
services, stage of life cycle, position within networks, or availability of capital? 
The second difference is that Kollmer & Dowling argued that licensing is a well-established 
strategy of biotechnology firms and contributes greatly to the revenues of the industry; while 
Pisano argued that the commercialization of patents is in fact impeding flow of information this 
industry, although the revenues grew very fast, the profit is close to zero. The negative impact of 
intellectual property is also suggested by other researchers (Murray & Stem 2007). 
Thirdly, Pisano argued that (2006) performance of the biopharmaceutical industry did not meet the 
perspective, mainly because "this sector has indiscriminately borrowed business models, 
organization strategy and approaches from other high tech industry". While other researchers were 
focused on a solution of all high tech industries (Gambardella, Giuri, & Luzzi 2007;Hall & Bagchi-
Sen 2(07). 
One important issue concerning the difference in these previous studies is the measurement of 
performance: in Pisano's study, the major indicator is the cost per new molecular entity (NMEs) by 
biotech and financial returns. However, as Kollmer & Dowling's study indicated, the patents 
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should also be considered as an important measurement of R&D performance. Industry structure is 
also an important issue of performance measuring: since this pharmaceutical and biotechnology 
sector requires specific knowledge, the number of players is limited by this barrier (Bruno et at. 
2008, P43). Bagchi-Sen suggests that the structure of the US biopharmaceutical sector is 
dominated by a few large and many small firms: the small firms are research focused or act as 
technology developers and several large firms are now integrated biopharmaceutical companies 
(Bagchi-Sen 2oo7a). In a sector with hierarchical structure, large companies played a profound role 
as dominant competitors. On one hand, these established companies who dominate the market are 
an obstacle to innovation: based on a survey during 2002-04, 15 per cent of biotechnology 
innovation companies regarded this factor as highly important barrier to their innovation activities 
(Cleff et at. 2008). On the other hand, for biotechnology companies, competitors are an important 
source of learning, 24 per cent of companies regarded competitors as information sources and 34 
per cent of companies collaborate with their competitors (Cleff et at. 2008). Another determinant 
would be R&D intensity: companies with high R&D intensity and low R&D intensity will adopt 
different strategies (Hall & Bagchi-Sen 2007). 
Based on the argument above, there are two research questions concerning the co-evolution of 
strategy networking and industry structures: 
3) Is there a divergence of strategies existing in the drug discovery and development 
subsector? If so what are the key factors that determine this divergence? 
4) How does the divergence of strategy influence the industry structure? 
In the next sections further literature will be reviewed, which will provide a broader context for the 
study. 
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2.2.2 Structure and dynamics 
Earl-Slater has observed that the number of UK biotechnology and pharmaceutical companies has 
grown from 286 in 1975, 310 in 1980, 326 in 1984, 352 in 1987, and 464 in 1998; with their R&D 
expenditure increasing from £359 million in 1982 to £1,113 million in 1996; and the value of 
exports (primary, semi-finished and finished drugs) increasing from £978 million in 1982, to 
£3,180 million in 1996 while the real value of imports has risen from £375 million in 1982, to an 
estimated £ 1,802 million in 1996 (Earl-Slater 1998). This suggests that an important characteristic 
of the industry is massive growth and R&D intensity, which is similar to the results of this study. 
Since this pharmaceutical and biotechnology sector requires specific knowledge, the number of 
players is limited by the ability to gain access to that knowledge (Bruno, Miedzinski, Reid, & Ruiz 
Yaniz 2008, P43). Bagchi-Sen suggests that the structure of the US biopharmaceutical sector is 
dominated by a few large and many small firms: the small firms are research focused or technology 
developers and several large firms are now integrated biopharmaceutical companies (Bagchi-Sen 
2007). This is a central focus of this study, and the UK biopharmaceutical subsector examined in 
this study showed a similar structure. This structure has an impact on the interactions between 
biopharmaceutical companies, between companies and universities and between biopharmaceutical 
and large pharmaceutical companies. In this study, empirical data indicated that the large 
companies are major knowledge contributors and that they play important roles in networking with 
other actors of the innovation systems. 
The relationship with universities, biotechnology or pharmaceutical or other large companies is 
essential for small firms to survive and grow (Bagchi-Sen 2007b). This is also an important feature 
of this sector: universities and public research institutes' basic scientific discoveries can be further 
developed and turned into new products and new processes (Patel, Paunov, & Arundel 2008). 
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Moreover, universities and public research institutes train highly skilled employees for this 
industry (Patel, Paunov, & Arundel 2008). Patel, Paunov, & Arundel suggest there are three 
diffusion mechanisms of basic biotechnology discoveries: 1) biotechnology firms spin-off from 
universities and public research institutions, e.g. university researchers establish new companies; 2) 
universities and public research institutions may form alliances with pharmaceutical and 
biotechnology companies, e.g. licensing out patents and co-development of products; 3) basic 
biotechnology discoveries are diffused via employment of highly skilled postgraduate students and 
researchers (Patel, Paunov, & Arundel 2008). 
As discussed in an earlier section, there is an argument about the existence of a 'biotech 
revolution', because the limited success in increasing the rate and scope of change in productivity 
or the quality of drugs has been over estimated (Hopkins, Martin, Nightingale, Kraft, & Mahdi 
2007). Hopkins et al. argued that biotechnology is "following a well-established incremental 
pattern of technological change and creative accumulation that builds upon, rather than disrupts, 
previous drug development heuristics" (Hopkins, Martin, Nightingale, Kraft, & Mahdi 2007). This 
is supported by the data collected from this study finding that many biopharmaceutical companies 
also use chemistry as a major technology in drug development. 
However, the performance of this sector cannot be explained by any single factor: "performance in 
knowledge creation is highly correlated with that in commercialization and finance ... thus 
countries with high levels of public and private knowledge creation activities are also countries that 
excel in terms of patents, start-ups and alliances" (Patel, Paunov, & Arundel 2008, P3). Empirical 
data indicates that countries' performance in biopharmaceutical development and clinical trials are 
positively connected with strategic alliances, supply of venture capital and biotechnology patenting 
(Patel, Paunov, & Arundel 2008). Furthermore, patents and strategic alliances are significantly 
correlated (Patel, Paunov, & Arundel 2008). Similar results are also indicated by the Biopolis Final 
Report, which argues that policy makers should adopt an approach focussed on both basic 
scientific research and commercialization (Enzing et al. 2007). 
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Industrial dynamics and competition are influenced by many factors, including market structure 
and patent protection expiry. Magazzini, Pammolli, & Riccaboni investigated the USA, UK, 
Germany, and France market, and suggest that the consequences of patent expiry have different 
impacts on innovators and followers: "in systems that rely on market-based competition, original 
products enjoy premium prices and exclusivity profits under patent protection, and face fierce price 
competition after patent expiry; and in systems that rely on administered prices, penetration by 
generic drugs tends to be rather limited" (Magazzini, Pammolli, & Riccaboni 2004, PI75). In fact, 
for the UK drug discovery and development companies, they face both markets: domestic systems 
that rely on administered prices and foreign systems (e.g. US) that rely on market-based 
competition. Both markets have impacts on this subsector's structure, knowledge production and 
networking. 
Since the companies of this sector all have specific knowledge and technology, we should ask how 
the hierarchical structure of the sector influenced knowledge production and the kinds of 
technology in use. As indentified in this project, both biotechnology and chemical technology are 
adopted in this sector, which raises several questions: how successful are these technologies in 
developing new drugs? What technologies have been involved in the alliances between drug 
innovation companies and big pharmaceutical companies? Why do drug discovery and 
development companies prefer these technologies? 
2.2.3 Globalization and clustering 
There is controversy between two contrasting perspectives regarding the geographical clustering of 
biotech firms: one view is that competences for learning are leveraged from open networks and 
collaborations, and others argue that, "as intellectual assets are protected by property rights, 
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knowledge adheres to specific locations mainly as a consequence of scientists' immobility" 
(Rosiello 2007, P787). In this section, we will first review studies on both sides: start with the 
global picture and move down to the regional level. 
Florida suggested that globalization of innovation is driven in large measure by technology factors 
(Florida 1997). This trend of globalization of biotechnology innovation is an important feature of 
both academia and industry research. Cooke investigated the global bioscience research system by 
adapting a global network analysis, which looked at collaborations between "star" scientists and 
their institutes in bioregions at a global level, with evidence from analyzing co-publication of 
bioscientific articles in US and EU SCI cited journals (Cooke 2006). He suggested that the 
strongest bioregions are in North America, particularly around Boston, San Diego and San 
Francisco. Sweden and UK are the strongest European research bases. Cooke also identified a 
hierarchical structure and the main network nodes in the global bioscience research system (Cooke 
2006). 
From a perspective of industry, many other studies have shown evidence of a geographical 
concentration of drug innovation. Achilladelis & Antonakis investigated 1,736 new drugs marketed 
between 1800 and 1990, and suggested that drug innovation was highly concentrated in the USA, 
UK. Gennany, Switzerland and France, which together accounted for 80 per cent of total drug 
innovations (Achilladelis & Antonakis 2001). The findings also indicated that the development of 
the drug innovation sector is influenced by globalization, from knowledge generation and 
commercialization to mergers and acquisitions. 
From a regional perspective, Cooke suggests that the biopharmaceutical companies tend to locate 
in knowledge-driven clusters centred upon universities, research hospitals and research institutes 
(Cooke 2003). The strong tendency towards geographical concentration of research and related 
economic activities is a crucial feature of the biotechnology industry (Rosiello & Orsenigo 2008). 
There are two major types of cluster formation: "spontaneous clusters, that are the result of the 
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spontaneous co-presence of key factors", and "policy driven clusters, that are triggered by the 
strong commitment of governmental actors whose willingness was to set the conditions for the 
cluster creation, either as a response to an industrial crisis or as a deliberate decision to foster the 
biotech sector" (Chiaroni & Chiesa 2006, PlO64). There are different opinions about policy driven 
clusters. Some researchers argue that policies to promote clusters are not necessary, "except for the 
"organically" developed clusters ... clusters as a policy concept, and particularly in relation to 
funding, have proven to be inadequate and have led to the creation of artificial clusters with none 
of the inherent interactions" (Bruno, Miedzinski, Reid, & Ruiz Yaniz 2008, P43). The important 
clusters of drug discovery and development companies indentified in this study are mainly 
"organically" developed clusters. Local governments are also important in cluster development. 
Economic geography research of science-based clusters is an important area of study (Cooke 
2001;Cooke 2004;Cooke 2005a;Cooke 2005b;Feldman & Francis 2003;Howells 2002). Casper 
argues that although regional technology clusters are an important source of economic 
development, few successful biotechnology clusters exist (Casper 2007). Casper uses social 
network analysis to examine the emergence of social networks linking senior managers employed 
in biotechnology firms in San Diego, Califorrna, and found that "labor mobility within the region 
has forged a large network linking managers and firms, while ties linking managers of an early 
company, Hybritech, formed a network backbone anchoring growth in the region" (Casper 2007, 
P438). Another study of California biotechnology suggest the positive impact of research 
universities on nearby firms relates to identifiable market exchange between particular university 
star scientists and firms (Zucker, Darby, & Armstrong 1998). 
In contrast, a study of Cambridge indicated that the University of Cambridge does not dominate the 
scientific linkages of the area's firms: a large percentage of Cambridge's firms do not derive from 
its university, and the majority of scientific collaborations are not with the University of 
Cambridge laboratories, nor do Cambridge scientists dominate the scientific advisory boards of 
these firms (Casper & Karamanos 2003). Moreover, the majority of scientists within the area's 
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biotechnology finns appear not to have left the University of Cambridge laboratories to move to 
industry (Casper & Karamanos 2003). However, Casper & Karamanos's research is about general 
finns, this may be not true for the biopharmaceutical sector because it is characterized by strong 
linkages with research institutions. 
There are different views of the impact of clustering, some researchers argued that geographic 
proximity does not influence company performance (Tallman & Phene 2007), while many others 
found that is very important. Audretsch and Stephan examined how biotech companies and 
universities were geographically bounded, and they observed that the specific role played by the 
scientist shaped this link (Audretsch & Stephan 1996). Murray investigated the biotechnology 
firms and their academic inventors, and suggested that scientist not only contribute human capital 
but also social capital to firms: scientist' social capital, which shaped by their career path, can be 
transformed into scientific networks the firm embedded (Murray 2004). Quintana-Garcia & 
Benavides-Velasco observed that firms located in knowledge driven clusters not only benefit from 
local upstream alliances with public research institutes, but also attract downstream alIiances with 
foreign companies (Quintana-Garcia & Benavides-Velasco 2006). Furthermore, many studies 
indicate that venture capital firms which fund biotechnology companies also cluster in the same 
regions, e.g. between 1988 and 1999, over half of the US biotechnology firms received locally 
based venture funding (Powell et al. 2002). 
Previous studies also indicated that how a company could benefit from clustering and geographic 
proximity is determined by the companies own attributes. Small firms' R&D activities benefit 
more from being in particular locations than large firms' R&D activities (Feldman 1994). Spill 
over of knowledge, from a university, research institute, or industrial corporation, to a start-up 
company "facilitates the appropriation of knowledge for the individual scientist(s) but not 
necessarily for the organization creating that new knowledge in the first place" (Audretsch & 
Stephan 1999, P97). Other factors also influence the clustering impact on companies. Van 
Geenhuizen & Reyes-Gonzalez found that companies involved in the first stage of the knowledge 
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chain in new drugs and diagnostics research would benefit from knowledge spillover. In contrast, 
for service companies, the stage in the knowledge chain does not matter (van Geenhuizen & 
Reyes-Gonzalez 2007). Moreover, firms embedded in alliance networks that exhibit both high 
clustering and high reach (short average path lengths to a wide range of firms) will have greater 
innovative output than firms in networks that do not exhibit these characteristics (Schilling & 
Phelps 2007). Furthermore, there are increasing returns associated with cluster size, but also 
"diseconomies of agglomeration play an increasingly important role as clusters evolve" (Folta, 
Cooper, & Baik 2006, P217). 
In short, the previous studies indicated the global competition and collaboration of 
biopharmaceutical subsector is in fact driven by several clusters which acted as main network 
nodes in the global bioscience research systems (Cooke 2006). The formation clusters were results 
of a combination oflocal factors or driven by policies (Chiaroni & Chiesa 2006). These key factors 
include collaboration with local research institutes and universities and financial support from local 
venture capitals. Clustering also attracts foreign companies and large pharmaceutical companies to 
downstream alliances with these companies. To what extent a company could benefit from 
clustering is determined by many factors, e.g. the nature of clustering, company size, company's 
product and service and management experiences. The question raised here is what the key factors 
are for the formation of clusters of the drug discovery and development sector. Is there any 
difference between clusters of pharmaceutical and biotechnology companies, and clusters of drug 
discovery and development companies? 
2.2.4 Alliance. and networking 
69 
The notion of alliances and networks are widely studied in different disciplines, such as economics, 
corporate strategy, and inter-organizational studies, and different theoretical perspectives and 
methodologies have been used to "understand the formation, evolution, operation and outcomes of 
organizational alliances and networks" (de Rond & Bouchikhi 2004;Osborn & Hagedoorn 1997, 
P261). 
Strategic alliances are defined as ''voluntary arrangements between firms involving exchange, 
sharing, or co-development of products, technologies, or services; they can occur as a result of a 
wide range of motives and goals, take a variety of forms, and occur across vertical and horizontal 
boundaries"(Gulati 1998, P293). Gulati, Nohria, & Zaheer suggest that a firms' conduct and 
performance could be better understood by examining the network they embedded (Gulati, Nohria, 
& Zaheer 2000). There are five key issues relating to alliances identified by Gulati: "the formation 
of alliances, the choice of governance structure, the dynamic evolution of alliances, the 
performance of alliances, and the performance consequences for firms entering alliances" (Gulati 
1998, P298-309). 
Therefore, to better understand the drug discovery and development sector, this study investigated 
the alliance agreements and the "intangible networking" of the drug discovery and development 
sector, i.e. co-publishing of scientific papers and patents. As indentified in this study the vertical 
and horizontal dimensions are both very important features of the drug discovery and development 
sector. 
Many researchers have indicated that the role of alliances has become very important in the drug 
innovation process; however, Arora and Gambardella argue that companies differed significantly 
in their ability to benefit from alliances (Arora & Gambardella 1994). Powell studied the networks 
in the pharmaceutical and biotechnological industry by using a theory of learning from alliances, 
and suggested that more greater efforts were needed to understand knowledge generating and 
transfer in these networks (Powell 1998). 
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From the perspective oflarge pharmaceutical companies, factors such as new product development, 
economies of scale, public ownership, and geographic location in a regional technology cluster, are 
alI important factors in forming alliances with biotechnology start-ups (Rothaennel 2002). 
Rothaennel drew this result from a study on 325 biotechnology finns' 973 alliances fonned with 
large pharmaceutical companies in a 25-year period (Rothaermel 2002). Colombo also observed 
that those firms which have patents and "developed ready-to use proprietary technological 
knowledge" will attract more partners to fonn alliances than firms which do not have patents 
(Colombo, Grilli, & Piva 2006). 
For foreign and domestic companies, the most attractive factors in forming alliances are different 
(Coombs, Mudambi, & Deeds 2006). Coombs et a!. studied 64 US public owned biotechnology 
companies between 1982 and 1993, and argued that US biotechnology companies' patent portfolio 
is a determinant for US domestic partners to form alliance, while US biotechnology companies 
"located in technologicalIy munificent environments are the preferred alliance partner for foreign 
firms" (Coombs, Mudambi, & Deeds 2006, P422). 
Rothaennel observed that the companies acting as buyer benefit more than R&D providers from 
the alliance (Rothaermel 2001). Rothaermel investigated 889 strategic alliances between 32 US 
large pharmaceutical companies which acted as buyers and biotechnology companies which acted 
as R&D providers, and found that "incumbents that focus their network strategy on exploiting 
complementary assets outperform incumbents that focus on exploring the new technology" 
(Rothaermel 2001, P687). In the case of biotechnology start-ups, network formation and industry 
growth are significantly influenced by the development and nurturing of social capital (Walker, 
Kogut, & Shan 1997). 
Based on a study of the Canadian biotechnology industry, Baum and Silvennan observed that a 
firms' alliance capital, in particular, downstream and horizontal alliances, as well as their human 
capital and intellectual capital are important factors for venture capitals to fonn ties with 
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biotechnology companies (Baum & Silverman 2004). Furthermore, substantial boosts in venture 
capital financed alliance activity, and increased potential of start-up Initial Public Offering (lPOs), 
will attract more reputable venture capital (Hsu 2006). This is important because companies with 
successful IPOs are more likely to attract further findings, and this may broaden the gap between 
companies. Gulati and Higgins found that the nature of ties and uncertainty of the marketplace 
have contingent impacts upon the alliances (Gulati & Higgins 2003). Based on a case study of new 
biotechnology firm, they observed that ''ties to prominent venture capital firms are particularly 
beneficial to [PO success during cold markets, while ties to prominent investment banks are 
particularly beneficial to [PO success during hot markets" (Gulati & Higgins 2003, P127). Based 
on two case studies, Schweizer also suggested the pressure from capital market led to strategic 
consolidation of the pharmaceutical and biological industry (Schweizer 2002). 
Firm specific uncertainties are also determinants for biotechnology firms to form alliances 
(Beckman, Haunschild, & Phillips 2004). Lerner and Merges suggest that the reasons that small 
R&D intensive firms which have novel technologies and seek alliances are that these companies 
frequently lack the necessary financial support for their research projects, or "lack complementary 
assets such as sales force and manufacturing know-how, which may take many years to develop" 
(Lerner & Merges 1998, PI26). Lerner and Merges investigated 200 randomly selected alliances 
from the Recombinant Capital database, and their observation suggest that for the firms which 
acted as R&D providers in alliances, their loss in prior year before forming alliances often 
accounted for "one-third of the average firm's shareholder equity and nearly one-half of its cash 
and equivalent"(Lerner & Merges 1998, PI40). This study also systematically collected data from 
the Recombinant Capital database. Together with data collected from government databases, the 
findings of this study indicated that continuously high R&D intensity is a more general reason 
explaining why companies form alliances, regardless ofloss or gain in the previous year. 
Moreover, the financial conditions of firms which acted as R&D providers have "profound effects 
on the allocation of control right" of alliance (Lerner & Merges 1998, P 153). These control rights 
72 
included many aspects, and the most important control rights suggested by Lerner and Merges are 
the management of clinical trials e.g. decision of drug candidates entering clinical trials and 
decision of disease indications, design of initial manufacturing process and design of 
manufacturing process after approval, and the plan of marketing strategy e.g. where firms acted as 
R&D providers they could have exclusive rights or co-market rights in one or more markets 
(Lerner & Merges 1998). These control rights have an impact on the development of R&D 
providers: decisions on clinical trials, e.g. indications and drug candidates, determine the potential 
returns of new drugs; manufacturing design determines the rights of manufacturing, because drugs 
approved by FDA only applied to specific facility which manufactured them, and it is expensive 
and time consuming to undergo another review if another company wants to produce these drugs; 
marketing and co-marketing rights would give R&D providers the opportunity to established their 
own sale force and gain experience, which will facilitate their further development (Lerner & 
Merges 1998). 
The number of alliances is positively connected to a firms' rate of new product development, 
according to Deeds and Hill's study of 132 biotechnology firms (Deeds & Hill 1996). However, 
this relationship is nonlinear, because each alliance contributes differently to the new product 
development and there are risk with alliances aimed at gaining access complementary assets; rather 
the relationship between the number of alliances and the rate of new product development may be 
an inverted U-shape, which means "at low levels strategic alliances are positively related to new 
product development, but as the number of alliances increases, the benefits begin to decrease, and 
at high levels the costs of an additional alliance actually outweigh the benefits" (Deeds & Hill 1996, 
P42). 
Based on their study of 554 biotechnology companies in a 15-year period, Oliver suggests that the 
number of alliances is connected with firm's life cycle: in particular, a lack of alliances was 
associated with firm death (Oliver 2001). 
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There are also arguments about the connections between the number of alliances and R&D stages. 
Pisano investigated 260 biopharmaceutical projects, and suggested that projects with partners have 
a higher failure rate than project development internally, because ''projects with poorer prospects 
for reaching the market tend to be licensed to collaborative partners while those with better 
prospects are commercialized internally" (Pisano 1997, PI). Similarly, Rothaermel & Deeds also 
observed that as firms and their technology capability grow, they tend to move their product from 
alliances to internal development (Rothaermel & Deeds 2004). This was also supported by Oliver's 
observation: the number of alliances increased during "exploration stage of the organizational 
learning ...,;yc1e" and number of alliances reduced during "the exploitation stage" (Oliver 2001, 
P483). For Dedicated Biotechnology Firms (DFSs), the firm's growth need, their capabilities and 
their awareness of alliances risk, which are all key factors of alliances formation, change during 
firm growth (Oliver 2001). 
The success of networking is influenced by many factors. Lane & Lubatkin suggest that the 
similarity of the partners' basic knowledge, lower management formalization. research 
centralization, compensation practices, and research communities were positively connected to 
inter organizational learning (Lane & Lubatkin 1998). 
Based on observation of 1910 compounds developed by US pharmaceutical and biotechnology 
firms between 1988 and 2000, Danzon et al. argued that drug candidates developed with partners 
have a higher rate of success, "at least for the more complex phase 2 and phase 3 trials, particularly 
if the licensee is a large firm, because experience increases the probability of success for late-stage 
trials" (Danzon, Nicholson, & Pereira 2005). 
There are also arguments about connections between alliance performance and inter-organizations 
learning routines (experience), which is defined as "stable patterns of interaction among two firms 
developed and refined in the course of repeated collaborations" (Zollo, Reuer, & Singh 2002, 
P70l). There are three types of alliance experience: partner-specific experiences, which are 
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obtained by repeated collaborations with the same partner and represent depth of knowledge; 
technological-specific experience, which are obtained from repeated alliances in the same domain 
and represent the technological depth; and general experience, which are gained from alliance with 
multiple partners (Hoang & Rothaermel 2005;ZoIl0, Reuer, & Singh 2002). Zollo et a!. argue that 
the partner-specific experiences influence alliance performance, while technological-specific 
experiences and general experiences do not (Zollo, Reuer, & Singh 2002). Hoang and 
Rothaermel's observation indicate that only general experiences have positive influence on alliance 
performance and show diminishing returns, while partner-specific experiences have negative 
influence on alliance performance. However, other researchers argue that for large pharmaceutical 
companies and small biotechnology firms, pervious alliance experience have a negative effect on 
their subsequent alliance formation (Roijakkers, Hagedoom, & Van Kranenburg 2005). 
Orsenigo et al (2001) have analyzed the structural evolution of the network of collaborative 
agreements in pharmaceutical R&D in the last 20 years (Orsenigo, PammoIli, & Riccaboni 2001). 
They suggested that both the growth of knowledge and the structural evolution of the network have 
been characterized by fast expansion, proliferation of research trajectories and techniques, and 
hierarchization: "the cumulative nature of such processes has been imposing different degrees of 
structural stability at different levels of the hierarchy ... major changes in the network structure have 
occurred in correspondence with the emergence of a new set of transversal technologies" 
(Orsenigo, Pammolli, & Riccaboni 2001). This study will investigate those same themes in the 
drug discovery and development sector, exploring how technology is involved in changes in the 
alliance agreements in the past two decades. 
In short, literature on alliances and networking are mainly focused on driving forces of alliances 
formation, alliances formation, performances and factors influenced alliances. Market uncertainty 
and firm specific uncertainty are determinants for biotechnology firms to form alliances (Beckman, 
Haunschild, & Phillips 2004). Finns' intellectual capital, human capital, alliance capital (Baum & 
Silverman 2004), economies of scale and geographic location (Gulati & Higgins 2003;Rothaermel 
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2002) are also factors to attract partners. For small companies, their partners include venture 
capitals, large pharmaceutical companies and other domestic and foreign companies. Number of 
alliances is connected with firms' rate of drug innovation (Deeds & Hill 1996) and stages of 
product development (Danzon, Nicholson, & Pereira 2005). To what extent companies could 
benefit from alliances determined by their competencies (Arora & GambardelIa 1994), their role 
played in alliances (Rothaermel 200 I), and financial conditions (Lerner & Merges 1998). This 
study emphasises the historical perspective of the drug discovery and development sector asking if, 
as the knowledge and experience accumulates, will the partners in alliances, content of the 
alliances and number of alliances change as well? 
2.2.5 R&D activities 
There are both external and internal forces driving innovation. AchilIadelis & Antonakis suggest 
that the driving forces for innovation include scientific and technological advances, market demand, 
societal needs, government legislation, new raw materials, competition among firms, and the 
creation of corporate technology traditions; and "the intensities of these driving forces and their 
synergies varied over time and thus determined the rate of technical change" (AchiIladeIis & 
Antonakis 2001, P585). The first and last factors suggested by AchiIladeIis & Antonakis are 
internal factors and others are external factors. 
As major forces driving innovation, technology advances have important impact on the drug 
discovery and development sector. A good example is biopharmaceuticals. Biopharmaceuticals are 
growing very fast in the past decades. "Biopbarmaceutical" was defined as "any biology-based 
therapeutic that structurally mimics compounds found within the body", including recombinant 
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proteins, monoclonal and polyclonal antibodies, peptides, antisense oligonucleotides, therapeutic 
genes, and certain therapeutic vaccines (Nagle, Lugo, & Nicita 2003, PSI24). 
US biopharmaceutical drug candidates are growing at an aggressive rate (16- 30 per cent), faster 
than the rate of growth observed for traditional "pharmaceuticals" (approximately 4 per cent) 
(Nagle et al. 2008, P229). About 150 biopharmaceuticals have been approved, and this class of 
therapeutics generates over $50 billion in sales every year (Redwan 2007). The majority of these 
products are developed and produced in mammalian cell lines (70 per cent), prokaryotic systems 
(15 per cent), and yeast (five per cent), respectively (Redwan 2007). However, the cost of 
discovery and development is also very high. The estimated R&D per each approved 
biopharmaceutical molecule is as much as $1,318 million (Redwan 2007). 
In terms of blockbusters, which refer to drugs with sales of more than $1 billion a year, 3 out of36 
blockbusters (eight per cent) were biological products in 2003, and this had risen to 18 of 101 
drugs (18 per cent) in 2006 (Lawrence 2007). Furthermore, eight out of 36 drugs with sales over $2 
billion ('super' blockbusters) were biological products (Lawrence 2007). This indicated the 
increasing importance ofbiopharmaceuticals. 
Nagle et al. investigated US biopharmaceutical pipeline drugs in May 2006, and observed that of 
111 biological drug candidates in phase II late stage development, 87 are new molecular entities, 
and 24 are already approved for other indications; moreover, 25 of the 111 drug candidates have 
completed phase III trials (Nagle, Nicita, Gerdes, & Schnneichel 2008). This suggests that there 
more biological drugs on market. Nagle et al. also observed that from 2003 to 2006, the number of 
drug candidates in phase II or later stages increased by nine per cent (from 102 to Ill), while the 
number of indications increased by 22 per cent (from 156 to 190) (Nagle, Nicita, Gerdes, & 
Schnneichel 2008). 
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These III biological drug candidates in 2006 were developed for 190 indications associated with 
38 disease categories. Cancer is the largest disease category: 43 biophannaceuticals (39 per cent of 
pipeline drugs) targeted 83 cancer indications (44 per cent of pipeline indications), which included 
primary therapy and supportive care for cancer; while in 2003, there were 30 cancer related 
biopharmaceutical drug candidates (29 per cent of pipeline agents) in phase II or later stage 
development targeted for 62 cancer indications (40 per cent of pipeline indications) (Nagle, Nicita, 
Gerdes, & Schnneichel 2008). This suggested that more and more drugs are developed for cancers. 
In terms of marketed drugs, most biophannaceutical blockbuster drugs in 2006 were also cancer or 
cancer-supporting products, while in the early 1980s blockbusters were mainly protein replacement 
therapies, e.g. Amgen's Epogen and Neupogen (filgrastim) prescribed for neutropenia (Lawrence 
2007). 
Immune-mediated inflammatory disorders are the second largest disease category, and more than 
20 per cent of drug candidates targeted these inflammatory diseases. Examples include rheumatoid 
arthritis, Crohn's disease, ulcerative colitis, psoriasis, type I diabetes melIitus, and 
multiplesclerosis (Nagle, Nicita, Gerdes, & Schnneichel 2008). Their results were very similar to 
the results of this study. Nagle also suggested the gap between cancer and other disease targets in 
the pipeline is widening. 
Research output can also be measured by scientific publications and patents (Rodriguez et al. 
2007). Deeds, DeCarolis, & Coombs observed that there is a strong positive relationship "between 
the impact-as measured by citations-<>fa team's prior research in the academic community and 
the productivity of that team in a commercial research laboratory" (Deeds, DeCarolis, & Coombs 
2000, P212). In the United States, while large firms often produce a larger number of patents per 
finn, the patenting rate for small firms is typically higher than that for large finns when measured 
on a per-employee basis (Audretsch 2002). Moreover, the breadth of patent protection significantly 
affects valuations (Lerner 1994). MacPherson & Boasson investigated the spatial distribution of 
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patent activity among publicly traded companies in the U.S. pharmaceutical industry and suggest 
that "patent counts respond positively to the degree of spatially concentrated production (density of 
competition)" (MacPherson & Boasson 2004, P319). 
Grabowski & Vernon have published a large number of studies on the topic of cost and returns. 
They investigated 100 new drugs launched in the US during the I 970s, and found that the return in 
R&D for the average new drugs was approximately equal to 9 percent industry cost of capital 
(Grabowski & Vernon 1990). They also investigated the returns to pharmaceutical research and 
development in the US (1980 -1984), and their findings indicated that the distribution of sales 
revenues for new drug was highly sloped, with the top deciles of new drugs accounting for more 
than half of the total sales (Grabowski & Vernon 2000). One of their later studies on returns for 
new drug introduced in the I 990s gave a similar conclusion (Grabowski, Vernon, & Dimasi 2002). 
More recently, Grabowski has suggested that the pharmaceutical industry was experiencing a 
transition period characterized with higher cost of innovation with fewer new drugs (Grabowski 
2004). 
Dimasi et al. surveyed 12 US pharmaceutical companies and found that average out-of-pocket 
costs per approved new chemical entity (NCE) was $ 114 million (dollars value of 1987), and 
average out-of-pocket costs to the point of marketing approval was $ 231 million (dollars value of 
1987) (Dimasi et al. 1991). In their later study, the average out-of-pocket costs per new drug was 
$ 403 million (dollars value of 2000), and average out-of-pocket costs to the point of marketing 
approval was $ 802 million (dollars value of 2000) (Dimasi, Hansen, & Grabowski 2003). These 
results indicate that bringing a drug to market is a very expensive process. 
Cohen & Levinthal suggest that a firm's R&D activity not only generate new knowledge, but also 
contributes to a company's absorptive capacity (Cohen & Levinthal 1990). Absorptive capacity is 
defined as ''the ability of a firm to recognize the value of new, external information, assimilate it, 
and apply it to commercial ends is critical to its innovative capabilities" and it is "a function of the 
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firms prior knowledge" (Cohen & Levinthal 1990, PI28). Knowledge base and internal R&D 
structure positively influence a company's absorptive capacity (Zhang, Baden-FulIer, & 
Mangematin 2007). Small finns mainly focused on discovery; and large firms, focused on both 
discovery and development (Mc Namara & Baden-Fuller 2007). 
Besides internal R&D, outsourcing of R&D is also very important for a company's growth. There 
are two types of factors influencing the outsourcing of R&D activities: factors which initiate the 
outsourcing R&D activity, and framing factors, which shape the outsourcing R&D activities; 
furthermore the framing factors are divided into implementation factors which occurred during the 
operation of outsourcing R&D, and outcome factors which determine the performance of alliances 
(Howells, Gagliardi, & Malik 2008). 
Howells, Gagliardi, & Malik observed that the major reasons for external outsourcing of R&D are 
access to necessary expertise which is not available in-house, reducing development time and time 
to market, and reducing development cost (Howells, Gagliardi, & Malik 2008). Moreover, firms 
experiencing declines in internal productivity tend to outsource R&D, in particular, acquiring 
pipeline drugs (Higgins & Rodriguez 2006). The key criteria for compannies selecting R&D 
partners include research and technical capabilities, ability to get the project done on time and their 
flexibility (Howells, Gagliardi, & Malik 2008). The barriers for formation of R&D alliances 
include confidence in a partner's ability, concern about the potential leak of key 
knowledge/intellectual property, and concern that the partnered research/technology is too central 
to finn's competitive advantage (Howells, Gagliardi, & Malik 2008). 
Studies of company innovation strategies suggest that internal R&D and external knowledge 
acquisition are complementary activities, because both internal R&D and outsourcing R&D are 
important path for companies obtain knowledge and technologies (Cassiman & Veugelers 2006). A 
fast product development rate will enable companies "to gain early cash flow for greater financial 
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independence, to gain external visibility and legitimacy as soon as possible, to gain early market 
share, and to increase the likelihood of survival" (Schoonhoven, Eisenhardt, & Lyman 1990, PI77). 
In short, both internal R&D and outsourcing of R&D contributed to a company's competency and 
capacity. In the past decades, the drug innovation in the US, in particular, biological drugs 
innovation, grow very fast in the last decades. At the same time, discovery and development cost 
are also increased dramatically. How has the British drug discovery and development sector 
generated knowledge since 1980s? What format of knowledge has it generated? How has 
networking influenced that knowledge production? 
2.2.6 Firm governance and strategy 
Dimasi suggests that besides factors such as cost of R&D trends, scientific opportunity, 
regulations and technology spill over, which have an impact on innovation of all pharmaceutical 
and biotechnology firms, firm specific factors, such as "individual organizational structures and 
how effectively a firm reacts to changes in its environment" should also be studied to give a 
comprehensive view of this industry (Dimasi 2000, PI 192). 
The large biotechnology companies and new established companies adopted different strategies 
mainly because they have different development histories, resources and knowledge bases (Senker 
1996). Hall & Bagchi-Sen suggests that biotechnology firms along with other more R&D intensive 
companies tend to adopt research focused strategies such as strengthening their own research 
capabilities, entering into research collaborations with universities, industry leaders and other 
biotech firms, and licensing their technology; while less R&D intensive companies tend to adopt 
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production based strategies such as gaining market access, maintaining connections with customers, 
and building their research base (Hall & Bagchi-Sen 2007). 
As Koza & Lewin suggested, a company's alliances are also part of a company's strategy, and 
most importantly, they co-evolve with the company's strategy, as well as the institutional, 
organizational, and competitive environments (Koza & Lewin 1998). However, Koza & Lewin did 
not provide further evidence for the framework they proposed. 
Dyer & Singh suggest four potential sources of inter-organizational competitive advantage: 
relation-specific assets, knowledge sharing routines, complementary resources and capabilities, and 
effective governance (Dyer & Singh 1998). The leadership a high technology firm needs is related 
to who has experience in R&D, but which is separate from the scientific team (Deeds, DeCarolis, 
& Coombs 2000). The practices of knowledge management vary among firms, because of the 
different organizational settings, technology domains and new product development (Ding & 
Peters 2000). Biotechnology start-ups may choose locations to access technologies advances 
developed by universities and public institutions (Audretsch, Lehmann, & Warning 2005). 
Furthermore, the prime locations for biotechnology startups would be expanding areas rather than 
established locations (Deeds, DeCarolis, & Coombs 2000). Arora & Ceccagnoli found that when 
effectiveness of patent protection increased, firms are more likely to patent; compared with firms 
lacking specialized complementary assets, firms have specialized complementary assets are more 
reluctantly to licensing (Arora & Ceccagnoli 2006). 
In short, in order to survive and grow, high-tech firms tend to adopt different strategies to access 
knowledge, develop novel technologies and build competitive advantages. This study will try to 
provide evidence of the co-evolution of companies' strategy and networking, and the co-evolution 
of companies' strategy and their position in industry. 
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2.2.7 Policies and regulations 
Innovation in policy making is closely connected to innovation in theory development, as 
suggested by the Biopolis Final Report. Policy making before the I 990s - first generation policy -
was based on the linear model of innovation. The emphasis was on encouraging applicable basic 
research and knowledge diffusion "along the innovation chain", its primary aim being to 
"compensate for so called market failures" (Enzing et al. 2007, P21). 
Since the 1990s, when ''the non-linear model and more interactive nature of innovation processes 
were recognized", the systematic approach was adopted in policy making, and its primary aim was 
to compensate for systemic failures, such as "inadequate framework conditions and infrastructure 
provision, or network and capability failures" (Enzing et at. 2007, P21). The primary activity of 
second generation policy making is to analyse systematic deficiency, or "bottleneck analyses" 
(Arnold 2004). Therefore, changes in policy making approach are the result of interactions 
between actors of innovation systems, i.e. policy makers, academics and firms. 
Reiss et al. proposed four areas that should be continuously supported by policies: 
I) The generation and maintenance of a suitable knowledge base for biotechnology and 
the availability of qualified human resources; 
2) The transmission of biotechnological knowledge from the sites of its generation to 
possible loci of application; 
3) The full integration of biotechnology into economic sectors via the successful 
introduction of biotechnology-based products into the markets; 
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4) The industrial development of the biotechnology sector including small and medium-
sized enterprises and larger firms. 
(Reiss et al. 2005, http://www.isi.thg.deltlprojekte/innopol-e-rt-policy-bench.htm) 
Comparing UK policy between 1994-98 and 2002-05, the four areas proposed by Reiss et al. were 
all covered. either by generic policy or biotech-specific policies (D'Este, Senker, & Costa 2007). 
Another major change is that new actors influenced innovation policy making. Since 1994 regions 
have been participating in policy-making for biotechnology: between 1994 and 1998, some local 
governments were active in supporting local university research and economic development, and 
later between 2002 and 2005, local governments were very active in biotech-policy making, e.g. 
commercialization of basic research and support SMEs (Enzing et a!. 2007, PI7). However, 
funding from the government at the national level accounted for the majority of the total policy-
directed grants. Take biotech-specific research funding for example, during the period 2002-2005, 
there were 539.4 million Euro funds from national governments and 45.9 million Euro funds from 
regional governments. Another example is biotech-specific commercialization funding of the same 
period. in which there were 108.1 million Euro from national governments and 2.5 million Euro 
from regional governments (D'Este, Senker, & Costa 2007). Currently there are two ways to grant 
funding: funds are granted by government through a competitive and peer-reviewed process, or 
through the allocation of block grants given to universities and research institutes (D'Este, Senker, 
& Costa 2007; Enzing et al. 2(07). 
The funding of basic research has profound impacts on innovation performance. Bruno et al. 
suggested that the supply side is more important than demand side in biotechnology innovation, i.e. 
the driving force of biotechnology innovation was research capacity, therefore, it is important to 
fund the research base of biotechnology and give researchers market advice at the same time 
(Bruno, Miedzinski, Reid. & Ruiz Yaniz 2008). Patel, Paunov, & Arundel argued that public 
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expenditures on biotechnology R&D were not directly connected with performance of 
commercialization and output indicators, but indirectly influence these performance via training 
highly skilled postgraduates, however, they also admitted the long R&D process was not 
considered in their research, and analyzing the R&D expenditure and output of the same periods 
may not map the real picture (Patel, Paunov, & Arundel 2008). 
The structure of policy making also has impacts on the performance of innovation systems. The 
Biopolis Final Report analyzed 18 national policy making systems of 18 European countries 
(Switzerland, Denmark, Sweden, Finland, Austria, UK, Belgium, the Netherlands, Ireland, 
Germany, Norway, France, Italy, Spain, Greece, Luxembourg, Portugal and Iceland), and 
suggested that the countries with "convergent innovation systems, with high interactions amongst a 
large diversity of actors and concentrated decision making processes with ex ante coordination" 
had better performance than other countries (Enzing, Giessen, Van der Molen, Manicad, Reiss, 
Lindner, Lacasa, Senker, Rafols, D'Este Cukierman, & Costa 2007, PI6). 
Since there are more actors involved in the policy making process, it is recommended that the 
national government of European countries should avoid coordination gaps (Enzing et a!. 2007, 
PI7). 
" ... it is highly recommended that national governments close the 'coordination gap'; not 
only between national departments, but also between national and regional governments 
and international institutions. This involves co-ordination of simultaneous policy actions 
addresSing the core set of innovation policies such as science, technology and education, 
as well as a re-direction of policy actions that pursue other primary objectives such as 
public health and regional development. " 
(Enzing et a1. 2007, PI7) 
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Moreover, innovation speed and direction are also influenced by public attitudes, e.g. there are 
public debates on "manipulation of human cells and embryos for pharmaceutical research, and 
human and animal cloning" (patel, Paunov, & Arundel 2008, P6). Therefore, the interactions and 
communications between public, policy makers, researchers and firms are very important to the 
innovation process. Researchers argue that policy makers should emphasise the risk factors of 
biotechnology innovation, and improve the "combination of strategic management and scientific 
knowledge" (Bruno, Miedzinski, Reid, & Ruiz Yaniz 2008, P43). In this study, policy implications 
will be discussed based on the empirical data collected from the drug discovery and development 
sector. 
2.3 Summary 
This chapter started with the two different observations of the biopharmaceutical industry, and 
generated two research questions that reflect the core elements of the Sectoral Systems of 
Innovation. 
As a highly R&D intensive sector, the drug discovery and development companies' major 
activities are directly or indirectly related to the competition of knowledge exploration and 
knowledge acquisition. For example, biopharmaceutical companies tend to cluster in locations near 
universities, research hospitals and research institutes. The formation of clusters are the result of a 
combination of local factors or driven by policies (Chiaroni & Chiesa 2006). These key factors 
include collaboration with local research institutes and universities and financial support from local 
venture capitalists. Clustering also attracts foreign companies and large pharmaceutical companies 
to forge downstream alliances with these companies. To what extent a company could benefit from 
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clustering is detennined by many factors, e.g. the nature of clustering, company size, the 
company's products and services and management experiences. The US and EU pharmaceutical 
and biotechnology industry has been growing very fast in the past two decades. The structure of 
the pharmaceutical and biotechnology industry is hierarchical. It is dominated by several well 
established companies, but there are also a large number of small to medium sized firms. These 
companies adopted different strategies due to their available resources, knowledge base and 
histories. 
The pharmaceutical and biotechnology industry is characterized by extensive alliances and 
networking, in particular, networking and alliances are important for small ftnns to survive and 
grow. As an R&D intensive industry, internal R&D and R&D outsourcing are both important for 
companies. Literature on alliances and networking are mainly focused on the driving forces of 
alliance fonnation, perfonnance and factors influencing alliances. Market uncertainty and ftnn 
speciftc uncertainty are detenninants in biotechnology ftnns' strategies in fonning alliances 
(Beckman, Haunschild, & Phillips 2004). Number of alliances is connected with ftnns' rate of drug 
innovation (Deeds & Hill 1996) and stages of product development (Danzon, Nicholson, & Pereira 
2005). To what extent companies could benefit from alliances detennined by their competencies 
(Arora & Gambardella 1994), their role played in alliances (Rothaennel 2001), and financial 
conditions (Lerner & Merges 1998). 
However, from a perspective of Sectoral Systems of Innovation, it is still not clear how alliances 
change when industry evolves. Considering the pharmaceutical and biotechnology industry as a 
Sectoral System of Innovation, this study will examine the emergence of new actors in this system 
of innovation, those being the drug discovery and development companies established after the 
1980s, when biotechnology first started to be applied to the drug innovation process. To what 
extent the emergence of the UK drug discovery and development companies established after the 
1980s contributed to the sectoral systems of pharmaceutical and biotechnology innovation, in 
tenns of knowledge production and technology, is the central question. How have these companies' 
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strategies developed? How do they aIly with other actors of this system? Who benefits from the 
emergence of UK drug discovery and development companies and the networks associated with 
them? 
In response to these questions, this study examines the subsector's structure, the size and age of 
firms, their clustering and concentration. In addition, it also investigates the knowledge production 
of the drug discovery and development subsector. It not only examines their R&D expenditures 
and product pipelines, but also focuses on their small scale contributions i.e. scientific publications 
and patents. This study also pays attention to the alliances of the drug discovery and development 
subsector, in particular, the number of alliances, the purpose alIiances, technologies, disease 
indications, and partners. From a perspective of dynamics, this study examines how alliances 
changed over time. Details of methodology and research design wiIl be discussed in the next 
chapter. 
Chapter Three: Research Design and Methods 
3.1. Introduction 
This chapter aims to discuss the research design and methods applied in this study. This study 
began with mapping the UK pharmaceutical and biotechnology industry, where the drug discovery 
and development sector is embedded, followed by an overview of the drug discovery and 
development sector. 
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The main data sets were used to describe and analyse this sector's R&D and alliance activities. 
There are three groups of indicators that are widely used in analysing science, technology and 
innovation (STI): R&D expenditures and sales; patent applications, grants and citations; and 
scientific publications and citations (Smith 2005b). These three groups of indicators will be 
covered in this study. Considering the accessibility of data sources and availability of data, R&D 
expenditures and sales, scientific publications and citations, and patent applications will be used as 
major indicators of innovation. In addition, the less standardized indicators, drugs and pipeline 
drugs, will also be used as supplementary indicators to measure the output of the drug discovery 
and development sector. Alliance agreements were used to analyse the collaborations and 
networking of this sector. 
This broad design of methodology was chosen because this study intended to examine the best 
available indicators for the knowledge produced by this subsector and industry dynamics. The 
reason for not chose interview company managers is that this study aimed to objectively describe 
this subsector and measure its output. 
This chapter will begin with introducing the data sources of this study: qualitative and quantitative 
information on the drug discovery and development subs ector was collected from various data 
sources, including government databases, commercial databases, scientific search engines, 
websites of industry associations, and the websites of individual companies. The next section will 
introduce the measurement and indicators chosen to describe the sectoral structure, innovation and 
alliance activities. The following section will discuss the sample selection criteria and the 
boundaries of this research: how the company list was identified and what data would be included 
in this study. In the next section, how the research design has been evolved will be presented, from 
a pilot study to the main research stages. Then methods and tools used in data analysis will be 
introduced. The limitations of this study will be discussed in the next section, followed by a 
summary of this chapter. 
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There were no ethical concerns about commercial confidentiality because data used in this study 
did not include interview with companies, and all data is publicly available. 
3.2. Data Sources 
3.2.1. Biotechnology Company Compendium: 2003/2004 
BioCommerce Data Ltd. published an industry directory of the biotechnology industry: 
Biotechnology Company Compendium 200312004 UK (BioCommerce Data 2003), whose data was 
mainly collected from a survey of companies. Different from the definition of biotechnology 
introduced in the Introduction Chapter, the Biotechnology Company Compendium 200312004 
adopted a very broad definition of biotechnology, which also included companies focused on 
traditional chemical technologies. 
The main body of the phannaceutical and biotechnology companies list was identified from this 
book. Major categories included biomaterial, chip arrays, diagnostic, drug delivery, drug discovery 
and development, equipment and reagents, non-drug product development, sequencing, software 
and I.T., and support services. 
However, considering its methods and publication date, information from this book was not 
enough to create a comprehensive list of the pharmaceutical and biotechnology industry to fulfill 
this study. Therefore, other sources were accessed to complete the industry list. 
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3.2.2. Websltes of Industry Associations 
In order to product a comprehensive list of the pharmaceutical and biotechnology companies, two 
major associations' websites were accessed. 
The Bioindustry Association (BIA), which was established in 1989, is a trade association for 
innovative enterprises in the UK's bioscience sector Cwww.bioindustrv.org). Their websites 
provided a list of over 300 members, including companies, organizations and public research 
institutions. This member list provided very valuable information of companies that were not 
included in the Biotechnology Company Compendium 200312004, in particular, those small 
companies established after 2003. 
The Association of the British Pharmaceutical Industry (ABPI) is a trade association of companies 
in the UK producing prescription medicines (www.abpi.org.uk). Their websites provide a list of 
memberships, which mainly included well established pharmaceutical companies. Their web sites 
also provided very useful statistics of these integrated pharmaceutical companies. 
Based on these data, a preliminary list of pharmaceutical and biotechnology industry was generated, 
which included all pharmaceutical and biotechnology companies that appearing in these resources. 
Further resources were accessed to validate the information on these companies. 
3.2.3. Company House, London Stock Exchange, Websltes of Individual 
Companies and Internet Archive 
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Companies on the preliminary list of the pharmaceutical and biotechnology industry were checked 
and validated on the Company House website (www.companieshouse.gov.uk), the London Stock 
Exchange website (www.londonstockexchange.com). websites of individual companies and the 
Internet Archive (www.archive.org). 
Company House is an executive agency ofthe Department for Business, Enterprise and Regulatory 
Reform (BERR). Their functions include storing company information and making this 
information available to the public (www.companieshouse.gov.uk). 
London Stock Exchange (www.londonstockexchange.com) provides detailed information and 
news releases on these companies which trade on the main market and alternative investment 
market (AIMt, This information and related news releases include companies' profiles, trading 
history and annual reports. 
Individual company's website provided information on each company's history, structure, current 
activities, contacts and archives of their news releases. Individual company's website was not only 
used to check and validate the basic information, but also provided very valuable information on 
their drug, pipeline and alliances. 
However, there were circumstances in which companies' websites were under maintenance, or 
removed because of merger and acquisitions. In these cases, the Internet Archive 
(www.archive.org) was used to retrieve companies' online information. Internet Archive is a non-
profit organization, which preserves web sites of different periods and provides valuable historical 
information which is not available at present. 
4 AIM is the London Stock Exchange's international market for smaller growing companies 
(www.londonstockexchange.com). 
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According to the criteria which will be discussed in a later section, a final list of 604 
pharmaceutical and biotechnology companies were identified after validating the preliminary list 
and a list of 81 drug discovery and development companies was also generated. These companies' 
basic information were recorded and analysed. After identifYing this list of drug discovery and 
development companies, details of these companies' activities, e.g. R&D expenditure and income, 
marketed drugs and pipeline drugs, scientific publications, patent publications and alliances 
agreements, were collected from several different databases. 
3.2.4. R&D Scoreboard Published by UK Government 
R&D Scoreboard is an annual UK government publication of top companies investing in R&D. It 
was firstly published in the 1990s by the Department of Trade and Industry (DTI). After the DTI 
was spilt on 28 June 2007 into the Department for Business, Enterprise and Regulatory Reform 
(BERR) and the Department for Innovation, Universities and Skills (OIUS), the R&D Scoreboard 
2007 was co-published by DIUS and BERR. 
The R&D Scoreboard series publications provide information on top UK companies R&D input 
and output: their R&D investment and income, which were collected from the audited annual 
reports and accounts of companies. This data was also accessible online (www.innovation.gov.uk). 
The data collection and analysis procedure of R&D Scoreboard series publications followed the 
Frascati Manual published by the OEeD (OEeD 2002). The Frascat; Manual was first published 
in 1963 and aims to provide a guideline for practicing surveys of R&D, and the current version is 
the sixth edition published in 2002 (OEeD 2002). 
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The limitation of the R&D Scoreboard series publications was that they did not provide 
information on small companies, and these small companies R&D information was also difficult to 
obtain from other sources. Therefore companies' R&D expenditure and income analysis of this 
study were focused on major drug discovery and development companies. 
3.2.5. Recombinant Capital Database 
Information on alliance, drugs on the market and pipeline drugs was partly obtained from 
companies' websites, and partly obtained from the Recombinant Capital (Recap) database. Recap 
is a consulting firm established in 1988 and based in San Francisco, providing a comprehensive 
archives of pharmaceutical and biotechnology alliances agreements (www.recap.com). All the 
pharmaceutical and biotechnology agreement held by the U. S. Securities and Exchange 
Commission (SEC) are available in Recap's database. Their other resources include biotechnology 
and pharmaceutical company press releases, company presentations made at investment 
conferences and other public meetings. Each agreement gives information on the R&D provider, 
client, country of companies, technology, alliance stage, indication and size. 
The Recap database also provided information on pipeline drugs, in particular, drug candidates in 
clinical trials. 
The limitation of the Recap database was that as a US based database, their information about the 
UK pharmaceutical and biotechnology industry was not comprehensive, therefore, data on 
alliances, drugs and pipeline drugs was also obtained from each company's website. Data from 
both sources were triangulated with each other. 
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3.2.6. Database of Science Citation Index Expanded 
The drug discovery and development sector's scientific publication and citation data were collected 
from the Science Citation Index (SCI) Expanded published by Thomson Reuters 
(http://isiwebotknowledge.com).SCIExpanded coved 6934 scientific journals published world 
wide and tracked back to 1900. Only research articles, reviews and letters were studied in this 
project, this is because research articles and reviews are usually peer reviewed (Lopez-Illescas, de 
Moya-Anegon, & Moed 2008;Moed 2008). Although letters may include peer reviewed letters and 
normal correspondence (Lopez-Illescas, de Moya-Anegon, & Moed 2008), they were considered in 
this research because letters are an important contribution from companies. Publications from 1982 
(the year of first paper published by any company identified in this study) to 2006 were included. 
Citation data were expanded to 2008, which allowed the papers published in 2005 and 2006 to be 
fully cited and calculated. 
3.2.7. Europe's Network of Patent Databases (esp@cenet) 
The data on patent publication analysed in this study were obtained from the European Patent 
Office (EPa) website, which provides a database (esp@cenet) of comprehensive patent 
publications from the 19th century to date. The online database esp@cenet 
Ortt.P://gb.espacenet.com) not only provides patent information on European countries, but also 
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documents at a worldwide level. The limitation of esp@cenet database was that abstracts were not 
available for some of the patent publications. 
3.3. Measurements and Indicators 
In order to answer the research questions proposed at the beginning of this thesis, this study will 
measure and describe the industry and sectoral structure, R&D activities and alliances activities. 
Considering the accessibility of data sources and availability of data, R&D expenditures and sales, 
scientific publications and citations, and patent applications will be used as major indicators of 
innovation. The main reason for their wide use is that these indicators are able to capture small 
scale changes in science, technology and innovation (Smith 2005b). In addition, the less 
standardized, but very important indicator- drugs on the market and pipeline drugs, which refer to 
the new product underdevelopment, will also be used as a supplementary indicator to measure the 
output of drug discovery and development sector. 
In this section, indicators and measurements used in this study will be introduced and how these 
indicators were reviewed and used by other researchers will also be discussed. The coverage of 
indicators includes industry structure, R&D investment, scientific publications, patent publications, 
and a\liances. Moreover, the advantage and limitations of these indicators and measurements will 
also be addressed. 
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3.3.1. Industry and sectoral background 
To provide a background on how the drug discovery and development subsector evolved, the 
pharmaceutical and biotechnology industry where the drug discovery and development subsector is 
embedded were described first, followed by an introduction of the structure of the drug discovery 
and development subsector. The background discussion was used to facilitate an understanding of 
the dynamics and evolution of the drug discovery and development subsector. 
As discussed in the literature review chapter, companies' locations, ages, sizes, products and 
services are all important factors, which have a combined impact on the industry and subsector. 
Therefore, information on 604 pharmaceutical and biotechnology companies' size, location, age, 
products and services was collected and analysed. Furthermore, similar information on 81 
companies which focused on drug discovery and development were analysed. 
3.3.2. R&D Investment, sale and R&D Intensity 
Three economic measurements of R&D were used in this study: R&D investment, sales and R&D 
intensity. According to the DTI, the "R&D investment" in these publications is defined as "the 
cash investment which is funded by the companies themselves: excludes R&D undertaken under 
contract for customers such as governments or other companies; and also excludes the companies' 
share of any associated company or joint venture R&D investment" (DTI 2002;DTI 2003;DTI 
2004;DTI 2005;DTI 2006b). "Sales" is defined as the "total (operating) income" {DTI 2002;DTI 
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2003;DTI 2004;DTI 2005;DTI 2006b). R&D intensity is defined as the ratio of expenditures by a 
finn on research and development to the firm's sales (Smith 2005b). 
R&D expenditure as a measurement was firstly available in the 1950s, and it is still one of the most 
popular innovation indicators (Kleinknecht, Van Montfort, & Brouwer 2002). The advantages of 
using R&D expenditure as an innovation measurement were that it could be collected and 
compared across time, countries and industries (Kleinknecht, Van Montfort, & Brouwer 
2002;Smith 2005b). The disadvantages are that "standard R&D surveys tend to severely 
underestimate the small scale and often informal R&D activities in smaller firms" (Kleinknecht, 
Van Montfort, & Brouwer 2002, PIlI), which is a) so a limitation of this study. 
The DTI started to use R&D intensity as an innovation indicator since its 2001 R&D Scoreboard. 
R&D intensity or R&D input/output ratios have been used to categorise countries, sectors and 
organizations, e.g. an industry with a high ratio is normally classified as a high technology industry 
(5 per cent), and an industry with a low ratio «1 per cent) is regarded as a low technology industry 
(Smith 2005b). Many studies have observed that there are regular patterns in the distribution of 
R&D intensity within any given indUStry, therefore to use R&D intensity to classify industries is 
problematic, because a high tech industry may also contain low R&D intensity firms (Cohen & 
Klepper 1992;Hughes 1988). Based on this characteristic intra-industry distribution of R&D 
intensity, this study classified the firms into different groups according to their R&D intensity, and 
made efforts to describe these different groups. 
3.3.3. ScIentific publications 
98 
The number of publications was used in this study to evaluate the productivity of the UK drug 
discovery and development subsector. The focus of company research was investigated by 
counting keyword frequency. The country of authors was studied to figure out the UK's partners in 
co-publishing. Countries of authors were analysed to indentify the most competitive region of the 
industry in terms ofpubJishing. 
In addition, the source of publications and references was investigated to map the publishing 
pattern of the drug discovery and development subs ector, and how their research has influenced 
other publications. The indicators used to measure the publication source and citing source were 
similar, both including the subject of journal, country of journal and the number of publications or 
references. 
In this study, the popular indicator Journal Impact factor was not used. The reason for this is that 
Journal Impact factor was calculated on a three yearly basis. However, the coverage of this 
research is 25 years. Therefore it is not very accurate to describe the impact of a journal over this 
long time period. Moreover, Journal Impact factor could only evaluate the impact of certain 
journals; it does not necessarily correlate with the impact of an individual article published in that 
journal. 
In order to measure the impact of companies' publications, total counts of citations and the h-index 
were adopted in this project. The presumption is that "a paper must have a certain quality in order 
to have an impact on the scientific community" (Okubo 1997, p.25). 
The h-index was proposed by Hirsh in 2005, and it is defined "as the number of papers with 
citation number >h" (Hirsch 2005,p.16569). It was quickly adopted by many researchers and the 
Web of knowledge started to used the h-index in their citation report (Bommann, Mutz, & Daniel 
2(08). The h-index was firstly used to measure the output of individual scientists, but was later 
used to evaluate "departments, institutions, or laboratories. The importance of the h-index can be 
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further enhanced when it is properly calibrated for the size of the group" (Kinney 2007p. 17943). In 
this study counts of citations and the h-index were used to evaluate the cumulative impact of the 
UK drug discovery and development companies' publications. 
It is important to note that these two indicators measured the cumulative impact of a company's 
pUblications. This factor should be taken into account because companies with a longer history 
may benefit from this measurement (Hirsch 2005). Moreover, these two indicators generally 
overlook the most influential publications (Hirsch 2005). For example, the total number of citation 
of A videx and Crusade Laboratories were 362 and 361 respectively, however, the most citied paper 
of Avidex had been cited 46 times, while that of Crusade Laboratories had been cited 197 times. 
Similarly, the h-index also overlooks the high-end of companies' publications, e.g. the h-index of 
Oxxon and Pharmagene were both 9, however, the most citied paper of Pharmagene had been cited 
68 times, while that of Oxxon had been cited 221 times. 
To solve the first problem, average citations per publication and average citations per year were 
adopted to evaluate the quality and impact of a company's research. In addition, the total citations 
of the most cited papers were counted in order to compare the high-end of a company's 
publications. 
Although the SCI citation database has been widely used by scholars, there are several limitations 
affecting the results of this study: firstly, it does not count citations in book and conference 
proceedings (Meho & Yang 2007). Secondly, it has citing errors "such as homonyms, synonyms, 
and inconsistency in the use of initials and in the spelling of non-English names (many of these 
errors, however, come from the primary documents themselves rather than being the result of 
faulty lSI indexing)"(Meho & Yang 2007,p.2105). In this study, because of the second limitation, 
3444 out of 79878 (4.9 per cent) references were discarded. Thirdly, self-citations were not 
eliminated from the citation analysis. Hirsch argues that the impact of self-citations on h-index is 
smaller than on the total counts of citations (Hirsch 2005). In this study, self-citations were 
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tolerated and considered. It is also important to note that some document types are cited more often 
than others, e.g. reviews are usually cited more often than research articles (Hirsch 2005). 
Moreover, some research fields have higher citation rates than other fields (Seglen 1997). 
3.3.4. Patent publications 
Two types of patent information could be used to describe the innovation activity of drug 
discovery and development firms: patent publications and granted patents. Patents are an indicator 
used to measure science and technology output. There are four principle knowledge indicators used 
by the OECD: R&D investment, employment of engineers and technical personnel, patents and 
international balance of payments for technology, and among these indicators, patents most 
directly measure knowledge output (OECD 1996). Publications of patents are applications under 
provisional protection, and could be easily browsed in the patent office database. There are two 
advantages of analyzing patent data, firstly they are available over a range of countries and years, 
and they contain details of knowledge formation, i.e. information on technology class, information 
on inventor and country of inventor (Hall 2008). Secondly, patents that cite other patents and 
non-patent documents provide information on knowledge diffusion (Hall 2008). 
Pavitt suggests that there are three sources of biases in granted patent counts (Pavitt 1988), and 
these biases are also applicable to patent publications. These three biases are on three different 
levels: country level, sector level and firm level. Firstly, there are different economic costs and 
benefits of patenting in different countries, e.g. time of examination, size of market and subject 
matter coverage (Pavitt 1988). For example, the United States Patent and Trademark Office 
(USPTO) processed patent applications faster than the European Patent Office (EPO) and Japan 
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Patent Office (JPO) (van Pottelsberghe & Francois 2006). Secondly, for different technologies and 
sectors, the importance of patents as protection against imitation is different (Pavitt 1988). Thirdly, 
the different strategies for innovation among firms also vary, e.g. filling innovation under different 
names (Pavitt 1988). 
Compared with analyzing granted patents, there are three advantages to analyzing patent 
publications. First of all, it is easier to access patent publications than granted patents via the 
European Patent Office database. Second, the time lag between application and patent publication 
is 18 months; this is much shorter than the 48 months from application to granting patents. The 
patent publication database will therefore provide more current information about firms' 
innovation actiVity. Third, the patent publications database will provide more comprehensive 
information on firms' research fields, because it includes all outputs with commercial potential, 
regardless of their originality. 
Compared with granted patent data, one disadvantage of using patent publications is that these 
patent publications were subjected to further examination which leads to further differentiation. 
Firstly, the substantive examination rates may vary. For USPTO, applicants do not need to send 
requests for substantive examination, while the EPO and JPO need a separate request. The 
examination rate of USPTO is 100 per cent, the examination rate of EPO is 87 per cent and only 54 
per cent for JPO (van Pottelsberghe & Francois 2006). Second, as discussed earlier, the rates of 
granting are also different between different offices. Therefore, the counts of patent publications 
are greater than the count of granted patents, while the general quality of patent publications is 
lower than granted patents. 
In short, both granted patents and patent publications have pros and cons as indicators. The patent 
publications were chosen as indicators because they were easier to collect and the information was 
more up to date. For each patent publication, the patent title, abstract, patent number, publication 
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date, inventors, applicants, European classification number and countries of inventors and 
applicants were collected. 
3.3.5. Alliances activities 
As discussed in the literature review chapter, collaborations and networking have been broadly 
studied by many researchers, and alliance agreements have been widely used in innovation studies 
(Arora & Gambardella 1994;Colombo 2003;Deeds & Hill 1999;Gerard et a!. 2001;Hynes & 
Mollenkopf 2008;Jeffi"ey & Maurizio 2005;Jones 1996;Lemer, Shane, & Tsai 2003;Reuer, Arino, 
& Mellewigt 2006;Smith 2005a;Staropoli 1998;Stuart, Ozdemir, & Ding 2007). In response to our 
research questions, agreements signed by drug discovery and development companies were 
collected, and details were recorded and analyzed, including signees, country of signees, date of 
agreements signed, disease indications, technologies, and stages of product development. 
The limitation of using alliance agreements was that it is difficult to know the status of 
collaboration. Moreover, it is also difficult to evaluate the performance of alliances. 
3.3.6. Drugs on the market and In development 
The marketed drugs and drugs in the development pipeline are very important indicators of the 
productivity of the pharmaceutical and biotechnology industry. Different from scientific 
publications and patent publications, which capture the small scale changes in science and 
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technology development, drugs and pipeline drugs are product innovations or potential product 
innovations. In particular, drugs and pipeline drugs in late stages have important implications to the 
innovation systems (Nagle, Nicita, Gerdes, & SchnneicheI2008;Nagle, Lugo, & Nicita 2003). 
However, because of the expensive and time consuming process of drug discovery and 
development, the majority of drug discovery and development companies investigated in this study 
do not have drugs on market. Although most of them have pipeline drugs, they may license these 
entities to other companies for royalties, or seIl them for cash. In these cases, these companies' 
capacity may be underestimated. On the other hand, a company having many pipeline drugs may 
not only represent its internal R&D capacity, but also many other competencies, e.g. its financial 
capacity if they acquired pipelines externally, and its experience of managing product development. 
Moreover, unlike scientific publications and patent publications which are available for public 
access, many companies are not willing to disclose detail of their pipeline drugs on their websites, 
and it is often hard to find out the stage of clinical development of if a product candidate has 
ceased development. 
Although drugs in development have many limitations as indicators to measure and compare 
individual firms, in this study they stiIl provided very useful information on the innovation 
activities of the whole subsector, e.g. the technology in use, disease indications, and stages of 
development. Drugs and pipeline drugs were analyzed in the background chapter to facilitate the 
understanding this subsector. 
3.4. Selection Criteria 
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This section will discuss the sample selection criteria and the boundaries of this research: how the 
companies list was identified and what data would be included in this study. 
3.4.1. Company selection 
UK Pharmaceutical and Biotechnology Company 
I) They must be a pharmaceutical or biotechnology (human medical related) companies 
2) Based in the UK (UK origin firms, foreign subsidiaries, new firm formed after 
merging with/acquired by other companies) 
3) Provide at least one of the following products or services: biomaterial, chip arrays, 
diagnostic, drug delivery, drug discovery and development, equipment and reagents, 
non-drug product development, sequencing, software and I.T., and support service. 
Drug dIscovery and Development Company 
1) Company's major activities / initial aims were drug discovery and development. Drug 
delivery, vaccine, antibody humanization and compound library were included. 
Companies which did not have clear product pipelines were included. However, their 
main activity should be in-house drug discovery or development. 
2) Companies only focusing on contact services were excluded from this study, e.g. Aeres 
biomedical, which provides antibody humanization service to other companies involved 
in product development 
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3) Based in the UK (UK origin firms, foreign subsidiaries, new firm formed after merging 
with/acquired by other companies).UK subsidiaries focusing on activities other than 
research were excluded. However, for UK research subsidiaries of foreign companies, 
they may be involved in research activities other than drug discovery and development. 
4) Established after 1977: after the creation of the ftrSt biotechnology firm -Genentech 
(United States). Data collected in this project covered until 0110112007. Therefore, 
company name and corporate structure referred to the company status on 01/0112007. 
Categorlzatlons of Drug discovery and Development Companies 
I) Group one: pure UK companies -- UK firms not involved in overseas expansion or 
acquisition (these companies may be involved in local merger and acquisitions) 
2) Group two: UK companies with foreign branches or which acquired foreign 
companies 
3) Group three: UK firms which were acquired by foreign small to medium sized 
companies 
4) Group four: UK firms which were acquired by large pharmaceutical companies 
5) Group five: Foreign subsidiaries in the UK 
Record of Company details 
I) Location: 
i. For firms in group one and two, locations were where the headquarters were 
located. 
II. For firms of group three and four, locations were where the original business was 
located. 
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iii. For finns of group five, locations were main UK research sites. 
2) Year of founded: 
i. For finns which was spun out from other firms, the year of founding was the 
year of forming the new business 
11. For firms which changed their names or were acquired by other firms, year of 
founding was that of the old business. 
111. For firms merged with or acquired by other firms, year founded was the founding 
year of the oldest business. 
3) Ownership refers to company ownership status in 2006. 
4) Country: for group two companies, countries of foreign branches were collected. For 
groups three, four and five, countries of foreign parent company were collected 
3.4.2. R&D expenditure 
I ) For UK companies which had foreign branches or acquired foreign companies, their R&D 
expenditure and sale were the figure of the UK headquarter. 
2) For foreign companies which have UK subsidiaries - their R&D expenditure and sale 
figure was for the UK subsidiaries. 
3.4.3. Scientific publications 
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I) At least one author was from a British company that had been identified as belonging to 
the drug discovery and development subsector (this included its domestic subsidiaries, 
laboratories, and UK. merger and acquisition). Because companies' name may be 
abbreviated when appearing in addresses, possible abbreviations were searched. Results 
were compared with companies' domestic addresses (and old domestic addresses if there 
were any), to eliminate any company with a similar name. This research was focused on 
UK. companies and their publications, therefore these companies' foreign subsidiaries 
were not considereds. 
2) Scientific papers published before 01/0112007. 
3) If the company was fonned by acquisition and merger of several companies, the number 
of SCI papers is the sum of papers published by all UK companies / branches. (These 
'old' companies which counted should be drug discovery and development companies 
and fulfil the basic criteria) 
4) SCI Publications types: articles, letters and reviews. 
3.4.4. Patent publicatIons 
I) Patents were counted only if one of the applicants/inventors was an employee of a UK 
branch or headquarter. 
2) Patents published before 0110112007. 
3) Patent publications data were collected from the database at worldwide level. The same 
patents which were published in different countries were counted as ONE patent 
publication. 
S Papers co-published by UK. companies and their foreign subsidiaries were included in this study. 
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4) Patents which belong to the same patent family, i.e. similar but slightly different patents 
(different patent number), were counted as individual patents in this study. 
5) If the company was fonned by acquisition and merger of several companies the number of 
patents is the sum of patents published by all UK companies 1 branches. (These 'old' 
companies which counted should be drug discovery and development companies and 
fulfil the basic criteria) 
3.4.5. Marketed drugs and drugs candidates 
I) Only clearly described product pipelines were recorded. Therefore, total number may be 
underestimated. 
2) For groups one, three and four, data may be missing after acquisition (underestimated). 
For group two companies, it is very difficult to identify where product are being 
developed, therefore, data may include several products developed overseas 
(overestimated). For group five companies, data was only available for a few companies. 
3.4.6. Alliance agreements 
I) Data covered the period from 01/01/1983 (first agreement in database) to 01/0112007 
2) For group one companies, data may be missing due to the size of companies. For group 
two companies, data may include several alliances signed by overseas subsidiaries 
(overestimated). For group three and four companies, data may be missing after 
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acquisition (underestimated). For group five companies, data was only available for a few 
companies which were managed separately from their parent companies. 
3.5. Research Stages 
3.5.1. Pilot study 
Based on the criteria discussed in previous sections, information on 128 drug discovery and 
development companies was collected and evaluated. There were very limited data on foreign 
companies' UK subsidiaries (group five). Data of companies which were acquired by foreign 
companies or by large pharmaceutical companies before 2004 were also largely unavailable (small 
fraction of group three and four). 
Therefore, from a pragmatic point of view, the companies list was further narrowed down. The 
redefined company list included pure UK origin companies (group one), UK origin companies with 
foreign branches or acquired foreign companies (group two), and UK origin companies which were 
acquired by foreign companies or by large pharmaceutical companies between 0110 I 12004 and 
01/01120076 (i.e. a fraction of group three and four). 
The rationale for including 'UK origin companies which were acquired by foreign companies or by 
large pharmaceutical companies between 2004 and 2006' was that: there is a time lag between 
patent applications and publications, scientific paper submission and acceptance, announcement of 
acquisition and completion of acquisition. The measurements of this study were still in effect 
6 This is cconsisted with the time scale of alliances data, SCI publication data and patent 
publication data. 
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within this three years window. Therefore, in practice, these companies could be roughly viewed as 
group one or two companies. 
Another pilot study was conducted to investigate problems that may occur in data collection and 
analysis. Take patent publication for example. 30 firms were randomly selected and their patent 
information was collected from the European Patent Office online database. In total data on 561 
patents was collected in the pilot study, and collated into an Excel datasheet. The first major 
problem was duplicate publications. In this study, patent publications data was collected from 
databases at worldwide level, therefore, one discovery or invention may have been published in 
different countries. The esp@cenet database provides a results list which eliminated duplicates in 
the first 500 search results, and after testing, in most cases, the results list were ready to use. 
However, patents which belonged to the same patent family, i.e. similar but slightly different 
patents, were counted as individual patents in this study, and could not be eliminated from the 
results. The second issue was that patent co-applicants or co-inventors were firms which both 
investigated in this study, therefore a patent may be counted twice. When searching patent 
applicants or inventors, these types of patents were identified to avoid putting them in the datasheet 
twice. Finally, the pilot study datasheet was designed and improved after preliminary analysis: the 
final version of the datasheet consisted of patent title, abstract, patent number, publication date, 
inventors, applicants, European classification number and countries of inventors and applicants. 
Similarly, pilot studies were also conducted for the other data sets to identify and solve problems 
that may occur in practice. 
3.5.2. Main research stages 
III 
Based on the pilot study, during the main research stages, several software and tools were used to 
facilitate the data processing. 
Data on publications and references were downloaded to a Microsoft Access database using 
bibliometric analysis software SITKIS (Schildt 2002), and analysed in SITKIS and Statistical 
Package for the Social Sciences (SPSS). Citation data were collected from SCI Expanded, which 
provides citation reports for a group of publications. The SCI Expanded citation report for each 
company's publications were collected and entered into Microsoft Excel spreadsheets. Query 
results for each company's publication in SCI Expanded Advanced Search were compared with 
publication data from each company to ensure the Citation Report included, and only included, the 
publications that fulfilled the criteria of this study. 
Based on the datasheet designed in the pilot study, a database of the patent publication information 
of the UK drug discovery and development firms was created. In total 2,827 patent publications 
from 81 British drug discovery and development firms between 1982 and 2006 were filed in the 
Microsoft Excel spreadsheets and analyzed. Patent analysis included year of publication, type of 
invention/discovery, countries of inventor/applicants, and research collaboration with other 
companies and institutes. Similarly, data on alliances agreements, marketed drugs and pipeline 
drugs, and R&D expenditures/sales were also recorded and analysed in Microsoft Excel 
spreadsheets. 
Data of alliances agreements were further imported to SocioMetrica VisuaLyzer 2.0 (Medical 
Decision Logic 2007). SocioMetrica VisuaLyzer 2.0 then transferred alliance agreements into 
graphically displayed networks, which illustrate how the drug discovery and development 
companies allied with other actors of the innovation systems. 
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3.6. Limitations of the Methods Used 
As discussed in previous sections, there are three limitations of this research, briefly speaking 
limitation of data sources, measurements and indicators, and research practice. Firstly, for the 
secondary data collected from the established databases, these databases have limitations in 
collecting, storing and distributing data. For examples, the Recap database is biased in collecting 
information on UK companies, the DTI innovation database is biased on collecting information of 
small companies, and the SCI Expanded is biased in collecting citation data from books and 
conference proceedings. Secondly, as discussed earlier, each measurement and indicator has 
limitations, e.g. alliance performance and consequent impact could not be evaluated from 
agreements, and commercial potential could not be precisely evaluate from patent publications. 
There are also time lags between submission and acceptance of scientific papers, and applications 
and the publication of patents. Thirdly, the limitations of research practice include availability of 
data, and the need to balance cost and effectiveness. 
Despite these limitations, there are several advantages of this study. Firstly, the data collected 
covered various sources, including government databases, scientific databases, commercial 
databases, industry associations and companies' websites. Secondly, data covered various aspects 
of the drug discovery and development subsector's R&D expenditure, drugs and pipeline drugs, 
scientific publications, patent publications, and their alliance agreements. Thirdly, according to the 
DTI R&D Scoreboard, the major actors in the UK drug discovery and development sectors were 
included in this study. Finally, this study also analyzed the background to the pharmaceutical and 
biotechnology industry, where the drug discovery and development subsector is embedded. This 
background analysis, together with the historical review of the industry, will facilitate the 
understanding of the drug discovery and development subsector. 
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In short, this chapter provides details of research design, data collection, criteria of company 
selection, the conduct of research and data analysis. The following chapter will present the 
background to the pharmaceutical and biotechnology industry in general, and to the drug discovery 
and development subsector in particular. 
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Chapter Four: Background 
This chapter aims to provide a background of drug discovery and development subsector: the 
pharmaceutical and biotechnology industry this subsector embedded, the nature of drug discovery 
and development subsector, the product produced and in development by these companies, and 
their R&D expenditures and sales. This chapter will plot this group of companies and provide a 
basic understanding of this study. 
The first section will focus on mapping the current British pharmaceutical and biotechnology 
industry, providing details about their activities, ages, and locations. This section will present an 
industrial background to the drug discovery and development subsector. 
The second section will provide an overview of the drug discovery and development subsector, 
more precisely, the drug discovery and development companies which were established after 
I 980s- when the biotechnological era began. This group of companies is the focus of this project: 
their activities of knowledge generation, knowledge transfer and knowledge diffusion will be 
discussed in the next three chapters. This section will pay attention to the extent of clustering and 
the age profile of the industry. 
The third section will provided account of marketed drugs and drugs in development of this 
subsector. These indicators provide very useful information on the R&D activities of the whole 
subsector, e.g. the technology in use, disease indications, and stages of development. 
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Other R&D indicators concerned in this chapter are R&D expenditure and R&D intensity. In the 
fourth section, the pattern of R&D expenditure and R&D intensity will be discussed. There will be 
a summary at the end of this chapter. 
4.1. Overview of the British Pharmaceutical and Biotechnology 
Industry 
In this project, 604 pharmaceutical and biotechnology companies have been investigated. Based on 
UK market share information (year 2004) published by the Association of the British 
Phannaceutical Industry (ABPI), these companies were categorized into two groups: large 
pharmaceutical companies (25, 4 per cent), and medium to small sized firms (579, 96 per cent). 
4.1.1. Large phannaceutlcal companies 
The 25 largest pharmaceutical companies accounted only for 4 per cent of total number of 
companies studied. however, their product sale was £ 7.9 billion, accounting for 66.8 per cent of 
the UK total market share in 2004 (Table 4) (ABPI 2008). Their primary care sales were £ 6.2 
billion in total, accounting for 68.1 per cent of the primary care market, and their hospital sales 
were £ 1. 8 billion, accounting for 62.7 per cent of the hospital care market. Pfizer had the largest 
share of primary care and total market share in the UK. and Roche had the largest share of hospital 
sales. 
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Twelve out of these 25 companies were American companies (48 per cent); three were German 
companies (12 per cent); and two (eight per cent) were from UK, France, Switzerland, Denmark 
and Japan respectively. 
Table 4 Market share of the 2S large pharmaceutical companies 
(ABPI2008) 
Ranking Corporation Country of Total market % share of 
origin sales £m total market 
I Pfizer USA 1273 10.7 
2 GlaxoSmithK.line UK 1065 9.0 
3 Sanofi A ventis France 755 6.4 
4 Wyeth USA 619 5.2 
5 Astrazeneca UK 591 5.0 
6 Novartis Switzerland 450 3.8 
7 Roche Switzerland 399 3.4 
8 Merck Sharp & Dohme USA 330 2.8 
9 Lilly USA 319 2.7 
10 Johnson & Johnson USA 284 2.4 
11 Boehringer Ingelheim Germany 241 2.0 
12 Novo Nordisk Denmark 183 1.5 
13 Abbott USA 174 1.5 
14 Schering Plough USA 153 1.3 
15 Bayer Germany 117 1.0 
16 Bristol-Myers Squibb USA 116 1.0 
17 Astellas Pharma Japan 110 0.9 
18 Ivax USA 108 0.9 
19 Servier France 105 0.9 
20 Schering Ag Germany 100 0.8 
21 Mundi International USA 93 0.8 
22 Procter & Gamble USA 91 0.8 
23 Eisai Japan 90 0.8 
24 Baxter USA 88 0.7 
25 Leo Pharma Denmark 76 0.6 
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The American companies' total UK market sale was £ 3,648 million, which accounted for 30.8 per 
cent of total UK market sales, followed by British companies (£ 1,656 million, 14 per cent), French 
companies (£ 860 million, 7.3 per cent), Swiss companies (£ 849 million, 7.2 per cent), Germany 
companies (£ 458 million, 3.8 per cent), Danish companies (£ 259 million, 2.1 per cent) and 
Japanese companies (£ 200 million, 1.7 per cent). 
The UK primary care market demonstrated the same pattern. The American companies' UK 
primary care market sales were £ 2,850 million, which accounted for 31.4 per cent of UK primary 
care market sale, followed by British companies (£ 1,387 million, 15.3 per cent), French 
companies (£ 684 million, 7.5 per cent), Swiss companies (£ 526 million, 5.8 per cent), German 
companies (£ 327 million, 3.6 per cent), Danish companies (£ 226 million, 2.5 per cent) and 
Japanese companies (£ 178 million, 2.0 per cent). 
The UK hospital market showed a different pattern, where Swiss companies performed second best 
to the American companies. The American companies' UK hospital market sales were £ 797 
million, which accounted for 28.6 per cent of UK hospital market sales, followed by Swiss 
companies (£ 322 million, 11.5 per cent), British companies (£ 269 million, 9.7 per cent), French 
companies (£ 176 million, 6.3 per cent), German companies (£ 132million, 4.6 per cent), Danish 
companies (£ 33 million, 1.2 per cent) and Japanese companies (£ 22 million, 0.8 per cent). 
In short, the largest pharmaceutical companies accounted for two thirds of total UK market sales, 
and large American companies, in particular, accounted for almost one third of the total UK market 
sales. 
4.1.2. Small to medium sized firms 
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Products and services 
In number, small to medium sized companies (579) accounted for 96 per cent of the industry. They 
were categorized into 10 groups according to their major products or services (based on the 
classification system developed by BioCommerce 2003/2004): these were biomaterial; chip arrays; 
diagnostic; drug delivery; drug discovery and development; equipment and reagents; non-drug 
product development; sequencing; software; and I.T. and support services. 
As shown in Chart 1, the equipment and reagents sector had the largest number of small to medium 
sized companies (226, 39 per cent), followed by the support services sector(129, 22 per cent), the 
drug discovery and development sector (128, 22 per cent), the diagnostics sector (46, 8 per cent), 
non-drug product development (20, per cent), software and I.T. (13, two per cent), drug delivery(6, 
one per cent), biomaterial(4, 0.7 per cent), chip arrays (4,0.7 per cent) and sequencing (3,0.5 per 
cent). 
250 
200 
150 
100 
50 
Cbart 1 Number of companies in each sector 
6 4 4 3 
o ~ ~ T - = = ~ ~ ~ ~ ~ = ; ~ = , - = = , - = = r - = ~ - - ~ ~
119 
A series of reports on the biotechnology industry were published by the DTI. They aimed to 
compare the performance of the biotechnological sector in different countries. They adopted a 
slightly different classification systems and definitions from this project (large pharmaceutical 
companies, equipment and reagents companies were excluded from their study). However, after 
converting data to the DTl's definition, their results were similar to this research. 
In their report, there were 382 UK companies in 2003 and 350 companies in 2004, whose "primary 
commercial activity depends on the application of biological organisms, systems or processes, or 
on the provision of specialist services to facilitate the understanding thereof' (DTI 2006a, P19). 
Excluding the equipment and reagents companies, the number of companies studied in this project 
was 353, which was similar to the DTI's results. 
Year founded 
Depending on the purpose of one's research, there are two ways to analyse the number of 
companies founded in each period. The first method is to collect historical information on the 
industry, and to compare the number of companies founded in different periods or different areas. 
However, it is very difficult to collect data on companies which are out of business. The second 
method, which was adopted in this project, is to collect information on existing companies from 
specified periods, and to map the industry by age groups. 
120 
L 
300 
250 
200 
150 
100 
50 
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As shown in Chart 2, 261 out of 575 (data of four companies were not available) small to medium 
sized companies (45 per cent) were founded during the 1990s. 29 per cent of the companies were 
founded 2000. The total number of companies founded after 1980 was 517, accounting for 90 per 
cent of all the small to medium sized firms. 
In the DTl's statistics, the age range was split into 5 groups: 0-2 years, 3-5 years, 6-10 years, 11-15 
years ad over 15 years. In 2003, 22 per cent of companies were aged between 0-2 years, 26 per 
cent were aged between 3-5 year, 24 per cent were aged between 6-10 years, 12 per cent were aged 
between 11-15 years, and 16 per cent were aged over 15 years (OTI 2006a). Based on the OTl's 
methods, 20 per cent of companies studied in this project were aged between 0-2 years, 27 per cent 
of companies were aged between 3-5 year, 21 per cent of companies were aged between 6-10 years, 
11 per cent of companies were aged between 11-15 years, and 21 per cent of companies were aged 
over 15 years. Compared with the OTl's statistics, the results were very similar and both indicated 
that there were fewer companies in the age group of 11-15 years than other groups. 
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Companies founded before the 1980s only accounted for 10 per cent of the total number of the 
whole industry. They were mainly equipment/device/reagents companies (41, 71 per cent), and 
support companies (II, 19 per cent). As shown in Chart 3, the equipment and reagents sector 
accounted for the largest percentage of the small to medium sized companies which were 
established during the 1980s and 1990s. From the 1980s until now, the numbers of surviving drug 
discovery and development companies and support services companies has been growing faster 
than other sectors. During 2000-2003, the number of new drug discovery and development 
companies was more than new companies of other sectors, followed closely by equipment and 
reagents, and support services. 
Chart 3 A comparison of companies founded in the 19808, 19908 and 2000-2003 
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One explanation for the fast growing number of these two sectors is that investors have been more 
and more interested in these two types of companies because both of them are working on the core 
products of the pharmaceutical and biotechnology industry. Drug discovery and development 
companies have their own product pipelines, which may lead to new drugs or intermediates; 
support services companies, of which the majority are contract research and clinical trial 
companies, are also indirectly involved in drug discovery and development. The large number of 
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equipment and reagents companies is not surprising: it is partially due to their close colIaboration 
with the large pharmaceutical companies, which provide a steady income stream. 
Locations 
There were 470 small to medium sized pharmaceutical and biotechnology companies located in 
England, 76 companies in Scotland, 26 in Wales and 7 in Northern Ireland. As shown in Table 5, 
Cambridgeshire (79, 17 per cent), London (39, eight per cent), Oxfordshire (37, eight per cent), 
Berkshire (29, five per cent) and Surrey (28, five per cent) have the largest number of companies. 
Cambridgeshire, in particular, had twice as many companies as London. The areas which had more 
than 20 pharmaceutical and biotechnological companies were all in southern England. As shown in 
Table 6, Glasgow (13, 17 per cent), Dundee (lO, 13 per cent) and Edinburgh (7, nine per cent) have 
the largest number of companies in Scotland. Cardiff (3, 12 per cent), Deeside (3, 12 per cent) and 
Swansea (3, 12 per cent) have the largest number of companies in Wales. 
Table S Number of companies in each County (England) 
Num. Nwn. of Num. of Nwn. of 
Area of com. Area com. Area com. Area com. 
Cambridaeshire 79 Lancashire 12 Leicestershire 6 Norfolk 2 
South 
London 39 West SU5SeX 12 Mersej'Side 5 Yorkshire 2 
OxfordJhire 37 West Yorkshire 10 N o t t i n ~ ~ 5 Cornwall 1 
Greater 
Berkshire 29 Manchester 9 Dorset 5 Cumbria 1 
Surrey 28 Middlesex 9 North Yorkshire 4 East Yorkshire 1 
B u c ~ i I l g l w n s h i r e e 24 West Midlands 9 Worcestershire 4 Shropshire 1 
H8IDIIShire 22 Gloustershire 8 Durham 3 Somerset 1 
Cheshire 19 Wiltshire 8 Staffordshire 3 Warwickshire 1 
Hertfordshire 17 Bedfordshire 7 ~ h i r e e 2 Northampshire 1 
Eaex 13 Suffolk 7 DevOll 2 
Kent 13 Tyne and Wear 7 East Sussex 2 
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Table 6 Number of companies in each county (Scotland) 
Number of Number of Number of 
Area CotnDaIlies Area Co11llllUlies Area Companies 
Glasgow 13 Livingston 2 East Lothian I 
Dundee 10 Paislev 2 Galashiels I 
Edinburgh 7 Penicuik 2 Inchinnan I 
Bellshill 5 Troon 2 Inverbervie 1 
Aberdeen 4 Arbroath I Irvine 1 
Roslin 4 AuchennuchlY I Oban I 
Perth 3 Avr 1 Tranen! I 
Stirling 3 Buckhaven 1 Uddin2stoo 1 
East Kilbride 2 Cupar I Walkerbwn 1 
Inverness 2 Dalkeith 1 
The biotechnology cluster research conducted by DTI in 1999 provided a different number of 
companies (Table 7); however, it demonstrated a similar pattern as the one above. They also 
suggested several factors which encourage cluster development: such as a strong science base, an 
entrepreneurial culture, growing company base, the ability to attract key staff, good premises and 
infrastructure, the availability of finance, business support service and large companies, skilled 
work force, effective networking and supportive policy environment (DTI 1999). 
Table 7 Biotechnology company and research strength in areas visited 
(DTI 1999: 15) 
Area No. of companies Premier research and regulatory institutes Top funded Universities 
bioscience 
Cambridge Approx.150 LMB, Sanger, Bahraham, EBI Cambridge 
Oxfordshire Approx.50 IMMM, Human Genetic Center Oxford 
London Approx.50 MCA,EMEA UCL, IC, UMDS, School of 
Tropical Hygiene 
Southeast (Surrey, 50-100 Sussex 
Suasex, Kent) 
Central Scotland Approx.50 Roslin Institute Edinburgh, Glasgow, 
Dundee 
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As mentioned before, southern England is very important for the pharmaceutical and 
biotechnology industry because of the high concentration and large number of companies. As 
shown in Table 8, over 60 per cent of companies in Cambridgeshire, London, Oxfordshire, Surrey, 
Buckinghamshire and Hampshire employed fewer than 50 staff; while over 40 per cent of 
companies in Berkshire employed more than 50 staff. 
Table 8 Size of Companies in Different Areas 
Over 
>10 10--50 51--100 101--500 500 Total 
Cambridgeshire 23 38 6 6 2 75 
London 13 17 3 4 1 38 
Oxfordshire 7 16 5 5 1 34 
Berkshire 4 12 3 7 2 28 
Surrey 6 17 2 2 0 27 
Buckinghamshire 5 12 2 3 2 24 
Hamjlshire 4 10 2 4 0 20 
Cambridgeshire has the largest number of small to medium sized equipment and reagents firms, 
support services firms, drug discovery and development firms, diagnostics firms and non drug 
development firms. In Cambridgeshire, Buckinghamshire, Berkshire, Herefordshire, and 
Hampshire, the largest sector of the local pharmaceutical and biotechnological industry was 
equipment and reagents, while in London and Oxfordshire, the drug discovery and development 
sector was the largest sector (Table 9). As shown in table 9, Cambridgeshire and London, which 
have the largest number of drug discovery and development companies, also have the largest 
number of support services companies. This may indicate that local supply sector and discovery/ 
development sector collaborate closely with each other. 
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Table 9 Products and services in each area 
Drug discovery Non drug 
Equipment, Medical Support and product 
devices, Rea2ents services development Dia2Dostics development Total 
Cambridgeshire 25 18 24 5 2 74 
London 8 8 19 I 0 36 
Oxfordshire 10 5 18 2 0 35 
Berkshire I3 6 8 I 0 28 
Surrey 8 8 4 4 2 26 
Buckinghamshi 
re 14 5 2 I 0 22 
Hampshire II 6 I 3 0 21 
Table 10 Company age groups of each area 
2000-
I 920s 1930s I 940s I 950s 1960s I 970s 1980s 1990s 2003 Total 
Cambridl!cshire 0 0 I I 4 I 9 32 29 77 
London 0 I 0 0 0 I 7 17 I3 39 
Oxfordshire 0 0 0 0 I 2 2 19 13 37 
Berkshire I 0 0 0 I 4 5 10 8 29 
Surrey 0 0 0 0 I I 5 IS 5 27 
Buckinghamshire 0 0 0 2 0 3 3 II 5 24 
Hampshire 0 I 0 0 0 I 2 8 8 20 
Chart 4 Company age group of each area 
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.19805 9 7 2 5 5 3 2 
.19905 32 17 19 10 15 11 8 
.2000-2003 29 13 13 8 5 5 8 
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As discussed earlier, ten per cent of the small to medium sized companies were established before 
the I 980s. These companies were mainly located in Cambridgeshire, Berkshire, and 
Buckinghamshire (Table 10). Companies established after the 1980s were mainly located in 
Cambridgeshire, London and Oxfordshire (Table 10 and Chart 4). This was connected with the 
phenomenon discussed before, that a large number of drug discovery and development companies 
were emerging after the I 980s in Cambridgeshire, London and Oxfordshire. 
Cooke conducted a study of biotechnology clustering in 2001. He identified that Cambridgeshire, 
Oxfordshire and Surrey were the three major biotechnology clustering centers in England (Cooker, 
2001), which is different from Cambridgeshire, Oxfordshire and London identified in this study. 
There are two main reasons for this difference: first, Cooke's data were focused on the 
biotechnology sector rather the pharmaceutical and biotechnology industry as in this study. 
Second, Cooke's data was collected before 2000. After the year 2000, as shown in table 8, more 
firms were established in London than in Surrey. Spending on biotechnology related research in 
London is estimated to be £300 million per annum, which is the largest in the UK (DTI 2003). 
Size of companies 
At the beginning of this chapter, market capitalisation used to distinguish the size of companies, 
which easily categorized the pharmaceutical and biotechnological companies into two groups. 
However, share value on market is normally used for large public companies for which financial 
information are easy to obtain. To further discuss the size of smaller private companies, another 
measurement will be used: number of staff, which was collected by Biotechnology Company 
Compendium 200312004. 
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As shown in Chart 5, 25 per cent of total companies employed fewer than 10 staff, 47 per cent of 
companies employed 10 to 50 staff, 11 per cent of companies employed 51 to 100 staff, 14 per cent 
of companies employed 101 to 500 staff, and 3 per cent of companies employed more than 500 
staff. For the largest four sectors (equipment and reagents, support services, drug discovery and 
development, and diagnostic companies), '1 0-50 staff' was the largest size group. 
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Table 11 Product and services of each size group 
>10 10--50 51-100 101--500 
Equipment, medical devices and 
reagents 52 119 23 26 
Support services 36 45 12 24 
Drug discovery and d e v e l ~ m e n t t 21 60 20 20 
Diagtlostics 16 21 2 7 
Non drug product development 5 11 4 0 
Software and I.T 5 6 I I 
Drq delivery I 2 0 0 
Biomaterials 3 I 0 0 
Chipslmicroarrays 2 I 0 0 
Sequencin2 0 2 0 0 
over 500 
6 
9 
3 
0 
0 
0 
0 
0 
0 
0 
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As shown in Table 11 and Chart 6, firms employing fewer than 10 staff were mainly equipment 
and reagents, and support services companies; firms employing 10-100 staff were mainly 
equipment and reagents, and drug discovery and development companies; companies employing 
101 to 500 staff were mainly equipment and reagents, and support services companies; and 
companies employing over 500 staff were mainly support companies, which provide contract 
research of clinical trials. 
Chart 6 Product and services of each size group 
• Equipment,Medical 
devices,Reagents 
• Diagnostics 
120 
100 
80 
60 
40 
20 
0 
>10 
52 
36 
21 
16 
10-50 51-100 101--500 
119 23 26 
45 12 24 
60 20 20 
over 500 
6 
9 
3 
0 
There are 128 drug discovery and development companies in the UK, accounting for 22 per cent of 
all small to medium sized companies. From the 1980s until now, the numbers of surviving drug 
discovery and development companies have been growing faster than other sectors. During 2000-
2003, the number of new drug discovery and development companies was more than other sectors. 
Cambridge has the largest number of drug discovery and development firms compared with other 
areas. In London and Oxford, the drug discovery and development sector is the largest sector of the 
local pharmaceutical and biotechnology industry. 65 per cent of the drug discovery and 
development companies employed fewer than 50 staff. However, in the size group of 50-1 00 staff, 
the drug discovery and development sector accounted for the largest percentage compared with 
other sectors. Based on this background, the next section will describe a picture of the drug 
129 
discovery and development companies established after 1980 - when the biotechnological era 
began. In particular, the study will focus on companies of UK origin. 
4.2. British drug discovery and development companies 
established during the modern biotechnology era 
The companies, which are directly involved in drug discovery and development, can be 
categorized into two groups; companies of UK origin, and UK subsidiaries owned by foreign 
companies or large pharmaceutical companies. Because the information on the foreign subsidiaries 
is always integrated with foreign parent company and other subsidiaries, it is very difficult to study 
them individualIy. Although they could be preliminarily identified as R&D sites, it is difficult to 
identify whether they are directly involved in drug discovery and development or other research 
activities. Therefore, this project will focus on drug discovery and development companies of UK 
origin. This section will discuss the age distribution, clustering and products produced by this 
sector. The next three chapters will continue to discuss how this sector has been involved in 
knowledge generation, transfer and diffusion. 
4.2.1. Location 
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Of the 81 British origin companies, Cambridgeshire (21, 26 per cent), London (15, 18 per cent) and 
Oxfordshire (11, 14 per cent) had the largest number of drug discovery and development 
companies. In other words, 58 per cent companies were in these three areas. 
As of 2006, 17 drug discovery and development companies had established their branches oversea-
four originally from Cambridge (24 per cent) and London (24 per cent) respectively. 
From 2003 to 2006, 19 companies had been acquired by foreign companies and big pharmaceutical 
companies. Five of them were in Cambridge (26 per cent), and three in Oxford (16 per cent), 
London (16 per cent) and Berkshire (16 per cent) respectively. Of the six companies which had 
been acquired by big pharmaceutical companies, two were in Cambridge and Oxford respectively. 
4.2.2. Year of establishment 
As of2oo6, 20 of the 81 drug discovery and development companies had been established for up to 
five years (26 per cent), 44 companies (54 per cent) were in the six to ten year age group, seven 
companies (eight per cent) in the 11-15 year group, and ten companies (12 per cent) had been 
established for more than 15 years (Chart 7). 
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Chart 7 Age groups of drug discovery and development companies 
- ------ "-- -
45 
40 
35 
30 
25 
20 
15 
10 
5 
0 
0-5 years 6-10 11-15 over 15 
• Firm acquired by large pharma 1 2 1 2 
• Firm acquired by foreign 1 9 2 1 
companies 
• Firm have oversea branches 0 9 3 
• Pure UK firm 18 24 1 2 
17 out of 19 companies which had been acquired by foreign companies or large pharmaceutical 
companies were established more than five years ago. All of the companies which had established 
foreign branches had been established more than five years ago; with five of them (29 per cent) 
had been established more than 15 years. This suggests that finns that survive and mature either 
establish operations outside the UK or are acquired. Only a small minority of finns retain a pure 
UK focus. 
In Cambridge, London and Oxford, the largest age group is 6-10 years. In total, 70 per cent of 
companies in these three areas had been established for more than five years (Chart 8). 
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Chart 8 Locations and age group of companies 
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Chart 10 New established companies in each area (0-5 years) 
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Drug discovery and development companies aged over 15 years were located in Cambridgeshire 
(20 per cent), London (20 per cent), Cheshire (20 per cent), Berkshire (20 per cent), Hampshire (10 
per cent) and Central Scotland (10 per cent) (Chart 9). Compared with this relatively even spread 
the pattern, the new established companies (0-5years) demonstrated characteristics of clustering 
(Chart 10). 40 percent of new companies were located in Cambridge. 70 per cent of the new 
established companies were located in Cambridge, London and Oxford. 
In short, because drug discovery and development is a long-term orientated procedure, these 
companies were inclining to launch near where there existed a strong science base and well 
developed support services, to ensure their sustained development. The clustering of research 
institutes, research-based companies and support companies, will lead to close collaboration 
among them, and this will further facilitate the knowledge generation, transfer and diffusion 
process. 
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4.3. Drugs on the Market and in Development 
4.3.1.0vervlew 
The data of marketed drugs and drugs in the development pipeline was collected from the 
Recombinant Capital (www.recap.com) database and company press releases. The difference 
between marketed drugs and drugs in the development pipeline is that marketed drugs are 
approved by authorities and drugs in the development pipeline are drug candidates in clinical trials. 
355 marketed drugs and drugs candidates from 63 companies were recorded and analysed. Product 
information on the other 18 companies was not available, because the information of product 
pipelines was not disclosed or the development programmes were still in the early preparatory 
stage. 
The data of marketed drugs and drugs candidateswas cumulative information: these pipelines also 
included candidate compounds which failed to enter the next clinical stage and product 
development programs which have been terminated due to other reasons, e.g. financial reasons. 
For drug candidates which have more than one potential indication, there may have been parallel 
development programmes. The same candidate compound which was developed to treat several 
diseases was recorded as one drug or one pipeline drugin this study. Around one tenth of the drug 
candidates had more than one indication. 
The average number of marketed drugs and drugs candidatesof these 63 companies was 5.6. Ten 
companies had more than ten products. This highly productive group had 155 marketed drugs and 
drugs candidates, which accounted for 44 per cent of total number (Chart II). The next group is 
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companies which had five to nine marketed drugs and drugs candidates. These 22 companies had 
134 marketed drugs and drugs candidates, and accounted for 38 per cent of the total. The third 
group of companies had one to four marketed drugs and drugs candidates. These 31 companies had 
64 marketed drugs and drugs candidates, and accounted for 18 per cent of the total. 
This highly hierarchical structure of output not only resulted from the intensive R&D investment 
by the top companies, but also was a result of merger and acquisition (see Chapter Seven). 
Chart llNumber of marketed drugs /drugs candidates of each group 
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The major indications of marketed drugs and drugs candidates were cancer, central nervous system 
diseases, infection, inflammatory diseases, blood disorders, pain, respiratory disorders and 
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cardiovascular diseases (Chart 12). Other indications included metabolic disorders, gastrointestinal 
diseases, kidney disease, bone, cocaine addiction, etc. 
Cancers were the most important indications, 89 drugs and pipeline drugs were discovered and 
developed to treat cancers, and accounted for 26 per cent of total number of product pipelines. 
There were 64 drugs and pipeljne drugs (19 per cent) with the potential to treat central nervous 
system diseases, 54 were for infection (J 6 per cent) and 39 drugs (J I per cent) for immune-
mediated inflammatory djseases. The marketed drugs and drugs candidates for these four major 
indications accounted for 72 per cent of total products. These four indications were also the major 
areas of alliances (see Chapter Seven). 
Cbart 12 Indications of marketed drugs and drug candidates (percentage) 
Cardiovascular, 
9,3% 
Respiratory 
Disorders, 11, 
3% 
Blood disorder, 
14,4% 
Inflammation, 
39,11% 
4.3.3.Stages of product pipelines 
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The stages of product pipelines were mainly concentrated at lead and preclinical stages. There 
were 69 drug candidates in lead stage, which accounted for 21 per cent of total products (Chart 13 
& 14). The largest group is drug candidates in preclinical stages, 94 candidates accounted for 29 
per cent of the total. 47 drug candidates, (14 per cent) were in Phase I, 58 (18 per cent) were in 
Phase II and 23 (seven per cent) were in Phase III. One per cent of drugs were waiting approval 
and ten per cent (give number) were approved. Late stage development was mainly conducted by 
large drug discovery and development companies, e.g. Shire Pharmaceutical accounted for 31 per 
cent of drug candidates in Phase III. One possible reason for the concentration of the early stages 
of development was that small to medium sized companies were young and generally had 
insufficient resources to move beyond Phase I. 
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Chart 14 Stages of marketed drugs and drugs candidates (percentage) 
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DTI ' s 2003/2004 report on the UK. biotechnology sectors also collected stage information7• The 
DTI' s report studied 350 companies, including service and technology providers. Because the 
methodologies were different, these two studies could be only roughly compared (Chart 15). The 
result of comparison indicated that the drug discovery and development subsector played a very 
important role in preclinical, Phase I, Phase II and Phase ill development. However, their approved 
drugs and marketed drugs only accounted for a small fraction of the whole healthcare industry. 
This is mainly because many drug candidates development is moved to larger pharmaceutical 
companies which are able to continue the expensive and time-consuming process of late stage 
development. Therefore, R&D activity of a drug discovery and development company should be 
measured by a range of indicators, which could give a more comprehensive view of their activity 
7 Comparative Statistics for the UK, European and US Biotechnology Sectors - Analysis Years 
2003 & 2004 
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and productivity, e.g. in the next two chapters, scientific publication and patents data will be 
discussed. 
Cbart IS Stages of drug development 
Drug discovery and development subsector vs. bealtbcare industry 
160 j,-__________ _ 
140 
120 
100 
80 
60 
40 
20 
o 
4.3.4. Technologies 
• UK Drug discovery and 
Developemnt 
companies- 2006 
Prodcut Pipelines 
• UK Healthcare 
companies - 2004 
Product pipeline (Data 
source: DTI) 
The technologies used in discovering and developing drugs included synthetics, semi synthetics, 
drug delivery, vaccine, peptides and protein, monoclonal antibodies, gene therapy, recombinant 
DNA, RNAi-based therapeutic, natural products, and stem cell. 142 drug candidates were 
synthesized or semi synthesized (i.e. based on chemistry), and this accounting for 41 per cent of all 
drug candidates. Drug delivery and vaccine accounted for 16 per cent and 13 per cent respectively. 
Major technologies which were used to discover and develop biological therapeutics included 
peptides and proteins (seven per cent), monoclonal antibodies (seven per cent), gene therapy (six 
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per cent) and recombinant DNA (three per cent) - these accounted for a total of23 per cent. Based 
on the study of agreements, these technologies were also major areas concerned in alliances. 
Chart 16 Technologies of marketed drugs and drugs candidates 
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50 per cent of the technologies used by drug candidates in lead and preclinical phase were using 
chemica) technology, 37 per cent were biotechnology, seven per cent were drug delivery and six 
per cent were other technology, such as natural products. In phase I and phase II, the chemical 
technology accounted for 40 per cent, biotechnology accounted for 39 per cent, and drug delivery 
increased to 17 per cent. In phase ill, chemical technology accounted for 48 per cent, 
biotechnology dropped to 22 per cent, and drug delivery increased to 26 per cent. Among the 
approved and marketed drugs, chemical technology only accounted for 16 per cent, 22 per cent 
were biotechnology, and drug delivery increased to 62 per cent. Biotechnology mainly appeared in 
the early stage development. The approved and marketed drug delivery products were mainly 
developed by Vectura and Skyepbarma. 
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4.3.5.Forrnatlon of product pipelines 
Drug discovery and development is a long term process and involves many actors and different 
technologies. To build their development portfolio, companies may rely on their original research, 
co-development, licensing in and out, and acquisitions. 
Many companies began to build their product pipelines by exploring their own technology 
platform and expertise. For example, Oxagen is a company that was established in 1997, and was 
focused on identifying drug targets through genetics. In 2003, it began to build its own pipelines 
based on G-protein coupled receptors program to treat inflammatory disease. Oxagen also 
collaborated with other companies: Oxagen signed agreements with DanioLabs to use DanioLabs' 
proprietary model to screen compounds from Oxagen's G-protein coupled receptor program. It is 
very common for companies to collaborate during drug discovery and development process (see 
Chapter Seven). Their partners come from both local regions and abroad, included large 
pharmaceutical companies, universities, public institutes, and small to medium sized companies. 
Licensing in and out is also very important for the drug discovery and development process. 
Cyclacel's drug candidate CYC 381 was in-licensed from the American company Lorus 
Therapeutics, and Lorus wiII receive an up front fee, milestones and royalties on product sales. 
Similarly, it is also very common for drug discovery and development companies to license out 
their patents. 
Acquisition is another way to expand a product pipeline. For example, Antisoma's drug candidate 
AS 1411 was in clinical trials to treat cancers. It was originally developed by Dr Paula Bates, Dr 
John Trent and Prof. Donald Miller at the University of Alabama and then at the University of 
Louisville, and formally named AGROIOO. AGROIOO entered clinical trials in Aptamera Inc., 
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which was founded by these three researchers. Then it became one of Antisoma's product pipelines 
when Aptamera were acquired by Antisoma in February 2005, and renamed as AS1411. 
The building of product pipelines is therefore based on the accumulation of science and technology. 
Various actors have contributed to the knowledge generation, transfer and diffusion process. 
4.4. R&D investment 
According to the Department for Innovation, Universities and Skills' 2006 report, the 
pharmaceutical and biotechnology industry was the largest investor in R&D compared with any 
other industry, and the top two were large pharmaceutical companies: GlaxoSrnithKline and 
AstraZeneca. 83 per cent of total UK R&D investment was conducted by the top 100 companies8• 
20 out of the top 100 UK R&D investors were pharmaceutical and biotechnology companies and 
five of these 20 companies were from the drug discovery and development subsector described 
here: Shire, Cambridge Antibody, Acambis, Vernalis and SkyePharma. 
To picture the activities of this subsector's R&D, investment and sale information were collected 
from database of Department for Innovation, Universities and Skills (www.innovation.gov.uk). 
Infonnation from 35 drug discovery and development companies was coIlected from this database. 
Infonnation of the two largest pharmaceutical R&D inventors GlaxoSmithKline and AstraZeneca 
was also recorded and used as benchmarks. 
8 http://www.innovation.gov.uklrd_scoreboardldefault.asp?p=3 
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4.4.1.R&O Investment (1995 .2006) 
The phannaceutical and biotechnology industry is the largest R&D Investor. The total investment 
of ''the top 15 companies of R&D investment" of this industry grew fast between 1995 and 2006 
(Chart 17). The investment in 2006 was double the investment in 1998. The average annual 
investment growth rate was 8 per cent between 1995 and 2006. 
Between 1995 and 1998, R&D investment increased steadily, followed by a dramatic increase 
between 1998 and 2002. Between 2002 and 2003, the R&D investment dropped back slightly, then 
increased steadily until 2006. Between 1995 and 1998, the average annual investment growth rate 
was 7 per cent. During the fast growing period 1998 and 2002, average annual investment growth 
rate was 16 per cent. Between 2002 and 2006, the average annual investment growth rate dropped 
to 2 per cent. 
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The R&D investment of the pharmaceutical and biotechnology industry were dominated by 
GlaxoSmithKline and AstraZeneca9 (Chart 17 & 18). As the largest R&D investors in the UK, they 
accounted for 90 per cent of total R&D investment of the "top 15 UK pharmaceutical and 
biotechnology companies invested in R&D" in 1996 and this number was 82 per cent in 2006. 
Although the drug discovery and development companies listed in the "top 15 UK pharmaceutical 
and biotechnology companies invested in R&D", only accounted for less than 6 per cent of the 
total 15 companies' investment, this group of companies on average spent 215 million pounds in 
R&D every year (Chart 19). The continuously heavy R&D investment produced large number of 
patents and drug candidates. 
9 GlaxoSmithKline's investment between 1995 and 1999 were calculated by adding up investment 
of Glaxo Wellcome and SmithKline Beecham. AstraZeneca's investment between 1995 and 1997 
were calculated by adding up investment of Zeneca and Astra Pharmaceuticals. 
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Chart 19 Top drug discovery and development companies of R&D investment 
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The drug discovery and development companies listed in the "top 15 UK pharmaceutical and 
biotechnology companies invested in R&D" are a group of the most successful companies of this 
subsector. 1999 and 2002 were two important years of R&D investments. In 1999, the total 
investment of this group of companies declined by 20 per cent, around 36 million pounds. The 
company's highest rank in R&D investment was 10, which was the least performance between 
1995 and 2006, and four companies entered the top 15 (Chart 20 & 21). However, the whole 
industry R&D experienced a dramatic increase by 43 per cent in 1999. This was mainly 
contributed by AstraZeneca. It is important to notice that Shire ranked 4th in R&D investment of 
the UK pharmaceutical and biotechnology industry, and 17th of R&D investment of all UK 
companies. This indicated that this subsector is highly R&D intensive, and building R&D 
advantage is an important strategy of this industry. 
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Chart 20 Drug discovery and development company's highest rank in R&D investment 
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The number of drug discovery and development companies listed in the top 15 did not increase 
since 2000(Chart 21). This was mainly due to the expanding and the consolidation of this industry. 
The highest rank of companies maintained at fourth and fifth after 2000. 
Year 2002 was another turning point. The R&D investments of this group of companies increased 
in 2000 and then decreased since 2003. This was mainly due to the merger and acquisition within 
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this industry. Oxford Glycosciences, the third largest R&D investment company within the drug 
discovery and development subsector in 2002, were acquired by Cell tech in 2003. However, the 
total R&D investment of Celltech in 2003 did not increase compared with the total investment of 
Oxford Glycosciences and Cell tech in 2002. Celltech, the second largest R&D investment 
company of the drug discovery and development subsector in 2004, was later acquired by the 
Belgium company VCB, and changed its name to CelItech R&D in 2005. The R&D investment of 
CelItech dropped from 95.7 million pounds in 2002 to 52.6 million pounds in 2006. 
Powderject, the fourth largest R&D investment company of the drug discovery and development 
subsector in 2002, was acquired by the American company Chiron in 2003. The R&D investment 
of Powderject, was later added to Chiron's R&D investment, but did not show in this indicator. 
Similarly, Cambridge Antibody Technology, the second largest R&D investment company of the 
drug discovery and development subsector in 2005, was acquired by AstraZeneca in 2006, and its 
R&D investment was added to AstraZeneca. 
The historic record of R&D investment of this subsector suggests that although this subsector had 
several successful stories, the whole subsector was stilI immature. Companies survived from R&D 
investment shortage in 1999, experienced consolidation within the subsector and a short time 
growth. Then their output was harvested by large pharmaceutical companies via acquisition. 
4.4.2.R&O Intensity 
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R&D intensity is defined as the ratio of expenditures by a firm on research and development to the 
finn's sales 10. The pharmaceutical and biotechnology industry is an R&D intensive industry, and 
the drug discovery and development subsector is characterized by exceptionally high R&D 
intensity. 
According to the Department for Innovation, Universities and Skills' 2006 report, the R&D 
intensity of the UK top 850 R&D investment companies was 1.8 per cent. The R&D intensity of 
the UK top 114 pharmaceutical and biotechnology companies was 15.2 per cent, and the median 
was 31.6 per cent. The average R&D intensity of the top 15 pharmaceutical and biotechnology 
companies was 36 per cent in 2006. 
The average R&D intensity of the UK top 29 drug discovery and development companies was 
1321 per cent in 2006, and this large number was due to several low sale companies. The median 
value of R&D intensity of these 29 companies was 141 per cent. Only one company's R&D 
intensity was lower than the 15.2 per cent average of the industry. Only 5 out of 29 companies' 
R&D intensity was lower than 40 per cent. 
4.5. Summary 
This chapter discussed the pharmaceutical and biotechnological industry and introduces the context 
where the drug discovery and development sector is positioned. The UK pharmaceutical and 
biotechnology industry is dominated by a few large international companies. The largest 
pharmaceutical companies accounted for two thirds of total UK market sales, and large American 
10 http://economics.about.comlodieconomicsglossary/glrandin.htm 
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companies, in particular, accounted for almost one third of the total UK market sales, followed by 
the large British biotech companies, which accounted for 14 per cent of the total UK market sales. 
Therefore, the drug discovery and development companies are positioned in an industry with fierce 
competition from both foreign and domestic large pharmaceutical companies. 
Through analyzing a set of descriptive data, i.e. locations, number of staff, products and services, 
and company ages, a picture of small to medium sized companies of the UK biotechnology 
industry was mapped. This chapter found that the growth of the UK biotechnology industry, in 
terms of number of firms, was due to certain products and services in the sector: equipment and 
reagents, drug discovery and development, and support services. These companies were mainly 
located in southern England, and most were established after 1990. From the 1980s until now, the 
numbers of surviving drug discovery and development companies and support services companies 
has been growing faster than other sectors. The data on the UK pharmaceutical and biotechnology 
industry collected in this study is similar in results to that of DTI's report of the UK 
pharmaceutical and biotechnology industry. This thesis also suggested a similar pattern to the 
DTI's report, in terms of products and services, age group and locations. 
One finding is that Cambridgeshire and London not only have the largest number of drug 
discovery and development companies, but also have the largest support service companies. This 
may indicate that the local supply sector and discovery/ development sector collaborate closely 
with each other. Interestingly, companies which are clustering in Cambridge and London are also 
the active players of global connection, in terms of international expansion and acquisition. Firms 
that survive and mature either establish operations outside the UK or acquired foreign companies. 
Only a small minority of firms retain a pure UK focus. The main reason for this is the importance 
of international markets, in particular, the need to have an operational base in the US. 
Newly established pharmaceutical and biotechnology companies indicated more concentrated 
pattern in locations such as Cambridgeshire, London and Oxfordshire. The result of clustering is 
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different from Cooke's research (Cooke, 2001) which suggested that Cambridgeshire, Oxfordshire 
and Surrey were the clusters of newly established biotechnology companies. The main reason for 
the difference is that this thesis extended the research time window, and obtained more information 
on newly established companies. After the year 2000, more firms were established in London than 
in Surrey. Spending on biotechnology related research in London is estimated to be £300 million 
per annum, which is the largest in the UK (DTI 2003). 
The new findings of this chapter are about the product pipelines of the drug discovery and 
development subsector, which has not been studied by other researchers before. There are several 
important features of the product pipelines of this subsector. Firstly, the drug discovery and 
development subsector has played a very important role in constructing product pipelines, in 
particular, in the early stages of drug discovery and development. The output of drug candidates 
was concentrated in well established firms. Late stage product development was also controlled by 
a small number of companies. Secondly, the major indications of marketed drugs and drugs 
candidates were cancer and central nervous system diseases, followed by infection and immune-
mediated inflammatory diseases. These results are similar to the findings of alliances studies in 
Chapter Seven. Thirdly, chemical technologies, e.g. synthetics and semi-synthetics dominated the 
technologies in use for the creation of products, followed by biologicals (vaccine, peptides and 
protein, monoclonal antibodies, gene therapy and recombinant DNA). Biologicals were mainly in 
early stage development. One important finding was that although chemical technologies were the 
most important technology in lead, preclinical, phase I, phase II, and phase III, drug delivery 
technologies were the most important technologies among approved and marketed drugs. These 
drug delivery products were mainly developed by two companies: Vectura and Skyepharma. 
Moreover, companies may rely on different sources of knowledge to build their development 
portfolio, e.g. their own original research, co-development with other companies or institutes, 
licensing in and out, and acquisitions. The pipeline indications are similar to the large 
pharmaceutical companies, which also suggested the influence of large pharmaceutical companies 
on this sector, as the most important clients and investors. 
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There are several findings of R&D investment: firstly, the phannaceutical and biotechnology 
industry invested heavily in R&D. The pharmaceutical and biotechnology industry is the UK's 
largest R&D investor. GlaxoSmithKline and AstraZeneca dominated over 80 per cent of all R&D 
investments in the pharmaceutical and biotechnology industry. The drug discovery and 
development subsector only accounted for a small fraction of total R&D investment. However, 
compared with other companies ofthe phannaceutical and biotechnology industry, this subsector is 
highly R&D intensive. Secondly, the product pipelines and R&D investment of the UK drug 
discovery and development companies are hierarchically distributed among firms. The top drug 
discovery and development companies ranked very high in terms of R&D investments of the 
pharmaceutical and biotechnology industry. The heavy investment of this subsector produced a 
large number of patents and drug candidates. 
The exceptionally intensive investment was a risk for the long term business development. Many 
companies invested more than 80 per cent of their sales into R&D. This continuous, exceptionally 
intensive investment produced large numbers of patents and drug candidates, but also produced 
high risks for long term business development. Exceptionally high R&D intensity could be a 
possibly explain why some of the most productive companies were easily harvested by large 
pharmaceutical companies and other foreign companies. 
Policy implications 
This subsector was highly influenced by other actors in the system, e.g. large phannaceutical 
companies (indication) and support subsector (clustering). As shown in this chapter, this subsector 
is very R&D intensive. R&D investment is the driving force of development, but also a restraint of 
many companies. Both well established firms and young small firms in the drug discovery and 
development subsector face intense competition from local clusters of firms and international rivals. 
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In Europe INNOVA Workpackage Nine, Cleff et al. suggested that the most important financial 
barrier for innovation is that lack of finance support, and the next two most important financial 
barriers are high innovation cost and economics risk (Cleff et al. 2008). 45 per cent of the 
biotechnology firms are influenced by shortage of finance support, 28 per cent of companies have 
problems of innovation because of high cost and 22 per cent of companies have problems with 
predicting and handling innovation uncertainties and risk (Cleff et al. 2008). For small startups, 
their major problems are how to survive in local clusters while attracting investors to finance their 
product pipelines. For large and well established firms the major problems are how to quickly 
develop and market new products while minimizing the financial risk. 
The main challenge for policy is how to support small companies which will help in creating a 
large number of jobs, and at the same time how to support established companies which will help 
enforce the leading status of UK drug discovery and development. 
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Chapter Five: Knowledge Generation: Scientific 
Publications 
5.1. Introduction 
Publication and citation analysis has been widely used by scholars to measure innovation 
performance (Cordero 1990). This chapter aims to analyse and discuss the knowledge generation 
of the drug discovery and development subsector using bibliometric data. As discussed in the 
Chapter Three, scientific publications and citations were examined to describe this subsector's 
contribution to knowledge generation. 
The first section will focus on analysing the drug discovery and development subsector's 
publications of articles, reviews and letters. In addition to examine productivity, subject of 
publications, location of authors, source of publications and sources of references are also analysed, 
giving more details about their regional performance and global cooperation. The second section 
will analyse citations, paying attention to the impact of scientific research. The final sections will 
discuss and summarise the findings of the bibliometric study. 
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5.2. SCI Publications 
5.2.1.Productlvlty 
In this study, 2663 SCI papers published by 81 British origin companies between 1982 and 2006 
were collected and analysed. The first pUblication collected in this project was dated 1982. 
In the 25 years between 1982 and 2006, 106.52 papers were published each year on average. As 
shown in Chart 22, only four papers were published in 1982. During the 1980s, the number of 
publications grew slowly, but steadily. Although the number of publications declined in 1993, 
overall it grew faster in the 1990s than in the 1980s. After 2000, the number of publications saw a 
dramatic accelerating growth, followed by turbulence in 2003 and 2004, then continuously 
declined from 2005 to 2006. The number of papers published in 2006 was only slightly higher than 
the number of papers published in 2001. 
One explanation for this decline is that since 2000 this industry experienced consolidation and 
restructuring, and some companies which had published large number of papers almost went out 
business, e.g. PPL. Another reason is that some of the most productive companies slowed down 
their rate of publications, e.g. Xenova, published 13 papers in 2002, 10 papers in 2003, and 18 
papers in 2004, but only published 4 papers in 2005 and 3 papers in 2006 after being acquired by 
Celtic Pharma Development (BERMUDA) in 2005. It therefore appears that industry structure and 
stability have a significant impact on publications output. The companies' strategy was also an 
important factor, which may lead firms to switch from publications to other activities. 
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Webster studied UK biomedical publications between 1989 and 2000. 355,188 articles, reviews 
and notes published in biomedical journals were generated from Research Output Database II 
(Webster 2005). UK authors published 24,141 papers in 1989 to 33,972 in 2000, at an average 
growth rate of2.3 per cent each year (Webster 2005). Roughly comparing Webster's research with 
this project yields an interesting result: although drug discovery and development companies' 
publications only accounted for as little as 0.1 per cent of the total UK biomedical papers in 1989, 
and 0.5 per cent in 2000, the average annual growth rate was as high as 18.4 per cene2 • It 
suggested that the publishing ability of this subsector was improved significantly, and this 
subsector played an increasing role in biomedical knowledge production. 
II The Research Output Database yield more publications than SCI in Webster's research, this 
mainly due to the searching and selecting criteria (Webster 2005). 
12 The formula used in this project to calculate average annual growth rate is 
fI- ( c r f - r ~ ~ - 1) X 100 
N is number of publications, and Y is year. This fonnula is different from the Webster's. Ifusing 
this formula, the average annual growth rate of UK biomedical publications would be 3.2 per cent, 
higher than 2.3 per cent in Webster's research. 
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The average publication per company was 32.8. The companies' performances were very different: 
the largest number of individual company' pUblication was as many as 794 papers, while some 
companies did not publish any. Therefore companies were grouped according to the number of 
their publications (this group is different from group in chapter eight). As shown in Chart 23, three 
drug discovery and development companies (four per cent) published more than 100 papers 
between 1982 and 2006 (Group one), and their publications accounted for over half of total 
publications; nine companies (11 per cent) published less than 100, but more than 50 papers 
(Group two), and their publications accounted for around one quarter of total publications; 25 
companies (31 per cent) published less than 50, but more than ten papers (Group three), and their 
publications accounted for one fifth of total publications; 30 companies (37 per cent) published no 
more than ten papers (Group four), and their publications accounted for less than one twentieth of 
total publications; and 14 companies (17 per cent) did not publish any article, review or letter 
(Group five). Comparing this with the data on biotechnology cluster of Scandinavia - Medicon 
Valley, where 63 out of 109 companies (58 per cent) had published paper (Coenen, Moodysson, & 
Asheim 2004), the British drug discovery and development companies appear to be more active in 
publishing. 
It is notable that 15 per cent of companies published around three fourths of total publications 
output. Celltech l3, which was at the top of the hierarchy, published the largest number of papers of 
all companies: 794 papers, which accounted for 30 per cent of the total. Vernalis 14 (formerly 
13 In 1999, Cell tech acquired Chiroscience (UK) and then merged with Medeva (UK); in 2000, 
Celltech acquried Cistron Biotechnology (USA) and in 2003, Celltech acquired Oxford 
Glycosciences (UK). Celltech was acquired by UCB (Belgium) in 2005. Data presented here 
included papers published by Celltech and other three British origin companies Chiroscience, 
Medeva and Oxford Glycosciences. 
14 In 2003, Vernalis mergered with British Biotech (UK), which merged with RiboTargets (UK) 
earlier in 2003; then Vernalis acquired Ionix Pharmaceuticals (UK) and Cita 
NeuroPharmaceuticals (Canada) in 2005. Data presented here included papers published by 
Vernalis, British Biotech, RiboTargets and Ionix Pharmaceuticals. It is important to notice that 
over 70 per cent papers published by this group were published by British Biotech. 
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British Biotech) published the second largest number of papers: 451 papers, which accounted for 
17 percent of all publications. Therefore just two firms accounted for nearly half of all publications. 
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To evaluate the productivity of the drug discovery and development subs ector, results from another 
study were compared with this research. McMillan and Hamilton investigated the bibliometric data 
of US pharmaceutical companies between 1981 and 1993, and found that the average number of 
publications per company was 2653 papers (McMillan & Hamilton 2000). These companies 
included some of the largest pharmaceutical companies in the word, Abbott Laboratories, 
American Home Products Corporation, Bristol-Myers Squibb Corporation, Johnson & Johnson, Eli 
Lilly and Company, Merck & Co., Inc., Pfizer Inc., Schering-Plough Corporation, Smithkline 
Beecham Group PLC, Syntex Corporation, the Upjohn, and Warner-Lambert. The reason they 
chose this period was that "it was one of the industry's most profitable (period) and 
pharmaceuticals were one of the most profitable industries in the US overall" (McMillan & 
Hamilton 2000,p.467). During the same period, Celltech IS, a newly established British 
biotechnology company, published 298 papers between 1982 and 1993 (all types of scientific 
IS Different from footnote 4, only Celltech were considered here. 
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publication are considered in order to be consistent with McMillan & Hamilton's study), 
representing II per cent of the average number of papers published by these wel1-established US 
pharmaceutical companies. 
Based on another study, between 1996 and 2000, the top two British Universities in publishing 
biotechnology paper were the University of Cambridge and the University of Oxford. The average 
publication (articles, notes and reviews) per year between 1996 and 2000 were both 536 (Patel 
2003a). The top three British companies in publishing biotechnology papers were Glaxo Well come 
Pic, Smithkline Beecham PIc and Astrazeneca. Their average publications (articles, notes and 
reviews) per year between 1996 and 2000 were 72, 53 and 47 respectively (Patel 2003a). The most 
productive drug discovery and development company, Cel1tech, on average published 50 papers 
per year between 1996 and 2000. This number was only one tenth of the University of Cambridge 
and University of Oxford, but is similar to a large phannaceutical company. This result indicated 
the strong research contribution of the biotechnology sector. One possible reason for this was the 
close connection between the drug discovery and development subsector and public institutions, 
with a significant number of papers involving academic co-publishing. 
In terms of publication number, a small group of the most productive companies published the 
majority of papers. They played a very important role in contributing to the output of the drug 
discovery and development subsector. One reason for this phenomenon was that Celltech was 
established in 1980, and British Biotech (now part of Vernalis) was established in 1986, therefore 
accumulating publications during their long period of operation. However, this single reason could 
not explain why these two companies were far more productive than other companies established 
in the 1980s. Many other factors may also influence the number of publications: company strategy, 
product and service, and connections with public research institutions. 
Interestingly, 14 out of the top 15 most productive companies had been involved in mergers and 
acquisitions, and 13 out of these 14 companies had been involved in international merger and 
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acquisitions before 2006. The connection between productivity and merger and acquisition activity 
will be discussed in the Alliances Chapter. 
5.2.2.SubJect of Publications 
From the database of 2663 publications, 10855 keywords were generated. After analysing the 
frequency of keywords in the database, 30 keywords which appeared most frequently were listed in 
Table 12. 
Cancer, immune diseases and immune mediated inflammation, and infectious diseases were 
studied most. Important research areas included protein expression and purification, cells, 
monoclonal antibodies, molecular structure and binding, gene cloning and expression, and drug 
design. It is notable that most of these terms are associated with biotechnology and molecular 
biology rather than synthetic chemistry. Therefore, the major subjects included genetics, oncology, 
immunology and immune mediated inflammation, infection, molecular biology and biochemistry. 
Webster's research on overall UK and world biomedical publications suggested that the sub-fields 
with the most number of papers published by UK authors were infectious diseases, genetics, 
endocrinology and oncology; and the worldwide research had the same trend (Webster 2005). 
Because the molecular biology and biochemistry publications were categorized into other sub-
fields in Webster's biomedical classification, the results indicated that the biotechnology 
companies have very similar research fields when compared to public institutions, and further 
suggested their roles as "key 'makers' as well as 'takers' of local and global (knowledge) 
spillovers" (Cooke 2006). 
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In other words, the drug discovery and development subsector followed a similar research direction 
as public institutes, and played the roles of both learner and inventors at the same time. 
Table 12 Keywords frequency in scientific pubUcations 
Keyword Count Keyword Count 
EXPRESSION 282 GENE 68 
PROTEIN 164 ruMOR-NECROSIS-FACTOR 65 
CELLS 141 THERAPY 55 
MONOCLONAL-ANTIBODY 119 ANTIGEN 54 
ACTIVATION 108 IMMUNIZA nON 53 
IDENTIFICATION 101 PURIFICATION 52 
CRYSTAL-STRUCTURE 99 ANTIBODY 49 
CANCER 93 DRUG DESIGN 49 
MICE 93 CLONING 48 
ESCHERICHIA-COLI 91 DESIGN 45 
IN-VITRO 91 IMMUNOTHERAPY 45 
BINDING 90 RESPONSES 45 
IN-VIVO 84 T-CELLS 43 
INHIBITORS 73 MATRIX 42 
MET ALLOPROTEINASES 
RECEPTOR 72 INFECTION 41 
5.2.l.Locatlon of Authors 
Authors in 47 countries and regions co-published papers with the UK drug discovery and 
development subsector. The total number of papers co-published with authors from foreign 
countries was 1271, accounted for 47.8 per cent of total publications. It indicated a close 
connection between the UK drug discovery and development subsector and researchers in foreign 
countries. In particular, US authors contributed to 21 per cent of total publications; followed by 
authors from Germany, Netherlands, France and Switzerland (Table 13). These countries all 
contributed two to three per cent of total publications. This study revealed similar results as 
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Webster's research, with the UK's leading partner in publication being the US, followed by EU 
countries (Webster 2005). 
Table 13 Countries of Co-authors 
Number of co-publishing Percentage of total 
papers publications 
US 561 21.\ 
GERMANY 81 3.0 
NETHERLANDS 72 2.7 
FRANCE 69 2.6 
SWITZERLAND 54 2.0 
ITALY 52 2.0 
AUSTRALIA 46 1.7 
CANADA 44 1.7 
SPAIN 32 1.2 
BELGIUM 29 1.1 
JAPAN 25 0.9 
DENMARK 21 0.8 
NEW ZEALAND 20 0.8 
IRELAND 18 0.7 
AUSTRIA 15 0.6 
Based on bibliometric analysis of the top ten journals contained in the SCI database, the overall 
picture of bioscience research showed a similar result: the US dominated the research publication 
collaboration with UK (Cooke 2006). Cooke argued that the five US "metacentres" were at the top 
of the co-publishing hierarchy, they were Boston, Cambridge (US), New York, San Francisco and 
San Diego; London, Cambridge (UK) and Stockholm were at the next level; followed by Oxford, 
Lund and Uppsala (Cooke 2006). In his study, London, Cambridge and Oxford were the 
"metacentres" of co-publishing within the UK. The results of earlier chapter have showed that 
London, Cambridge and Oxford have the largest number of drug discovery and development 
companies. The clustering in these three places is a possible reason for the attracting foreign 
researchers to co-publish papers with the local drug discovery and development subsector. 
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The study of UK authors also showed a concentration of publishing in southeast England. In this 
study, each author's address was taken as one count of contribution. 16 Within the UK, 90 per cent 
of the authors' addresses were located in England, nine per cent in Scotland, and only one per cent 
in Wales (Chart 24). In England, 20 per cent of addresses were from Cambridge and Oxford 
respectively, and 19 per cent were from London, giving a total of nearly 60 per cent for these three 
areas (Chart 25). 
Chart 24 Number of authors contributed to publications (UK) 
Englandj 
4395j90% 
Chart 25 Contributions of different region in England 
BERKS; _____ _ 
CAMBRIDG 
16 Suppose co-authors contributed equally in publishing. 
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However, the pattern of industry publication is different from the publications of public research 
institutes. In Webster's study, public research institutes and Universities in London published 36 
per cent of UK total biomedical publications, Cambridge and Oxford published around 5 per cent 
each (Webster 2005) giving a total of 45 percent for these three areas. The difference was probably 
due to the large number of leading research institute in London. There are four leading public 
research institutes in Cambridge l ? and five leading public research institutes in Oxford l8, but only 
in London West and West Central area, the number of public institutes is as many as 1419 (Webster 
2005). However, both Webster's research and this study indicate that the publishing was highly 
concentrated in the Southeast of England. One reason for this concentration was that the most 
productive companies were heavily clustered in the South East. 
S.2.4.Source of Publications 
The 2663 articles, reviews and letters were published in 718 journals. 670 out of 718 journals 
published less than ten papers which were written by British origin drug discovery and 
development companies. However, 48 journals (seven per cent) published 1104 papers, which 
accounted for 41 per cent of total publications. 
17 University of Cambridge, Laboratory of Molecular Biology, Addenbrooke's Hospital and 
Babraham Institute 
18 University of Oxford, John Radcliffe Hospital, Radcliffe Infrrmary, laboratories of Medical 
Research Council and Churchill Hospital 
19 University College London, London School of Hygiene and Tropical Medicine, Imperial Cancer 
Research Fund, Institute of Child Health, King's College, Institute of Neurology, Great Ormond 
Street Hospital, National Hospital of Neurology and Neurosurgery, Birkbeck College, 
Hammersmith HospitaVRoyal Postgraduate Medical School, St Mary's Hospital, Charing Cross 
Hospital, University College and Middlesex School of Medicine, and Imperial College of Science, 
Technology and Medicine. 
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The top ten journals which published most of the drug discovery and development subsector's 
papers were Bioorganic & Medicinal Chemistry Letters (78, 2.9 per cent), VACCINE(53, 2.0 per 
cent), Journal of Biological Chemistry (52, 2.0 per cent), Tetrahedron Letters (47, 1.8 per cent), 
The Journal of Immunology (41, 1.5 per cent), Biochemical Journal (37, 1.4 per cent), Journal of 
Medicinal Chemistry (37, 1.4 per cent), Cancer Research (35, 1.3 per cent), British Journal of 
Cancer (31, 1.2 per cent) and British Journal of Pharmacology (31, 1.2 per cent). 
As shown in Table 14, eight of the top 15 journals which published most of the subsector's papers 
are chemistry or biochemistry related. The focus of the other six journals included vaccine, 
immunology, biology, pharmacology and cancer. One of these covered all scientific disciplines 
(Nature). Therefore, in terms of subjects of journals, chemistry and biochemistry slightly 
outweighed the biotechnological research. Given the keyword findings, this suggests that the 
majority of pUblications were focused on molecular biology and biotechnology, but were published 
in chemistry and biochemistry journals. This provides a useful insight into the type of knowledge 
produced by these firms. 
Table 14 PubUcations on Each Journal (Top IS) 
Journal Subject Countty Articles Total Number of 
Cites papers (this 
study) 
Bioorganic & Interface of chemistty and ENGLAND 1264 16692 78 
Medicinal biology 
Chemistry Letters 
VACCINE Vaccines and vaccination ENGLAND 928 15193 53 
Journal of Biochemistty and molecular UNITED STATES 4336 410903 52 
Biological biology 
Chemistry 
Tetrahedron Letters Organic chemistry ENGLAND 1989 68926 47 
The Journal of Immunology UNITED STATES 1846 117464 41 
Immunology 
Biochemical Biochemistry and cellular and ENGLAND 529 47296 37 
Journal molecular biology 
Journal of Chemical-biological UNITED STATES 864 38868 37 
Medicinal relationships, mainly the bond 
Chemistry between molecular structure 
and biological activity 
Cancer Research Cancer UNITED STATES 1493 112911 35 
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British Journal of Cancer ENGLAND 541 28295 31 
Cancer 
British Journal of General pharmacology ENGLAND 379 22441 31 
Pharmacolo2Y 
Journal of Organisms or their components UNITED STATES 981 64356 29 
Molecular Biolo2Y at the molecular level 
Drug Discovery Drug discovery associated ENGLAND 129 4122 27 
Today technologies, the management, 
commercial and regulatory 
issues 
Journal of Chemistry and Materials NETHERLANDS 50 2437 27 
Computer-Aided Science 
Molecular Design 
NATURE All disciplines of science ENGLAND 962 390690 27 
Nucleic Acids Physical, chemical, ENGLAND 943 74972 26 
Research biochemical and biological 
aspects of nucleic acids and 
proteins involved in nucleic 
acid 
According to the lSI Journal Citation Reports 2006, of the 15 journals, Journal of Biological 
Chemistry, Tetrahedron Letters and The Journal of Immunology published the largest total number 
of publications in 2006. 
Nine out of the 15 journals are British Journals, five are American journals, and one is a 
Netherlands' journal. This indicates that the drug discovery and development subsector are more 
inclined to publish in British Journals. 
S.2.S.Source of References 
By analysing the pattern ofeiting reference and the source of references it is possible to understand 
the role of the drug discovery and development subsector played in knowledge flow. It will also 
map how the subsector's research has been influenced by existing research. 
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The 2663 papers citied 67434 references in total. The top three references are Laemmli's (1970) 
paper 'Cleavage o/structural proteins during the assembly o/the head o/bacteriophage T4' which 
was cited 98 times, Nobel Prize Winner Sanger's (1977) paper 'DNA sequencing with chain-
terminating inhibitors' which was cited 52 times, and Berman's (2000) paper 'The Protein Data 
Bank' Which was cited 44 times. 
These 67434 references were published in 8171 different journals or books. Table 15 lists the 
journals which were citied most. These top 15 out of8171 journals (0.2 per cent) accounted for 40 
per cent of total citations. The top 81 journals (one per cent) accounted for 76 per cent of total 
citations. Therefore, this citation pattern was highly hierarchical. Although these publications were 
cited widely, there were a small group of journals which have much greater impact than the rest of 
the journals. In other words, the one per cent most cited journals were the major knowledge base of 
the drug discovery and development subsector. 
Table 15 Most cited Journals (Top 15) 
Journal Country Time of citation 
P NATL ACAD SCI USA UNITED STATES 3552 
JBIOLCHEM UNITED STATES 3507 
NATURE ENGLAND 3225 
SCIENCE UNITED STATES 2226 
JIMMUNOL UNITED STATES 2075 
CANCER RES UNITED STATES 1606 
CELL UNITED STATES 1587 
JMEDCHEM UNITED STATES 1519 
JMOLBIOL UNITED STATES 1459 
BIOCHEMISTRY-US UNITED STATES 1336 
JEXPMED UNITED STATES 1095 
JVIROL UNITED STATES 1063 
JAMCHEMSOC UNITED STATES 1001 
NUCLEIC ACIDS RES ENGLAND 978 
EMBOJ UNITED STATES 812 
167 
Further investigation showed interesting a result: 13 out of the 15 top journals were American. As 
discussed earlier, when publishing their work, the drug discovery and development companies 
were inclined to choose British journals, followed by American journals. However, their references 
are mainly from American journals. Although this may not directly indicated a knowledge flow 
from American to the UK, because these journals are very internationalized, this phenomenon did 
suggest the positive impact of American academic publication upon British drug discovery and 
development research. This is perhaps unsurprising given the very large scale of US academic 
research in this area, but highlights the key role public research plays as the foundation for 
commercial research. 
In short, the pattern of citing references was very hierarchical and the publications were heavily 
influenced by American journals. This result suggested that American academic publications are 
very important to the UK drug discovery and development subsector's research. 
5.3. Citations 
S.3.1.Counts of citations 
The 2663 papers were cited 89,992 times since first published: each paper was citied 33.8 times on 
average. If compared with the average citation to UK biotechnology publications - 4.8 citations per 
item in 1995/1996, and 5.2 in 1999/2000 (Calvert, Senker, & Schenk 2003), the average number of 
citations per firm's publication was far above average20• Although the high number of citations was 
20 Calvert, Senker, & Schenk's research included publications of plant biotechnology, animal 
biotechnology, environment biotechnology, bioprocessing, diagnostics and therapeutics, platform 
biotechnology, and ceIl factory. 
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partly due to the higher citation rates of biomedical publications than other research areas, e.g. 
plant science (Kinney 2007,p.17943), and partly due to the long time accumulation of citations, the 
average number of citations per firm's publication were still far greater. As discussed later, one 
possible reason for the significant citation rate was that this subsector was the first mover in many 
research fields, and therefore their papers were highly cited. 
The top ten of the 81 companies' publications accounted for 85.6 per cent of the total citations. 
This also presented a hierarchical pattern. As shown in Table 16 and 17, Celltech, Vernalis, and 
Cambridge Antibody's publications were ranked highest in terms of total counts of citations: each 
having 31682 (35.2 per cent) ,21082 (23.4 per cent) and 6773 (7.5 per cent) citations respectively. 
Citations to publications of these three companies accounted for 66.2 per cent of total citations. 
The Pearson correlation test was conducted to examine if there was a significant correlation 
between total number of publications and total number of citations (r=O.985, p<O.Ol) and showed 
that the number of publications and total number of citations were statistically significantly 
correlated. This is a very strong correlation, which suggests that the most productive companies 
were also the most influential companies in publication. 
Moreover, Celltech, Vernalis, and Cambridge Antibody also had the largest number of average 
citation per year: 1173, 958, and 356 citations per year respectively. The results of total citations 
and average citation per year suggests that Celltech, Vernalis, and Cambridge Antibody not only 
had a strong cumulative impact on research, but also continuously influenced the research field 
since they started to publish papers. In other words they are very significant producers of scientific 
knowledge. 
169 
Table 16 Publication and Citations (Top 10 companies) 
company name Number of Sum of the Average Average h- Most 
Publication Times Citations Citations index citied 
Cited per Item oer Year Dauer 
Celltech Group pic (Acquired Chiroscience in 794 31682 39.9 1173.4 88 689 
I 999;merged with Medeva in 1999; acquried 
Cistron Biotechnology US in 2000; acquired 
Oxford Glycosciences in 2003; acquried by UCB 
Belgium in 2005) 
Vernalis (formally known as Vanguard 451 21072 46.7 957.9 78 995 
Medica;acquired by British Biotech and name 
change to Vernalis in 2003; British Biotech merged 
with RiboTargets in 2003; acquired Ionix 
Pharmaceuticals in 2005; acquired Cita 
NeuroPharmaceuticals Canada in 2005) 
Cambridge Antibody (Acquried Aptein US in 1998; 91 6773 74.4 356.5 28 939 
Acquired by AstraZeneca in 2006j 
Xenova (acquired KS Biomedix in 2003; acquired 181 4531 25.0 206.0 37 384 
Cantab Pharmaceuticals in 200 I; acquired by Celtic 
Pharma Development BERMUDA in 2005)· 
PPL Therapeutics pic (Acquired by QED in 2004) 55 3837 69.8 274.1 21 1450 
Astex Therapeutics (merged with metaGen 64 2288 35.8 286 24 259 
Germany in 2003) 
Oxford BioMedica pic 81 2214 27.3 147.6 25 142 
Oxagen 66 1664 25.2 151.3 22 201 
Cyclacel Ltd (founded in the UK, headquarter in 78 1644 21.1 149.5 23 116 
US, primary research facility is located in The UK) 
Acambis (1992-1999 Peptide Therapeutics; 51 1281 25.6 98.5 18 169 
acquired OraVax US and changed name in 1999) 
Cambridge Antibody, PPL therapeutic and Vernalis had the highest average citation per 
publications: 74.4, 69.8 and 46.7 citations per publication respectively. The results suggest that 
these three companies' publicationa were of the highest quality. In terms of the most cited papers, 
these three companies all had papers cited over 900 times (Gearing & Newman 1993;Mccafferty et 
a1. 1990;Wilmut et a1. 1997). PPL Therapeutics' famous paper about Dolly the sheep -"Viable 
offspring derived from fetal and adult mammalian cells", which was published in Nature in 1997, 
has been cited 1450 times. Cambridge Antibody's original research "Phage Antibodies -
Filamentous Phage Displaying Antibody Variable Domains", which was also published in Nature 
but seven years earlier, was cited 939 times. British Biotech's (acquired by Vernalis) review paper 
"Circulating Adhesion Molecules in Disease ", which was published in Immunology Today in 1993, 
was cited 995 times. It is important to notice that these three papers had been published for over 
170 
ten years, even over 15 years; therefore their impact on biotechnology research showed a 
cumulative effect. 
Table 17 Ranking of Companies by Different Citation Indicators 
Rank Number of Sum of the Average Average b-index Most citied paper 
Publication Times Cited Citations per Citations 
Item per Year 
I Celltecb Celltecb Cambridge Celltech Celltech PPL 
Antibody Therapeutics 
2 Vernalis Vernalis PPL Vernalis Vernalis Vernalis 
Therapeutics 
3 Xenova Cambridge Vernalis Cambridge Xenova Cambridge 
Antibody Antibody Antibody 
4 Cambridge Xenova SRPharma Astex Cambridge Celltech 
Antibody Therapeutics Antibody 
5 Oxford PPL Oxxon PPL Oxford Xenova 
BioMedica Therapeutics Therapeutics BioMedica 
6 Cyclacel Astex Celltech Xenova Astex Protherics 
Therapeutics Therapeutics 
7 Vectura Oxford KuDOS Oxagen Cyclacel Astex 
BioMedica Pharmaceuticals Therapeutics 
8 Oxagen Oxagen Crusade Cyclacel Oxagen Oxxon 
Laboratories 
9 Astex Cyclacel Astex Oxford PPL SR Pharma 
Therapeutics Therapeutics BioMedica Therapeutics 
10 Arnarin Acambis CeNes KuDOS Arnarin Oxagen 
Pharmaceuticals Pharmaceuticals 
S.3.2.h-lndex 
The average h-index was 8.8, Maximum was 88, minimum was 0, Standard deviation was 14.3, 
and median was 4. This result suggests a hierarchical pattern of publication output with a small 
number of top firms producing the large majority of citations: h-indices for a few companies were 
very high, and for the majority of companies were relatively low. This result is consistent with the 
results obtained by other indicators. 
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The Pearson correlation test was conducted to examine if there was a significant correlation 
between total number of publications and h-index (r=O.926, p<O.OI). This is a very strong 
correlation, i.e. the number of publications and h-index were statistically significantly correlated. 
In other words, the most productive companies normally had the highest h-index. As discussed 
earlier, the total number of citations was also statistically significantly correlated with the total 
number of publications, therefore, the impact of companies' publications correlated with its 
number of publications. 
However, as a new indicator emerging since 2005, there are many discussions about applying the 
h-index to analysing output of organizations and universities. It should be adjusted before 
analysing different subjects to account for varying norms, and should be interpreted carefully. 
Unfortunately there is not enough data to benchmark this industry at present. Kinney compared 
American Universities' output by using an adjusted h-index. This method was based on 
observation of when "evaluating sets of publications greater than several hundred, the h-index vs. 
the size of the set (N) is characterized by an approximately universal growth rate" (Kinney 
2007,p.17943). However, because the paper concerning methodology adopted by Kinney is still in 
press, details are not available at this stage. Therefore, further study is needed to investigate this 
issue. 
Table 18 h-index for UK Drug Discovery and Development Companies 
h-index Minimum Maximum Mean Standard Median 
deviation 
Value 0 88 8.84 14.28 4 
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5.4 Discussion and Summary 
In this chapter, three aspects of SCI publications have been addressed: productivity and impact of 
companies' research, regional perfonnance and global cooperation, and knowledge flow. 
There are several major findings in this chapter. First of all, the drug discovery and development 
subsector is a major producer of knowledge. It is clear that the output of these companies is highly 
innovative and important, as seen by the high h-factors and number of citations. 
Roughly comparing Webster's research (Webster 2005) with this project yields an interesting 
result: although drug discovery and development companies' publications only accounted for a 
smalI fraction of total UK biomedical papers (including publications of universities and research 
institutes), the publishing ability of this subsector has improved significantly, and this subsector 
played an increasing role in biomedical knowledge production. 
If compared with the biotechnology sector of other countries, such as the biotechnology cluster of 
Scandinavia - Medicon ValIey for example (Coenen, Moodysson, & Asheim 2004), the British 
drug discovery and development companies appear to be more active in publishing. 
If comparing with wen established phannaceutical companies, the successful drug discovery and 
development companies published as many as large British pharmaceutical companies (Patel 2003). 
Drug discovery and development companies are also active in publishing compared with well 
established US pharmaceutical companies (McMillan & Hamilton 2000). 
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An important finding is that this subsector's publications and citations data indicates a very 
hierarchical structure: a few companies dominated the publications produced by the subsector, in 
terms of both quantity and impact. One possible reason is that many of these high-end companies 
were established in the 1980s and so may be the first movers in their fields, which enables them to 
accumulate larger numbers of pUblications and citations, as well as research experience. Although 
the total output of this subsector only accounted for a small proportion of all UK biomedical 
publications, the growth rate of publications and the impact of publications are far above average. 
An important finding was that the impact of the leading companies' publications was strongly 
correlated with its number of publications. This also supports the idea that the leading firms are 
very important producers of knowledge. 
Secondly, this subsector was highly geographically concentrated in terms of knowledge production 
and international networks. The pattern of industry pUblication is different from the publications of 
public research institutes. In Webster's study, public research institutes and Universities in London 
published 36 per cent of UK total biomedical publications, Cambridge and Oxford published 
around 5 per cent each (Webster 2005). In the drug discovery and development sector 20 per cent 
of addresses were from Cambridge and Oxford respectively, and 19 per cent were from London, 
giving a total of nearly 60 per cent for these three areas. 
This subsector collaborated widely with other countries in publishing: the US dominated in co-
publishing within this subsector, followed by EU countries. Within the UK, Cambridge, Oxford 
and London were active centres in publishing. Total publishing and co-publishing were both highly 
concentrated in the Southeast of England, which was correlated with company clustering in these 
three places. Publication was even more concentrated than the number of companies in these areas. 
Thirdly, whilst the papers were published across a wide range of joumals, they were concentrated 
in a small group of journals. If compared with the average citation to UK biotechnology 
pUblications (Calvert, Senker, & Schenk 2003), the number of citations per firm's publication was 
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far above average. Furthermore, although a wide range of journals were cited, the references in 
these publications also presented a pattern of concentration. Interestingly, the major journals 
publishing these papers were mainly British, but the major journals these papers cited were mainly 
American. These results suggest the impact of American institutions upon this subsector's research. 
Together with results of co-publishing, research in the US strongly influenced the UK drug 
discovery and development companies in a direct way through co-publishing and in an indirect 
way through citation. 
Finally, this subsector published in both biological and chemical knowledge, but with a greater 
emphasis on molecular biology and biotechnology. It followed a similar research route and 
direction as the public institutes, and has produced very significant papers. Therefore it played the 
roles of both learner and inventor at the same time. 
ImpUcations for poUcy: 
This chapter indicated that companies' capability of publishing is enhanced by learning from 
networking; therefore policies could aim at encouraging the collaboration between companies, 
universities and public institutes, for example, this could be achieved by enhancing the mobility of 
highly skilled researchers and postgraduates, and encourage collaboration between researchers and 
industry. Furthermore, the networking between different actors in scientific publications would 
also facilitate the commercialization of scientific discoveries. 
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Chapter Six: Knowledge Production: Patents Publications 
6.1. Introduction 
This chapter will continue to discuss the R&D output of the UK drug discovery and development 
subs ector. This chapter will focus on the publication of patents by firms in the drug discovery and 
development subsector, one of the firm's intangible assets. Patents are defined by the European 
patent office as "a legal title granting its holder the right to prevent third parties from commercially 
exploiting an invention without authorization"(The European Patent Office 2008). 
A normal European patent grant procedure has seven steps: first, the inventors should send an 
application to the European patent office. This application consists of a grant request, a description 
of the invention, claims and an abstract. The application will be examined and filed after the patent 
office receives it. Then a search report which contains a list of all relevant documents will be 
generated and sent to the inventor. After 18 months, the patent application will be published 
together with the search report. At this stage, the application is protected by provisional protection. 
If the inventor decides to pursue the application, a substantive examination will be carried out. 
Then the Patent Office will decide on whether to grant the patent, and, if so, it takes effect on the 
date of publication. It normally takes 48 months from application to patent grant. The final step is 
validation in each state belonging to the European Union (Figure 4). 
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Figure 4 The European patent grant procedure 
Stage 2: Filing and examination 
Stage 3: Search report 
Stage 4: Publication (after 18 months) 
Stage 5: Substantive examination 
Stage 6: Grant patent (after 48 months) 
Stage 7: Validation 
From the perspective of a biotechnology and pharmaceutical company, patents, trademarks, 
copyrights and trade secrets constitute a companies' intellectual property, and this has an impact on 
almost every aspect of a company's business, i.e. revenues, management, alliances, market 
awareness, and financing (Schneider 2002). 
As an industry focusing on innovation, there are two types of output: product innovation and 
process innovation. This chapter will examine both product innovation e.g. new therapeutics and 
devices, and process innovation, e.g. fermentation and separation. The main aim of this chapter is 
to describe the innovation activities of drug discovery and development firms by analyzing patents 
publications. In this chapter, patent analysis included year of publication, type of 
invention/discovery, countries of inventor/applicants, and research alliance with other companies 
and institutes. 
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There are four sections in this chapter: the first section will describe how the drug discovery and 
development subsector performed in patenting. The second section will focus on patent content and 
types. In the third section, co-patenting between British and foreign inventors will be analyzed. 
The final section will be the discussion and conclusion. 
6.2. Productivity 
6.2.1. Growth of patent publications 
From a view of the UK pharmaceutical and biotechnology industry, two UK-based large 
Pharmaceutical firms are amongst the world leaders in a number of fields of biotechnology, 
whether measured by volume or by impact of patenting: GlaxoSmithKline and AstraZeneca (Patel 
2003b, p29). However, since late 1990s, other institutions and specialized biotechnology company 
have started to a play more important role (Patel 2003b). 
In this study, 2827 patents from 81 companies have been collected. The earliest patent date was 
1982, which was granted to the first British biopharmaceutical firm: Celltech. 
The number of patents published has grown dramatically from 1982 to 2006 (Chart 26&27). (It is 
important to note that the year in the chart is the publication date and there is an 18 month time lag 
between application and publication). There are three leaps: the first in 1997, the second in 
200112002, and the third in 2006. From 1982 to 1996, the number of patents published each year, 
grew slowly and steadily. In 1997, patent numbers increased by 61 per cent compared with 1998, 
and then in 200 I and 2002, patent numbers increased by 56 per cent and 39 percent compared with 
previous years. 2006, in particular, saw an output of published patents that was equivalent to one 
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fifth of all the patents published since 1982. The number of published patents increased 75 per cent 
compared with the previous year, 2005. It is also important to notice that before the dramatic 
increase in 200 I 12002, and 2006, there were three years 'preparation' periods: the line between 
1997 and 2000, and the line between 2002 and 2005 were flat or slightly 'U' shape. 
Thumm investigated patent applications of 103 European biotechnology companies (103 
biotechnology firms in several European countries, including 22 Dutch, 28 German, 20 British,19 
Spanish, 10 Italian, and 4 others), and found that the number of European patenting applications 
grew 4 per cent between 1991 and 1997 (Thumm 200 I), and the UK led the growth. Compare with 
Thumm's research, the growth rate of the British drug discovery and development subsector's 
worldwide patenting application, which was obtained from this study, was much higher: 29 per 
cent every year between 1991 and 1997. Although Thumm focused on European patents 
application, and this research included worldwide patent information, the performance of this 
subsector was still far above the average of the European biotechnology industry between 1991 and 
1997. One possible reason is that many biotech firms only supply services, reagents etc. - whereas 
the drug discovery and development forms are focused heavily on products and have a much 
greater likelihood to patent. 
Another interesting trend was found in this study: comparing the total patents in each five-year 
period (Chart 27), the numbers of patent publications were twice as many as previous five-year 
period, i.e. between 1987-1991 firms published twice as many patents as periods between 1982-
1996, similarly, 1992-1996 firms published twice as many patents as 1987-1991, 1997-200 I 
published twice as many patents as 1992-1996, and 2002-2006 published twice as many patents as 
1997-2001. This is a dramatic increase and an important trend in the subsector. As discussed in 
Literature Review Chapter, number of patents is an important factor to attract financial support 
(Baum & Silverman 2004); therefore, one possible reason for the dramatic increase was that 
companies published more patents in order to attract potential partners. 
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All the results above suggested that the UK drug discovery and development subsector grew fast in 
patenting, and played an important role in the EU biotechnology and pharmaceutical industry. 
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There are several reasons for the fast growth of patent publications. Firstly, this growth was partly 
driven by the overall growth of the patenting activity of the UK phannaceutical and biotechnology 
industry: between 1986 and 1990, 313 biotechnology patents invented by UK companies were 
granted by USPTO, and between 1996 and 2000, there were 1164 patents granted by USPTO 
(PateI2003b). The number of UK patents granted in the US also showed a fourfold increase, which 
was similar to the trend of patents granted worldwide to the drug discovery and development 
subs ector. The fast growth of the UK drug discovery and development subsector in patenting was 
also partly driven by the global trend of patenting in this industry. From 1980 to 2003, the number 
of patents on therapeutically active compounds at USPTO grew very fast, in particular, between 
2000 and 2003 (Hopkins et al. 2007). Another driving force would be the fast growth of US 
pharmaceutical and biotechnology. The US was the largest partner of the UK drug discovery and 
development subsector (see Chapter Seven), and the total number of genetic engineering and 
pharmaceuticals patents granted to US institutes and companies between 1982 and 1998 were as 
many as 13982 (Gittelman 2006). 
Comparing the patent publications with SCI publications between 1982 and 2006 (Chart 26), 
highlights three features. First, between 1989 and 2000, the patent publications and the SCI 
publications followed similar trends, but SCI publications were slightly greater than patent 
publications in most years. Second, between 2001 and 2004, the patent pUblications and the SCI 
publications still followed similar trends, but patent publications were slightly more than SCI 
publications. Third, from 2005 to 2006, the number of patent publications grew dramatically while 
the number of SCI publications decreased dramatically. This suggests that the drug discovery and 
development subsector have been paying more attention to patent publications rather than scientific 
publications since 200 1. One explanation is that the increasing number of patents, both grant 
patents and patents publications, will provide potential opportunities for companies to generate 
income by licensing out, contract service and research alliances, promote market awareness, attract 
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and motivate expertises, and further attract more investment (Schneider 2002). This correlates 
with the busting of the biotech bubble after 2001, when many companies encountered financial 
problems, and an increased number of patents would increase the likelihood of attracting 
investment. 
Table 19 Number of Publications in 2005 and 2006 (Top firms) 
Company Name Patents Patents Net Total Number 
Published in Published in Increase Published Patent 
2005 2006 1981-2006 
Astex Therapeutics Z I 5 39 34 58 
Vernalis U 23 45 22 306 
A videx Ltd 23 5 23 18 41 
Vectura l4 24 40 16 210 
Oxford BioMedica 2 ~ ~ 5 19 14 108 
Domantis Ltd 8 21 13 43 
KuDOS Pharmaceuticals 26 5 18 13 40 
Cambridge Antibody· 9 18 9 71 
21 Astex Therapeutics merged with metaGen (Germany) in 2003. 
22 In 2003, Vernalis mergered with British Biotech (UK), which merged with RiboTargets (UK) 
earlier in 2003; then Vernalis acquired Ionix Pharmaceuticals (UK) and Cita 
NeuroPharmaceuticals (Canada) in 2005. Data presented here included papers published by 
Vernalis, British Biotech, RiboTargets and Ionix Pharmaceuticals. 
23 Avidex Ltd was acquired by Medigene (Gemany) in 2006. 
24 Vecture acquired Innovata (UK) in 2006; Innovata was formed in July 2005 when ML 
Laboratories PLC (UK) acquired Quadrant (UK). 
2 ~ ~ Oxford BioMedica acquired Oxxon Therapeutics (UK) in 2007 (OXXOD Therapeutics was 
recorded separately) 
26 KuDOS Pharmaceuticals Ltd was acquired by AstraZeneca (UKlSweden) in 2005. 
27 Cambridge Antibody acquired Aptein (US) in 1998 was acquired by AstraZeneca (UK/Sweden) 
in 2006. 
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Further investigations into the years 2005 and 2006, found that the increased number of 
publications had several features. First of all, the whole subsector contributed to the increasing 
number of publications. 50 of the 81 firms (62 per cent) published more in 2006 than in 2005, 
seven (nine per cent) published the same number, nine (11 per cent) of the firms in 2006 did not 
publish as many patents as in 2005, and 15 (18 per cent) firm did not publish any patents in 2005 
and 2006. Secondly, a small number of companies' contributions accounted for the majority of the 
increase. Eight (ten per cent) firms contributed 61 per cent of the 200512006 increase in number of 
publications (Table 19). Thirdly, the top performing firm in 2005 and 2006 was Celltech28, which 
had 44 patents published in 2005 and 51 in 2006, did not contribute much to the increase. The net 
increase number was only seven, which ranked 12th in terms of net increase of patents. This was 
mainly due to the recent acquisition of Celltech by UCB. 
6.2.2 Distribution of output 
The average number of patents published by each company between 1982 and 2006 was 34.9. Five 
(six per cent) of the 81 companies published more than 100 patents (group one), 34 (42 per cent) 
companies published more than ten but less than 100 patents (group two), and 42 (52 per cent) 
companies published ten or less patents, including six companies which did not published any 
patents before 2007 (group three) (Chart 28). 
28 In 1999, Cell tech acquired Chiroscience (UK) and then merged with Medeva (UK); in 2000, 
Celltech acquried Cistron Biotechnology (USA) and in 2003, Celltech acquired Oxford 
Glycosciences (UK). Celltech was acquired by UCB (Belgium) in 2005. Data presented here 
included papers published by Celltech and other three British origin companies Chiroscience, 
Medeva and Oxford Glycosciences. 
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Five (six per cent) of the best perfonnance firms contributed 57.6 per cent of the total patent 
publications. Celltech, from 1982 to 2006, had published 879 patents, which accounted for 3 I. I per 
cent of the total patent publications, and Vernalis29 had published 306 patents (10.8 per cent). 
According to Patel's research, SmithKline Beecham PIc, which has the largest number of patents, 
was granted 629 US patents between 1986 and 2000, while Celltech, published 579 patents 
between 1986 and 2000. The performance of Celltech' s patents is very significant. According to 
Patel, in terms of UK inventing patents granted by USPTO between 1996 and 2000, Cell tech 
ranked fifth in the UK biotechnology and pharmaceutical industry, next to AstraZeneca, the 
Medical Research Council, SmithKline Beecham Pic and Unilever PIc, and British Biotechnology 
30 ranked II tho This result indicates that the drug discovery and development subs ector, in 
particular the top companies, played very important roles in patenting, with levels of activity 
comparable to large pharmaceutical companies. This is remarkable given their difference in size. 
29 In 2003, Vernalis merged with British Biotech (UK), which merged with RiboTargets (UK) 
earlier in 2003; then Vernalis acquired lonix Pharmaceuticals (UK) and Cita 
NeuroPharmaceuticals (Canada) in 2005. Data presented here included papers published by 
Vernalis, British Biotech, RiboTargets and lonix Pharmaceuticals. It is important to notice that 
over 70% papers published by this group were published by British Biotech. 
30 In 2003, British Biotech (UK) merged with RiboTargets (UK), later merged with Vernalis in the 
same year. 
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34 companies of group two contributed to 38 per cent of total patents publications. Similar as SCI 
publications, the performance of patent publications was dominated by several outstanding 
companies. The main reasons for this were that these companies, e.g. Celltech and VemalislBritish 
biotech, have been established a long time, and experienced many mergers and acquisitions, which 
enable these companies to accumulate large numbers of patents and research experiences. 
It should be noted that the continuously growing trends of the whole drug discovery and 
development subsector, and the outstanding performance of several top firms in patent publications, 
were two possible reasons for attracting acquirers. Since 2000, many top performing firms with 
large numbers of patents publications have been acquired by foreign companies, in particular, large 
pharmaceutical companies. For example, the top company Celltech, was acquired by UCB for £ 1.5 
billion in May 2004. Similarly, Cambridge Antibody Technology was acquired by AstraZeneca for 
£702 million in May 2006. 
6.3. Content and Classification of Patent Publications 
6.3.1. Content of Patent Publications 
Considering the extremely large amount information contained in patent abstracts and descriptions, 
this study adopted a novel method in analysing patent content. This method was used to obtain 
preliminary results of patent content analysis, and still needs to be improved in future studies. This 
method was based on keyword analysis. There were two sources of keywords. The first set of 
keywords was identified from the results of previous research of alliances and company technology. 
The second set of keywords was identified from patent abstracts. Patent abstracts were imported 
into software Hermetic Word Frequency Counter to identity frequently appearing keywords in 
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patent abstracts. Then all of the keywords were categorized into different groups and browsed in 
patent abstracts. The 'find' function of Excel was used to identity the frequency of keywords. The 
advantage of this simple step is that no matter how many times a keyword appeared in an abstract, 
each keyword was only counted once for that abstract. 
The frequency of how often these keywords occurred in the abstracts reflected the activities and 
focus of these firms. This method, combined with a European patent classification analysis will 
describe the innovation activities of the drug discovery and development firms. 
There were several limitations of this method: first of all, abstracts of 447 patents (16 per cent) 
were not available in the database. Secondly, as stated earlier, this study included many similar 
inventions/discoveries which belonged to the same patent family, in particular, these patents were 
about compounds rather than method/procedure, therefore the frequency of keywords may be 
slightly biased. Although this method still needs improving, it did provide valuable preliminary 
results. 
The keywords which appeared most were categorized into three groups. The first group described 
the patent, which included compound, composition, formula, method, process, treatment, device, 
and reagent (Table 20). 
TabJe 20 Keyword (Group 1) 
K ~ o r d d Frequency 
Compound 776 
Treatment 725 
Formula 660 
Method 571 
C o m ~ o s i t i o n n 245 
Process 203 
Device 67 
Reagent 50 
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The results of the first group of keywords (Table 20) indicated that the largest category of patents 
were related to compounds! compositions and their fonnula, followed by patents describing new 
method/process, which in many cases were linked to the new compounds. The third largest 
category was devices and reagents. The top three categories are all about products or drug 
candidates. 
The second group was about technology, which included both biological related technology and 
chemical related technology, e.g. gene, genome, sequence, virus, vector, nucleotide, peptide, 
polypeptide, protein, antigen, antibody, immune, herb, polynucleotide, mutation, vaccine, honnone, 
stem cell, drug delivery, toxin, generics, micro array, recombinant, monoclonal, synthetic, 
screening, natural, etc (Table 21). 
Table 21 Keyword (Group 2) 
Keyword Frequency Keyword Frequency Keyword Frequency 
Peptide/protein 696 Delivery 84 Mutation 25 
Gene/ genome! 558 Vaccine 80 Toxin 25 
Antibody 280 Natural 79 Honnone 18 
Vector 200 Screening 48 Stem cell 11 
Recombinant 150 Monoclonal 44 Array 5 
Virus 112 Synthetic 41 Generic 5 
Polynucleotide/ nucleotide 109 Library 31 Herb 3 
The results of technology/product keywords research (Table 21) indicate that the peptide/ protein 
were the most popular area in patents, and in many this type of patents, relevant 
gene/polynucleotide/ nucleotide were also patented. Antibody was another product group which 
was preferred by these finns. Other products described in these patents included synthetics, 
vaccines, toxins, honnone, natural compounds, and small numbers of stem cell and generics. The 
patented technologies also include screening and libraries. The biological technologies accounted 
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for the majority of patent publications, while chemical technologies such as synthetics, screening, 
library etc. only accounted for a small fraction. 
The third group was about indications, which included cancer, central nervous system, neural, 
arthritis, pain, respiratory disorders, cardiovascular, inflammatory, infection, antibiotics, antiviral, 
obesity, auto immune, gastrointestinal, antibacterial (Table 22). 
Table 22 Keyword (Group 3) 
Keyword Frenquency Keyword Frenquency 
Immun(e) 344 Cardiovascular 28 
Inflammatory 197 Obesity 22 
Cancer 136 Gastrointestinal 22 
Infection 60 Respiratory 21 
Nervous / neuro 51 Brain 13 
Pain 44 Leukaemia 7 
Antibacterial 34 Antiviral 5 
One fourth of the patents had described possible indication of a compound. As shown in Table 22, 
large groups of indications included immune disorders and immune mediated inflammatory 
diseases, cancer, Infection, and nervous system diseases. Small groups of indications included pain, 
cardiovascular, obesity, gastrointestinal disorders and respiratory disorders. This result was similar 
to the results of SCI pUblication: cancer, immune disorders and immune mediated inflammatory 
diseases, and infectious disease were the major subject of SCI publications. 
In short, based on the three sets of key words, the patent publications are mainly about therapeutics 
which developed with biological technology, in particular therapeutics treating cancer, immune 
disorders and immune mediated inflammation, and infection. 
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6.3.2. Classification of Patent Publications 
The European patent classification system (ECLA) was built on the International patent 
classification (IPC). There are nine categories: A stands for human necessities, B for performing 
operations and transporting, C for chemistry and metallurgy, D for textile and paper, E for fixed 
constructions, F for mechanical engineering, lighting, heating, weapons, blasting engines or 
pumps, G for physics, H for electricity, and Y for general tagging of new technological 
development. The patent publications of drug discovery and development subsector were mostly 
classified as A and C, and a small number of publications were classified as B, G and Y. The 
classification system is very complex, and an example will be cited here to explain it. 
Celltech published a pharmaceutical product for antineoplastic therapy in 1990 with foreign 
inventors. Its publication number was W09001950, and it was classified as A61K39/395 and 
C07K16/24B. It belongs to two different categories. This is very common in publication 
classification. For the first classification: A61K39/395, A stands for human necessities, 61 stands 
for medical and veterinary science and hygiene, K stands for preparation for medical, dental, or 
toilet purposes, 39 stands for medicinal preparations containing antigens or antibodies, 395 stands 
for antibodies, immunoglobulins and immune serum. There are further categories as 
A61K39/395A, A61K39/395B, A61K39/395C, A61K39/395D, A61K39/395E, A61K39/395S 
stands for their source, for example A61K39/395C stands for "against materials from animals". 
There are further subcategories for A61K39/395C: e.g. A61K39/395C3 stands for against tumour 
tissues, cells and antigens. Similarly, for C07K16/24B, C stands for chemistry and metallurgy, 07 
stands for organic chemistry, K stands for peptides, 16 stands for immunoglobulins, e.g. 
monoclonal or polyclonal antibodies, 24 stands for against cytokines, lympbokines or interferons, 
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and B stands for tumour Necrosis factors. According to this classification system, each patent 
publication could be classified to one or more categories. However, this system was very 
complicated, e.g. the 2316 publications which had European classification numbers could be 
classified into over 1300 categories. Therefore, in this project, a simplified system was used (Table 
23 & Appendix 2). 
Table 23 Product innovation and process innovation 
Innovation EU 
type Classification classification Description 
code Number 
Biological C07K Peotides 716 
molecule CI2N Micro-organisms or enzymes; compositions thereof 488 
C07D Heterocvclic compounds 645 
Product C07C Acyclic or carbocyclic compounds 194 innovation Chemical C07J Steroids 26 
molecule 
C07H Sugars; derivatives thereof 34 
Acyclic, carbocyclic or heterocyclic compounds 
containing elements other than carbon, hydrogen, 
C07F halogen, OXV2en, nitrogen, sulphur, selenium or tellurium 31 
Device A61M Devices for introducin2 media into, or onto, the body 72 
A6lK Preparations for medical, dental, or toilet purposes 642 
Preparation C40B Combinational chemistry; libraries 35 
Process and process Fermentation or enzymes-using processes to synthesize a 
innovation desired chemical compound or composition or to 
Cl2P separated optical isomers from a racemic mixture 52 
Investigating or analysing materials by deterring their 
Measurement GOIN chemical or ohvsical oroperties 170 
and analysis Measuring or testing processes involving enzymes or 
Cl2Q micro-organisms 77 
From Table 23 & Appendix 2, several categories had large numbers of pUblications. For product 
innovation, there were 716 patent publications about peptides and 488 about micro-organisms and 
enzymes. 645 patent publications were about heterocyclic compounds and 194 about acyclic or 
carbocyclic compounds. Heterocyclic compounds are organic compounds that contain a ring 
structure containing atoms in addition to carbon, such as sulfur, oxygen or nitrogen, as part of the 
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ring. They may be either simple aromatic rings or non-aromatic rings. Some examples are pyridine 
(C5H5N), pyrimidine (C4H4N2) and dioxane (C4H802). Acyclic compounds are organic 
compounds have open chain structure and do not form a ring. Carbocyclic compounds are 
compounds with a homocyclic ring in which alI the ring atoms are carbon, for example, benzene. 
Micro-organisms, enzymes and the majority of peptides are biological molecules. Heterocyclic, 
acyclic and carbocyclic compounds are all chemical molecules. This distribution is similar to the 
results obtained from previous keyword methods, that patent publications were favoured 
biologicals to chemicals. For process innovation, there were 642 publications about preparations 
for medical and dental, and 170 publications about analysis of compounds' chemical and physical 
properties. 
According to the European Patent Classification system, "Peptides" (C07K) and "Heterocyclic 
compounds" (C07D) were the largest two sub categories of "Organic chemistry" (C07), and they 
accounted for 49 per cent and 44 per cent of C07 respectively. Furthermore, "Peptides having more 
than 20 amino acids; gastrins; somatostatins; melanotropins; derivatives thereof" (C07K14) and 
"Immunoglobulins, e.g. monoclonal or polyclonal antibodies" (C07K16) were major groups of 
"Peptides" (C07K). 
"Medicinal preparations containing organic active ingredients" (A61 K31) was the largest sub 
category of "Preparations for medical, dental, or toilet purposes" (A6l K), and it accounted almost 
for half of the total patents published in this category. 
"Inhalators" (A61Mll) was the largest sub category of "Devices for introducing media into, or 
onto, the body" (A61M), and it accounted for 89 per cent of the total patents published in this 
category. 77 per cent of "Combinational Chemistry" (C40) patents were about "Libraries" 
(C40B40). Inhalators are the most important categories of drug delivery, and libraries are the most 
important categories of combinational chemistry. 
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The largest sub category of "Biochemistry; microbiology; enzymology; mutation or genetic 
engineering" (C12), is "Micro-organisms or enzymes" (C12N), whose largest sub group was 
"Mutation or genetic engineering" (C12N15). C12N15 accounted for 74 per cent ofC12N. Other 
researchers also investigated C12N patents. The growth of British biotechnology companies in 
C12N patenting was around averagely 12 per cent every year between 1985 and 1997 (Thumm 
2001). Compared with this research, although the number of Cl2N patenting accounted for less 
than 2 per cent of the total British C 12N patenting from Thumm's research, the average growth 
rate was higher, around 16 per cent every year between 1985 and 1997. This indicated that 
although the drug discovery and development subsector published slightly fewer patents on C 12 
compared to other biotechnology sectors, e.g. agriculture and food science, this sector's publication 
increased faster than average for the biotechnology industry. 
Immunoglobulin (C07K16) and genetic engineering products (C12NI5) (Appendix 3) were two of 
the most important publication fields, in terms of both number of patent publications and 
significance. Publications of these two categories had several sub-categories. For immunoglobulin 
(319 patent publications), over two thirds of patent publications were about antibodies obtained 
from animals or humans, in particular from tumour celIs. These patents were focusing on 
antibodies against cytokine, Iymphokine, and interferon (100 patent publications), and antibodies 
against receptors, cell surface antigens, and celI surface determinants (107 patent publications). 
There were also 60 patents of hybrid immunoglobulin. Antibodies have been a major focus of the 
products developed by Celltecb and other parts of the UK industry (e.g. CAT) - the same is also 
true of the cytokines. 
For genetic engineering products (331 patent publications), 93 patent publications were concerned 
with viral vectors adapted for animal cell hosts (i.e. gene therapy). 58 patent publications were 
about extracting or separating nucleic acids from biological samples, isolating an individual clone 
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by screening libraries and cDNA synthesis. There were also 52 patent publications about using 
DNA or RNA fragments to produce fusion proteins, for use in MAbs and similar products 
Another important application of the European patent classification was to analyse the innovation 
activities of the drug discovery and development firms in different periods. This method was used 
to describe the dynamics of technology in use. Four categories of patents were selected and 
analysed to picture the output of this subsector: peptides (C07K), heterocyclic compounds (C07D), 
device for drug delivery (A61M) and combinational chemistry products (e.g. libraries) (C40B). 
From 1982 to 2006, the published patents on peptides have been increasing dramatically (Chart 29). 
There were two leaps of peptide patent publications in 200 112002 and 2006, with several year flat-
line ''preparation periods". This trend was very similar as the total patent publications. Another 
similarity between total number of published patents and peptide patents was that, the number of 
peptide patents published also doubled every five years (Chart 30), which suggests that this 
category grew very fast between 1982 and 2006. As the largest sub category, the growth in number 
of peptide patents was also represented by the trend of total growth of published patents. However, 
in terms of the percentage of the four selected categories (Chart 31), the peptide patents showed an 
unsteady decrease between 1987 and 1996. The next ten years, the percentage of peptide patents 
begin to increase, and reached its peak in 2001, then followed by a steady decrease. Although in 
terms of 5-year periods, the percentages of peptide patents were kept at around 50 per cent of the 
four sub category between 1992 and 2006 (Chart 32), the weight of peptide patents actuaIly 
decreased after 2001. One reason was the increase of patent publications on heterocyclic 
compounds after 200 I. 
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The growth of patent publications on heterocyclic compounds has not been steady over the past 25 
year. The first patent of heterocyclic compounds was published 5 years later than the first patent of 
peptide (the chemical molecule patents published before 1986 were focusing on sugar and steroids). 
In tenns of number of published patents, heterocyclic compound patents showed an uneven 
increase between 1982 and 2006. It experienced a decrease in 1999 and 2000 (Chart 29), and 
increase afterwards. From Chart 32, the percentage of heterocyclic compound patents were 
increase dramatically in the second five- year period (1986-1991), then kept still in the next three 
five-year periods (1992-2006). 
Numbers of all four categories showed a steady growth in each 5-year period in the past 25 years 
(Chart 30). Peptides and heterocyclic compounds had similar fast growth trend, in particular 
between 2005 and 2006, while devices for drug delivery and combinational chemistry products had 
similar slow and uneven growth (Chart 33). 
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An important reason for uneven growth of device was that three fourths of device patent 
publications were contributed by ML lab and its subsidiaries 3 1 • Their company strategy and 
research activities had a significant impact on the number of patent publications on devices. 
Similarly, the patent publications on libraries were dominated by two companies: Domantis Ltd32 
(43 per cent) and Cambridge Antibody Technology 33 (37 per cent). The overall number of patent 
publications on libraries increased dramatically after 2001, and this was mainly because of the 
founding of Domantis Ltd in 2000. In other words, because only a few companies were involved in 
patent publications on devices and libraries, and these two areas were dominated by even fewer 
companies, the total numbers of patent publications were much less than that of peptides and 
Heterocyclic compounds. Their numbers were also influenced by one or two companies' activities. 
6.4. Patent Co-publishing 
6.4.1. Country of patent co-publishing 
401 out of 2827 patents in this study (14 per cent) were published in collaboration with foreign 
companies and institutes: 59 were co-published by more than two different countries. There were 
32 countries involved in patent co-publishing, and major countries included US, Australia, 
Germany, Switzerland, France, Finland, China, Italy, Belgium and Netherlands (Table 24). The 
United States, in particular, has the largest number of patent co-publishing with British companies. 
31 ML Lab PIc merged with Quadrant in 2005, and changed its name to Innovata Pic. Innovata 
Biomed was a subsidiary ofML Lab. In 2007, Innovata PIc was acquired by Vectura Group pIc. 
32 Domantis Limited was acquired by GlaxoSmithKline in 2007 
33 Cambridge Antibody Technology was acquired by AstraZeneca in 2006 
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This patent co-publishing involved cooperation with universities and companies. These countries 
were located in four economic regions: Europe, North American, Asia Pacific, and Africa (Table 
25). Europe has the largest number of patent co-publishing with British companies, 209 
publications, which accounted for 43.9 per cent of the total co-publications; followed by North 
America, which has 167 co-publications with British companies, accounted for 35.1 per cent of the 
total co-publication. Rest of the world accounted for 21.0 per cent. 
Table 24 Countries of patent co-publishing 
NUMBER NUMBER 
COUNTRY NAME COUNTRY OF CO- COUNTRY COUNTRY OF CO-
CODE PATENTS NAME CODE PATENTS 
USA US 162 Canada CA 5 
Australia AU 37 Czech Republic CZ 5 
Gennany DE 30 Israel IL 5 
Switzerland CH 28 Republic of Korea KR 5 
Finland FI 26 Norway NO 5 
China CN 25 South Africa ZA 4 
France FR 22 Greece OR 3 
Belgium BE 16 Ireland IE 3 
Italy IT 16 Spain ES 2 
Netherlands NL 13 Hungary HU 2 
Sweden SE 13 Latvia LV 2 
Austria AT 12 India IN 1 
Japan JP 9 Lithuania LT 1 
New Zealand NZ 8 Poland PL 1 
Denmark DK 7 Portugal PT 1 
Gambia GM 6 Ukraine UA 1 
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Table 25 Regions of co-pubUshing 
Region Countries NUMBER OF Percentage 
CO-PATENTS 
Europe Gennany, Switzerland, Finland, France, Belgium, 209 43.9% 
Italy, Netherlands, Sweden, Austria, Denmark, 
Czech Republic, Norway, Greece, Ireland, Spain, 
Hungary, Latvia, Lithuania, Poland, Portugal, 
Ukraine 
North America USA, Canada 167 35.1% 
Asia Pacific Australia, China, Japan, New Zealand, Israel, 90 18.9% 
Republic of Korea, India 
Africa Gambia, South Africa 10 2.1% 
If compared with results from networking alliances (Chapter Seven) (Chart 34 & 35), these two 
studies show both similarities and differences. Several countries that have strong research 
connections with British drug discovery and development ftrms are also major co-applicants! 
inventors, e.g. US, Germany and Switzerland. However, there were exceptions. Finland and China, 
which did not show strong connection in research alliances according to firms' press releases, 
published over twenty separate patents. While Japan and Canada, which showed relatively strong 
connections with British ftrms, published only 9 and 5 patents. The number of co-publishing 
patents with scientists from Gambia was the highest of African countries, and they were mainly 
about malaria vaccines. 
The main reason for this was the difference of alliance purposes. For example, Japan showed very 
strong connections with the UK drug discovery and development subsector, however, the number 
of co-patenting publications was very small. One possible reason is that Japanese companies 
involved in alliances were large pharmaceutical companies; the agreements signed with Japanese 
companies were focused on licensing in, licensing out and acquisitions, rather than co-patenting. 
Another example is Switzerland which also showed strong connections with this subsector, 
however, many agreements signed with Swiss companies were about manufacture and supply. 
Therefore the number of co-patents did not connect with the number alliances. 
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Chart 34 Number of co-patenting by country 
Number of Patent Co-publishing of 
Each Country 
Chart 35 Country of alliances compared with country of co-publishing 
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6.4.2. Counts of patent co-pUblications 
The drug discovery and development subsector started co-publishing patents in 1986, but the real 
increase was from 1995, and then dropped down in 1996 and increased from 1999. 79 per cent of 
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patent co-publications were published after 2000 (Chart 36). Before 200 I, the number of co-
publications with an inventor from a foreign country was less than 20 in each year. In 200 I, the 
number of co-publications increased by 78 per cent compared with the number in 2000. The other 
increase is in 2006, which increased 68 per cent compared with the number of 2005. This trend 
was similar to the total patent publications (Chart 37 & 38). However, the percentage of publishing 
patents with foreign inventors was no more than 21 per cent. Therefore, the overall increase of 
patent publications was mainly due to UK firms, rather than to co-publishing patents with foreign 
countries. 
Chart 36 Number of co-patenting of each year 
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Ahrweiler, Gilbert, & Pyka investigated the UK and German based biotechnology based-industry, 
and suggested that international network formation increased between 1990 and 2000 (Ahrweiler, 
Gilbert, & Pyka 2006). This result was based on granted co-patents, and they further suggested that 
the UK firms have a higher proportion of co-patenting than German firms (Ahrweiler, Gilbert, & 
Pyka 2006). 
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Chart 38 Patents co-pubUsbed with foreign inventors (%) 
100% 
I I ' I I " ' I I I " " " " ' ~ ~50% 0% 
1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 
J 
• Patents published by solely British inventors 
• Patents published with inventors from other country 
Table 26 Types of patent co-publications 
Innovation Classes EU Description Number of Total 
type classification publications 
C07K ~ e p t i d e s s 124 
Biological Micro-organisms or enzymes; 196 
molecule Cl2N compositions thereof 12 
C07D Heterocyclic compounds 57 
C07J Steroids 12 
C07C A ~ c l i c c or carbocyclic compounds 8 
Product Chemical C07F Acyclic, carbocyclic or heterocyclic 5 95 
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innovation molecule 
Process 
Devices 
Preparations 
and 
processes 
C07H 
C08B 
B05B 
A61M 
A61K 
compounds containing elements other 
than carbon, hydrogen, halogen, oxygen, 
nitro2en, sulphur, selenium or tellurium 
SUgars; derivatives thereof 12 
Polysaccharides; derivatives thereof 1 
Spraying apparatus; atomising 
apparatus; nozzles 0 
Devices for introducing media into, or 
onto, the body 10 
Preparations for medical, dental, or toilet 
purposes 111 
Fermentation or enzymes-using 
processes to synthesize a desired 
chemical compound or composition or 
to separated optical isomers from a 
innovation C 12P racemic mixture 5 ~ C ~ 1 ~ 2 R ~ - - - - ~ P r ~ o c ~ e = s ~ s e ~ s ~ ~ ~ i n ~ g n u ~ ' c - r ~ - - o r - - g : a n - I ~ ' s - m s - - - - - - ~ ~ 1 ~ - - - - ~ ~
Measuring 
and 
analysing 
other 
C40B Combinational chemistry; libraries 11 
BO ID Separation 1 
C12Q 
GOIN 
YOIN 
Measuring or testing processes 
involving enzymes or m i c r ~ o r g a n i s m s s 3 
Investigating or analysing materials by 
deterring their chemical or physical 
properties 15 
Nanotechnology: 
nanotechnology 
surface science 
Nanobiotechnology; 
for materials and 
1 
6.4.3. Contents of co-publishing patents 
10 
129 
18 
1 
According to the European patent classification codes, two thirds of the co-patenting publications 
were focused on product innovation, and one third on process innovation (Table 26). There were 
three types of product innovation: macro molecules, small molecules and devices. In co-patenting, 
65 per cent of the product innovations were biological molecules, 32 per cent were chemical 
molecules, and only 3 per cent were devices. 87 per cent of the process innovations were focused 
on preparations and processes, 12 per cent were on measurement and analysis. Therefore, the main 
field of co-publishing patents with foreign inventors focused on biological molecules. This 
suggests that patenting publications and co-patenting were both more active in biological research 
than chemical research. 
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6.5. Summary 
In this chapter, three aspects of patent publications have been addressed: the productivity of the 
drug discovery and development subsector in terms of patent publications, patents co-publishing 
with other countries, and the contents of patents. 
There are four major findings of this chapter. First of all, this subsector played an important role in 
patent publication. The number of patent publications grew fast in the past 25 years. Before 2005, 
patent publications presented a similar trend as SCI publications. However, after 2005, the number 
of patent publications increased dramatically, while the number of SCI publications began to fall. 
The increase of patent publications was contributed by the whole subsector rather than a few 
companies. One possible reason was that in order to attract investment, many small to medium-
sized companies paid more attention to patents publications rather than scientific publications. 
Another possible reason is competition, as MacPherson & Boasson argued, the number of patents 
are positively correlated with the density of competition (MacPherson & Boasson 2004, P3 I 9). 
Secondly, similar to the pattern of SCI publications, the patent publications pattern also indicated a 
hierarchical structure. A small number of companies published the majority of patents. The top 
company, Celltech, even published as many patents as many large pharmaceutical companies. This 
high output of patents was mainly the result of the large amount of R&D investment of this 
subsector (DTI 2006a). 2004/2005 R&D investment of Shire Pharmaceutical and Celltech were 
£112 million and £106 million. They ranked fifth and sixth among the UK biotechnology and 
pharmaceutical industry, following GlaxoSmithKline (£2839 million), AstraZeneca (£1981 
million), Pfizer (£597 million) and Eli Lilly (£147 million). 
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Thirdly, knowledge fonnation was also enhanced by networking with foreign countries. In 
particular, after 2000, the amount of patent co-publishing increased dramatically and co-
publications were focused on both product and process innovation. American companies and 
institutes have been the largest partner in co-patenting. Comparing data on alliances (next chapter) 
with data of co-publications, several countries which have strong research connections with the 
British drug discovery and development finns are also the major co-applicants/ inventors, e.g. US, 
Gennany and Switzerland. However, this is not always the case. The largest region of co-
publishing patents was Europe, followed by North America. Compared with Gennan companies, 
the UK finns have a higher proportion of co-patenting than Gennan finns (Ahrweiler, Gilbert, & 
Pyka 2006). 
Finally, major indication groups included immune disorders, inflammatory diseases, cancer, 
infection, and nervous system diseases, which is similar as the results obtained from SCI 
publication study. Overall, patent publications of biological compounds are more than that of 
chemical compounds. For individual technologies, patents of pep tides and heterocyclic compounds 
grew very fast, while devices for drug delivery and combinational chemistry products were slow 
and steady. Unlike patent publications of peptides and heterocyclic compounds, which were 
contributed by a large number of companies, patent publications of devices and libraries were 
contributed by a few companies. These latter two areas were dominated by even fewer companies, 
and the total number of patent publications was much less than that of peptides and heterocyclic 
compounds. Their numbers were mainly influenced by one or two companies' activities. 
In short, in tenns of counts of patent publications, the output of the UK drug discovery and 
development subsector was very remarkable. Furthennore, these outputs indicated a hierarchical 
structure: a few successful companies, which have been established for a long time, have large 
amounts of R&D investment, and accumulated large numbers of patent publications, and thus 
dominated the patent publications. The fast growing numbers of patent publications between 1982 
and 2006 suggested that these companies were very successful in knowledge output, in particular, 
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research and development on biological compounds and small molecules. This was partly driven 
by the large domestic R&D investment, global trend of industry development and networking with 
other fast growing countries. 
Implications for policy: 
Patel argued that UK finns have great potential to commercialize biotechnology discoveries, and 
its perfonnance is influenced by factors such as "availability of venture capital and the continuing 
supply of well trained scientists and engineers from the UK science system, both of which have the 
potential to be greatly influenced by government policies" (Patel 2003b, P4). 
Based on the data of both scientific publications and patents publications, the accumulation of 
knowledge is also very important to a finn's patenting. As Malerba suggested, knowledge 
accumulation and diffusion is central to innovation activities and cumulativeness was affected by 
the learning process, the finn's capability and feedback from the market, and high cumulativeness 
leads to high appropriabiJity of innovation (Malerba 2005). Therefore, policies could also aim at 
enhancing networking and advisories of market. Enhancing networking and advisories of market 
would help companies commercialize their knowledge (e.g. licensing out) and get funds for their 
further development. 
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Chapter Seven: Alliances 
7.1. Introduction 
As reviewed in Chapter two, the notion of alliances and networks are widely studied in different 
disciplines, such as economics, corporate strategy, and inter-organizational field, and different 
theoretical perspectives and methodologies have been used to "understand the formation, evolution, 
operation and outcomes of organizational alliances and networks" (de Rond & Bouchikhi 
2004;Osborn & Hagedoorn 1997, P261). 
This chapter aims to describe the alliance activities of the UK drug discovery and development 
firms by analyzing agreements signed with other companies. This chapter also aims to find out 
why drug discovery and development companies are networked with other companies and what 
roles they play in networking? Moreover, how these companies networked during different periods 
and to what extent they networked? What technologies and disease indications were involved in 
these alliances? These questions are essential to answer the issue whether the British drug 
discovery and development subsector benefited from policies which aimed to promote the 
biotechnology and pharmaceutical industry. 
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In this chapter alliance agreements signed by drug discovery and development companies will be 
analyzed. 943 alliance agreements dated from 1983 to 2006 were collected. As discussed in thc 
Methodology Chapter, data were collected from Recombinant Capital database and companies' 
websites. The Recombinant Capital database was also use by other researchers (Lerner & Merges 
1998). According to types of signees, there are two types of agreements: agreements signed within 
the drug discovery and development section, or agreements signed between drug discovery and 
development companies and other pharmaceutical and biotechnological companies. This 
classification is used to describe the roles the drug discovery and development subsector played in 
the pharmaceutical and biotechnology industry. According to country of signees, there are two 
types of agreements: agreements signed with British companies, and agreements signed with 
foreign companies. This classification is used to describe the roles the drug discovery and 
development subsector played in international knowledge flow. 
The first section will describe an overview of alliances between 1983 and 2006, and further details 
of these alliances will be analyzed in later sections, including geographical networking, purpose of 
alliances, disease indications, technology and stage of alliance, followed by discussion of key 
features of alliances in different periods. The final section is the summary and conclusion. 
7.2. Overview of Networking 
The networking of UK drug discovery and development companies has been changing 
dramatically in the past decades. During the I 980s, shortly after the UK first generation 
biotechnology firms were born, they established connections with the pharmaceutical and 
biotechnology industries from other countries: 32 agreements in total during 1980s. The data 
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presented in this study were data of the UK first generation companies which was still in operation 
in 2006. Therefore, the real number of agreements was actually underestimated. As shown in Chart 
39, the yellow dot in the middle represent the British drug discovery and development subsector 
established during 1980s. Other dots represented the domestic and foreign partners of this 
subsector. Lines represented the alliance agreements signed between these drug discovery and 
development companies and their partners. The largest group as partners during the I 980s was US 
pharmaceutical and biotechnological industries, in particular, the US large pharmaceutical 
companies (Chart 39). During the 1980s 19 agreements (59 per cent) were signed with US 
companies. The drug discovery and development subsector also established a few connections with 
European and domestic large pharmaceutical companies, and other biotechnology and 
pharmaceutical companies from Europe and the rest of the world. 
In the 1990s, the UK first generation firms established wider connections with other companies. 
US companies were still the largest group of partners. However, these companies cooperated more 
with the US small to medium sized biotechnology and pharmaceutical companies, rather than with 
large pharmaceutical companies. The emerging British drug discovery and development companies 
also rapidly established collaborations with US and EU companies. These companies which were 
founded after 1990 not only allied foreign and local companies, but also with their domestic 
competitors: the first UK generation drug discovery and development companies. The rapid 
growth of second generation firms changed the structure ofthe network (Chart 40). 
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Chart 39 Networking of the UK biotechnology subsector during the 1980s 
(powered by VisuaLyzer 2.0) 
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Chart 40 Networking of the UK biotechnology subsector during the 1990s 
(powered by VisuaLyzer 2.0) 
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Both first generation and second generation finns played important roles in networking. There 
were 290 agreements signed in total during the 1990s. Besides small scale collaboration between 
first and second generation finns, many local support companies also joined the network. The 
alliances between the British drug discovery and development subsector and the US also expanded 
during 1990s. However, large US pharmaceutical companies were no longer the major group of 
partners, instead, medium and small sized US finns started collaborating with the UK drug 
discovery and development subsector, taking the place of the US large pharmaceutical companies, 
and becoming the most important partners of the this subsector. There were 95 agreements signed 
with medium and small sized US finns, and only 39 agreements signed with the US large 
pharmaceutical companies. The total agreements (134) signed with US companies were as many as 
seven times than that during 1980s. 
The alliances with EU large pharmaceutical companies, as well as medium and small sized finns, 
also increased to 54 agreements: as many as nine times than that during 1980s. The top three 
countries were Gennany (12 agreements), Switzerland (nine), and France (seven). The 
collaboration with the UK pharmaceutical companies was also expanding, but less than 
collaboration with the US and the EU. Connections with companies in other geographic regions 
also increased during 1990s, in particular alliances with Japanese companies (15) and Canadian 
companies ( five). 
After 2000, the networking of UK drug discovery and development companies expanded more 
quickly than before. The alliances within this subsector were increasing. Large numbers of new 
companies34 established after 2000 attracted more foreign and domestic company collaborators 
(Chart 41). Medium and small sized companies from the US, as well as those from the EU, rapidly 
expanded their networks with the UK drug discovery and development subsector. 181 agreements 
34 The UK drug discovery and development companies established after 2000 are also part of 
second generation finns. 
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were signed with medium and small sized companies from the US, and 91 agreements were signed 
with medium and small sized companies from EU. 
Cbart 41 Networking oftbe UK biotechnology subsector after 2000 
(powered by VisuaLyzer 2.0) 
Large pharmaceutical companies from the US, EU, Asia and UK all played important roles in 
collaborations. However, the number of UK partners was less than that of the US and the EU. The 
increasing number of alHances from areas other the EU and the US, were mainly the results of 
connections with Japan, Australia and Canada. The top three EU countries which signed 
agreements with this subsector were Switzerland (27 agreements), Germany (24 agreements) and 
Belgium (nine agreements). 
In short, the path of networking of UK drug discovery and development subsector began with 
collaborating with US companies, in particular large pharmaceutical companies, and then moved 
on to collaborate with small and medium sized companies from the US and the EU. One possible 
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reason for this was that in the last decade, the UK companies moved from research and 
development providers (R&D provider) to clients or co-developers. These worldwide alliances 
between small to medium sized companies also indicated a trend towards the division of labour in 
research and development in this subs ector. 
The growth of the drug discovery and development subs ector, in terms of both size of individual 
companies and number of companies, enabled this subsector to become more and more active in 
networking. Therefore this subsector was characterized by a large number of alliances and density 
of networking. 
7.3. Partners 
7.3.1. North American companies 
Since the start of the industry, US firms have been the most important partners for the UK drug 
discovery and development subsector in terms of number of alliances. US firms have been 
involved in 41 per cent of all alliances (386 agreements); this is even higher than the 38 per cent of 
local alliances (355 agreements). In total, United States and Canada have been involved in 45 per 
cent of all alliances. The main reason for this is the leading role and the sheer size of the North 
American industry since 1980s. One important motivation for drug discovery and development 
subsector to form alliances with US companies was to access the technology advances. 
In the 1980s, 59 per cent of agreements were signed between the UK drug discovery and 
development subsector and the US companies. On most occasions they acted as R&D buyers. 
However, in the 1990s, the percentage of US partners dropped to 46 per cent. Large American 
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pharmaceutical companies were still major buyers; however, a significant number of American 
companies became R&D providers in British-American alliances: 87 British companies were R&D 
providers and 47 US companies were R&D providers in British-American alliances during 1990s. 
Three companies were very active in sourcing R&D in American: they were Shire Pharmaceutical 
(five agreements), Cambridge Antibody (four agreements), and Celltech (including smaller UK 
finns that were acquired by CeIItech such as Chiroscience, Medeva, and Oxford GlycoSciences, in 
total 18 agreements). These drug discovery and development companies accumulated knowledge 
and experience through aIIiances. 
After 2000, the percentage of British-American alliances decreased to 37 per cent. UK companies 
became more active in acquiring American companies, which would enable them to enter the 
North American market and to expand their products portfolio. The total number of agreements 
acquiring or purchasing assets of the US companies was 20 after 2000. For example, Shire 
Pharmaceutical, had acquired three US companies and subsidiaries of one US company before 
2000, and after 2000, Shire Pharmaceutical acquired another three US companies and one 
Canadian company. In 1997 Shire Pharmaceutical acquired drug delivery company Pharmavene, 
which is key for drugs CARBATROL and ADDERALL XR, and marketing company Richwood 
Pharmaceutical Company to enter US market. In 1999, Shire Pharmaceutical acquired the German, 
French and Italian sales and marketing subsidiaries of Fuisz Technologies Ltd, and merged with 
American company Roberts Pharmaceutical Corporation to build market cap. In 2001, Shire 
acquired Canadian company BioChem Pharma to build market cap. In 2002, Atlantic 
Pharmaceutical was acquired by Shire, and turned into a principle manufacturing site of its US 
operation. In 2005 and 2007, shire acquired Transkaryotic Therapies Inc and New River 
Pharmaceuticals Inc respectively for their technology platform and pipelines (www.shire.com). 
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7.3.2. Domestic and European Companies 
UK drug discovery and development companies became increasingly active in networking within 
both local companies and companies from other European countries after 1990. 
Firstly, connections were strengthened among UK companies, in particular, within the drug 
discovery and development subsector. For the British-British alliances identified in the study, the 
percentage grew from 16 per cent in 1980s to 22 per cent of total alliances number in 1990s, and 
increased to 23 per cent after 2000. The alliances among British companies, in particular the 
internal connections within the drug discovery and development subsector, was actually 
strengthened. However, the total number of British-British alliances only accounted for a small 
fraction of the total alliances. Mergers and acquisitions within the subsector after 2000 also led to 
consolidation of this industry: large drug discovery and development firms were formed after 2000, 
e.g. Celltech and Cambridge Antibody, although many of them were later acquired by large 
pharmaceutical companies. 
Secondly, companies from other European countries also became more active in networking with 
the UK drug discovery and development subsector after 1990s. Most of these companies were 
large pharmaceutical companies from Switzerland (e.g. Novartis), Germany (e.g. Bayer) and 
France (e.g. Rhone-Poulenc Rorer). After 2000, large pharmaceutical companies from Belgium 
(e.g. UCB) and Ireland (e.g. Elan) also became important clients of the UK drug discovery and 
development firms. Their major interest was research collaboration, licensing, and acquisition, and 
this will be discussed in details in later sections. 
Companies from Switzerland and Germany also acted as service providers: German companies 
were mainly focused on research collaboration and licensing, and Swiss companies were mainly 
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suppliers and manufactures to UK firms. The number of alliances with Belgium companies was 
very small; however, one third of these alliances were about acquisitions, e.g. Celltech was 
acquired by UCB in 2004, Inpharmatica and Prostrakan's French subsidiary ProSkelia were both 
acquired by Galapagos NY in 2006. This trend was partly driven by the motivation of European 
biotechnology and pharmaceutical industry to access technologies and markets. 
7.3.3. Asia and Pacific companies 
Companies from Japan, in particular large pharmaceutical companies, had allied with the UK drug 
discovery and development subsector since the I 980s. They mainly acted as buyers and were 
interested in research development and licensing. Companies from Australia also became more 
important partners after 2000 (16 agreements). They were not only buyers but also R&D providers. 
There were also partners from other countries of this area after 2000, e.g. China, India, Singapore 
and Korea. However, their alliances only accounted for less than two per cent of the total. 
Why did these companies ally more with foreign companies than local companies? Learning 
knowledge from alliances, gaining access to complementary assets and novel technologies and 
building technology advantages could be the main reasons they allied with foreign companies, in 
particular, US companies. Based on research on the UK genomic firms, Cooke observed that the 
British companies are more innovative in partnering with US and Asian firms (Cooke 2006). He 
suggested that "firms have no desire to conduct R&D with local competitors because they already 
know its likely content due to 'open science' and localized knowledge spillovers among firms 
competing in highly specific local niches" (Cooke 2006, PI274). 
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7.4. Purposes of Alliances 
7.4.1. licensing, research and clinical development 
The major purpose of alliances was licensing in and licensing out: 34 per cent of total alliances in 
the 1980s were concerned with licensing; later this number grew to 57 per cent in the 1990s, and 
64 per cent after 2000. The main reason for this was that intellectual capital accumulated since 
1990s attracted many partners to form alliances with the UK drug discovery and development 
companies (Coombs, Mudambi, & Deeds 2006;Hsu 2006). 
Although the number of alliances concerned with research and development has grown steadily 
since the I 980s, the growth rates were slower than that of licensing. As a consequence, 50 per cent 
of total alliances in the 1980s were concerned with clinical development. This number decreased to 
39 per cent in 1990s, and fell further to 22 per cent after 2000. The percentage of aIIiances 
concerned with research has been stable at one fifth since 1980s. 
This fast growth in licensing, steady growth of research and slower growth in development may 
suggest that many UK drug discovery and development companies start discovery and 
development internally. These companies which began exploring new product pipelines, due to the 
constraint of financial support, they licensed out products with poorer prospects in early stages 
rather than continued to development stage (as mentioned in the Literature Review Chapter). This 
also indicated their relative maturity in early stage product discovery and development. 
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7.4.2. Acquisition. Asset purchases. Joint Venture and Equity Investment 
In the 1980s, acquisitions were very rare, and later in 1990s, there were 22 acquisitions, and since 
2000, 70 acquisitions have been recorded including ten brand acquisitions. Similarly, the number 
of asset purchases also grew fast, from 18 cases in 1990s, to 46 cases after 2000. At the same time, 
the growth of numbers in joint venture slowed down. 
One possible reason for the fast growing number of acquisitions, as suggested by Walsh, was that 
the acquisitions were more attractive and less risky than normal collaborations if companies 
wanted to develop products internally (Walsh 2002). Other possible motives for acquisitions 
included moving away from R&D weakness by accessing technology and expertise, i.e. large 
pharmaceutical companies acquired biopharmaceutical companies, and to achieve market presence, 
i.e. UK. drug discovery and development companies acquired US biopharmaceutical companies 
(Walsh 2002). One example was in 1997 Shire Pharmaceuticals acquired specialty sales and 
marketing company Richwood Pharmaceutical Company to enter the US market. In 1999, Shire 
Pharmaceutical acquired the German, French and Italian sales and marketing subsidiaries of Fuisz 
Technologies Ltd to enter major European markets. 
As discussed earlier in this chapter, merger and acquisitions have a very important impact on the 
structure of this industry. Since the 1990s, merger and acquisitions enabled several drug discovery 
and development companies to go into the top biopharmaceutical companies of Europe, such as 
Celltech and Shire Pharmaceutical. On the other hand, large scale merger and acquisitions after 
2000 also lead to dramatic changes in the subsector structure. 
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After 2000, drug discovery and development companies acted as buyers in 55 per cent of 
acquisitions and asset purchases, including acquisitions and assets purchases within the drug 
discovery and development subsector (Table 27). Drug discovery and development companies 
were mainly focused on buying domestically or from North American. 24 per cent of total 
acquisitions and asset purchases were UK drug discovery and development companies buying 
North American companies, and European companies only accounted for six per cent. 25 per cent 
of total acquisitions and asset purchases were UK drug discovery and development companies 
buying domestically, divided into 18 per cent buying within drug discovery and development 
subsector, and seven per cent buying out of this subsector. 
North American companies were also a major buying force in acquiring UK drug discovery and 
development subsector, accounted for 22 per cent of total acquisitions and asset purchases, which 
is slightly less than the UK drug discovery and development companies purchasing from North 
American (Table 28). 12 per cent of total acquisitions and asset purchases were European 
companies acquiring UK drug discovery and development companies, which is twice as much as 
the UK drug discovery and development companies buying from Europe. 
There are three types of domestic buyers: buyers within the drug discovery and development 
subsector were the largest buyers, and accounted for 18 per cent of total acquisitions and asset 
purchases. This is the determinant of subsector structure change and dynamics. Buyer companies 
out of this subsector accounted for eight per cent of total acquisitions and asset purchases, 
including large pharmaceutical companies such as GSK and AstraZeneca. 
Although the number of acquisitions by large pharmaceutical companies (including large 
pharmaceutical companies from other country) was less than that of other companies, the large 
pharmaceutical companies actually conducted the largest acquisitions in this subsector: they 
'harvest' the well established companies, in particular, those most successful companies, of the 
drug discovery and development sector. 
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Table 27 Acquisitions/asset purchases of other companies 
Categories Region Number Percentage 
Of all NA 
North US 22 24% 
American Canada 6 
Acquisitions/assets purcbases of Europe Germany 3 
foreign companies Switzerland 2 6% 
Sweden I 
Spain 1 
Acquisitions/assets purchases 21 18% 
within UK drug discovery and UK 
development subsector 
Acquisitions/assets purchases of 8 7% 
other UK companies 
Table 28 Acquisitions/asset purchases by other companies35 
Categories Region Number Percentage 
Of all NA 
North US 21 22% 
American Canada 5 
Europe Belgium 3 
Acquisitions/assets purchases Ireland 3 12% 
by foreign companies Sweden 3 
Switzerland 3 
Netherlands 1 
Germany 1 
Other Australia I 3% 
Japan I 
India 1 
Acquisitions/assets purchases 4 3% 
by UK large pharmaceutical 
companies UK 
Acquisitions/assets purchases 6 5% 
by other UK companies 
35 Total number was slightly different from simply adding up because some company belong to 
more than one country, e.g. AstraZeneca was a UK-Sweden company. 
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7.5. Disease indications and Technologies 
Alliances were mainly focused on cancer and central nervous system diseases, as well as infection, 
inflammation and pain. Cancer was the major indications of alliances. In the 1990s, there were 27 
alliances focused on cancer, accounted for nine per cent of total alliances during 1990s (Table 29). 
After 2000, this number grew to 92 alliances, accounted for 15 per cent of total alliances after 2000. 
No alliance focused on the central nervous system in the 1980s. There were 22 alliances concerned 
with the central nervous system diseases in the 1990s accounting for eight per cent of total 
alliances during 1990s. This number increased to 75 after 2000, which accounted for 12 per cent of 
alliances during this period. Treatment for infection, inflammation and pain were other concerns of 
the alliances, which have grown fast in the last decades. In the 1990s, there were 16 agreements 
focused on infection; after 2000, this number grew to 42. In the 1990s, there were 16 and 13 
alliances on inflammation and pain respectively; after 2000, these numbers grew to 31 and 35. 
Table 29 Indications of Alliances 
Indications I 990s After 2000 
Number of Percentage Number of Percentage 
alliances alliances 
Cancer 27 9 92 15 
Central Nervous System 
Disease 22 8 75 12 
Infection 16 6 42 7 
Inflammatory disease 16 6 31 5 
Pain 13 4 35 6 
Alliances slowly expanded on researching cardiovascular diseases, respiratory, genito-urinary, 
autoimmune, blood and haernatopoietic factors, gastrointestinal, kidney disease and wound care. 
Records of other indications also presented an increase trend in the number of alliances; however, 
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they were still on a smaller scale. These indications included cardiovascular diseases, respiratory, 
genito-urinary, autoimmune, blood and haematopoietic factors, gastrointestinal, kidney disease and 
wound care. For example, cardiovascular diseases were major indications in the I 980s: there were 
five alliances concerned with cardiovascular diseases (16 per cent), more than cancer and 
infections. In the 1990s, there were II alliances and the percentage dropped to four per cent and 
after 2000, the number of alliances focused on cardiovascular diseases were 13, and only 
accounted for two per cent of the total number. The alliances concerning diagnostics, ophthalmic, 
dermatologic, metabolic disorders, and obesity were relatively less active in the last decades. 
7.6. Technologies 
Both chemical and biological technologies have been involved in alliances. The number of 
alliances involving synthetics, screening, drug delivery, rational drug design, monoclonals, 
bioinfonnatics, gene expression, vaccines and proteomics, grew very fast since I 990s. 
Technologies related to chemistry were very popular in alliances, e.g. synthetics, screening and 
rational drug design after 2000. In the 1980s, the total number of alliances focusing on synthetics, 
screening and rational drug design was five. However, in the 1990s, the number of alliances 
concerning synthetics, screening and rational drug design increased to 39, 27 and 14 respectively, 
and after 2000, there were 123, 87 and 45 alliances respectively (Table 30). This made synthetics 
and screening the most popular technology in alliances, accounting for 20 per cent and 14 per cent 
oftotal alliances after 2000. 
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Table 30 Technologies most in use in alliances during 2000 and their use during 1990536 
Technologies 1990s After 2000 
Involved in Alliances Number Percentage Total Number of Percentage Total 
of alliances 
alliances 
Synthetics 39 13 123 20 
Chemistry ScreeninR 27 9 69 87 14 184 
Rational drug 14 (24 per (30 
design cent) 45 per 
5 7 cent) 
Monoclonal 31 II 69 II 
Bioinformatics 2 I 65 47 8 205 
Biotechno- Gene 22 (22 per 44 (33 
logy expression 8 cent) 7 per 
Proteomics 7 2 42 7 cent) 
Vaccines 16 6 40 6 
Biological technologies, such as monoclonal, bioinfonnatics, gene expression and proteomics, also 
became more important in alliances during last decades. The number of alliances concerning 
monoclonals grew from 31 in the 1990s to 69 after 2000. There were only two cases of use of 
bioinfonnatics before 2000; however, this number was 47 after 2000. This made the bioinfonnatics 
the fastest expanding technology in alliances. Gene expression, vaccines and proteomics also have 
shown a fast growing trend since the I 990s. Although each individual biological technology did 
not dominated after 2000, the total percentage of biological technologies increased, i.e. monoclonal, 
bioinformatics, gene expression, proteomics and vaccines, accounted for 33 per cent of total 
alliance after 2000. This percentage was more than the 30 per cent of alliances using chemical 
technologies, which suggests that although both chemical and biological technologies are very 
important in alliances, overall biological technologies were expanding faster than chemical 
technologies in alliances since 1990s. 
Technologies such as peptides, gene sequencing and cell therapy were also expanding in use in 
alliances. There were only four agreements concerned about peptides during 1990s, after 2000, this 
36 The total number of alliances using chemical and biological technologies was less than adding 
up individual technologies, because an alliance may involve more than one technology. Also there 
are small amount of alliances involve in using both chemical and biological technologies. 
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number increased to 26. Alliances about gene sequencing were ten during 1990s and 13 after 2000. 
There was only one agreement about cell therapy before 2000, and after 2000, there were 1 I 
agreements. 
Apart from the popular technologies discussed above, there were also many technologies less in 
use in alliances, such as natural products, separation, immunoassay, immunoglobulin and 
transcription factors. One reason for this was that these technologies were very mature, and 
companies could use these technologies without partnership. 
7.7. Stage of drug discovery and development 
Alliances were signed at an early stage of discovery in 1980s. During 1980s, except for one 
alliance which was signed after the drug was approved, all others were signed at discovery (5, 16 
per cent), lead molecule (5, 16 per cent) and formulation stages (5, 16 per cent)37. None of them 
had entered the preclinical or clinical stage. This indicates that in the1980s, drug discovery and 
development companies, such as Celltech, were focusing on early stage drug discovery. This also 
suggests that this subsector was still immature. 
In the 1990s the stages of alliances extended to all eight stages, from discovery, lead molecule, 
formulation, to preclinical, phase I , phase II, phase III, BLAINDA filed and approved stages. 
There largest groups were alliances signed at discovery and formulation stages, accounting for 22 
per cent and 14 per cent of the total respectively. Alliances signed at preclinical and later stages 
accounted for 27 per cent (Table 31). Although there were only a few alliances signed at phase III, 
37 Some data were not available, therefore the total percentage were less than lOOper cent. 
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this still indicated that the drug discovery and development subsector started to enter into late 
stages of drug development. 
Table 31 Stage of drug discovery and development in alliances 
Stage of 1980s 1990s After 2000 
signing Number of Percentage Number of Percentage Number of Percentage 
agreements A2I"eements A2I"eements A2I"eements 
Discovery 5 16 65 22 193 31 
Lead Molecule 5 16 14 5 29 5 
Formulation 5 16 42 14 32 5 
Preclinical 0 - 22 8 23 4 
Phase I 0 - 14 5 22 4 
Phase II 0 
-
12 4 29 5 
Phase III 0 - 9 3 21 3 
BLAINDA 
-
filed 0 2 1 6 1 
Approved 1 3 16 6 34 5 
After 2000, the numbers of alliances increased in aU stages except the formulation. Since the 1990 
the drug discovery and development subsector was involved in all stages of drug discovery and 
development, and this subsector kept active in networking after 2000. The agreements concerning 
with discovery grew very fast, from 65 agreements (22 per cent) in the 1990s to 193 agreements 
(31 per cent) after 2000. The number of alliances signed at lead molecule grew steady, from 14 
agreements (five per cent) in I 990s to 29 agreements (five per cent) after 2000. On the other hand 
the number of alliances signed at formulation stage decreased after 2000 (Table 31). There are 42 
agreements (14 per cent) signed at lead molecule stage during the 1990s, this number dropped to 
32 (five per cent) after 2000. The number of agreements signed at preclinical stage increased from 
22 in 1990s to 23 after 2000, while the percentage dropped from eight per cent of total alliances 
during 1990s to four per cent after 2000. The overall number of agreements signed at discovery, 
lead molecule, formulation and preclinical stages grew steady and dominated the total number of 
agreements. 
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The numbers of alliances signed at phase I, phase II, and phase III increased steady after 2000. The 
number of agreements signed at phase I grew from 14 (five per cent) during 1990s to 22 (four per 
cent) after 2000. The number of agreements signed at phase II grew from 12 (four per cent) during 
1990s to 29 (five per cent) after 2000, and the number of agreements signed at phase III grew from 
nine during 1990s (three per cent) to 21 after 2000 (three per cent). The overall percentage of 
agreements signed at phase I, phase II, and phase III kept at 12 per cent since 1990s. 
7.8. Alliance activity in different periods 
One of the most notable features of this data is that alliance activities had different characteristics 
during different time periods: not only has the number of alliances fluctuated over time, but also 
the purpose, technologies and disease indications have changed. This section will describe the 
alliances from a perspective of dynamics. 
7.8.1. 19805 
SmaIl scale alliances focused mainly on R&D providing during the 1980s. During the 1980s the 
number of alliances created by the UK drug discovery and development subsector was no more 
than ten each year (Chart 42). There were only eight finns involved in alliances. Two of them were 
major participants: Celltech involved in 15 agreements, accounted for 47 per cent of all aIliances in 
the 1980s, and Vernalis involved in seven agreements, accounted for 20 per cent. Other important 
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finns included Shire Pharmaceutical, Xenova, Amarin, Controlled Therapeutics, Chiroscience 
(acquired by Celltech in 1999) and Cantab Phannaceuticals (acquired by Xenova in 2001). These 
six companies accounted for 33 per cent of all alliances. 
12 
10 
8 
6 
4 
2 
o 
Chart 42 Agreements signed during 19805 
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Another important feature during 1980s was that in most of the 32 alliances (with only two 
exceptions) the UK drug discovery and development finns played the role of R&D provider rather 
than purchaser. Their partners were mainly from the US: 19 agreements (59 per cent) were signed 
with US companies. The majority of these clients were large pharmaceutical companies, which 
included Lilly, SmithKline, Abbott, Baxter, Pifzer, Roche and DuPont. The major fields of 
research varied, including drug delivery, monoclonals, recombinant DNA and synthetics. Major 
indications were cardiovascular diseases and cancer. 72 per cent of agreements were about research, 
development and license. 
7.8.2. 19908 
Alliances grew steadily during the 1 990s. Although there was a slight decrease in terms of 
agreements in 1993 and 1996 (Chart 43), the overall trend was a growth: from eight agreements in 
1990 to 61 agreements in 1999. The main reason for the growth was that the newly established 
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drug discovery and development finns started networking. The new important players included 
Acambis, Cambridge Antibody, Medeva, Oxford BioMedica, Oxford GlycoSciences, and 
Phannagene. They signed 165 agreements in total, which accounted for 57 per cent of total 
agreements signed during the 1990s. 
Celltech was still the most active player in networking, not only because it was involved directly in 
14 per cent of the total number of alliances during the 1990s, but also because of two mergers and 
acquisitions in 1999, which made Celltech the largest biotechnology company in Europe. One 
merge was between Chiroscience and Celltech to fonn Cell tech Chiroscience pIc in June 1999, and 
the other was when Celltech Chiroscience pIc acquired Medeva PIc in November 1999. Another 
important acquisition also happened in the same year when Shire Phannaceutical acquired Robert 
Pharmaceutical, a US company, for one billion US dollar in stock. These signs indicated that the 
UK drug discovery and development finns were not only active R&D providers, but also active 
buyers, and collaboration within the UK discovery and development subsector was becoming more 
and more common. This further suggests increasing maturity of these companies during 1990s. 
Chart 43 Agreements signed during 1990s 
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One direct result of the growing intra-sector alliances was that the percentage with foreign 
companies, in particular, US companies, decreased. The number of agreements signed with US 
companies increased from 19 during 1980s to 134 during 1990s. But the percentage of alliances 
with US companies decreased: 59 per cent of total alliances during the 1980s, compared with 46 
per cent during the 1990s. 
Major collaboration fields not only included synthetics, monoclonals, recombinant DNA and drug 
delivery, but also expanded to gene expression, gene therapy, proteomics, peptides, vaccines, 
bioinformatics, combinational chemistry, screening, rational drug design, and natural products. 
Cancer, central nervous system diseases and anti-inflammatory diseases became the most 
important indications of alliances during 1990s, compared with cardiovascular diseases and cancer 
during 1980s. Other disease major indications included autoimmune, cardiovascular, dermatologic, 
gastrointestinal, infection, metabolic disorders, pain, respiratory disorders, and wound care. There 
was also a small number of research alliances on blood & hematopoietic factors, 
gynecologicaVgenito-Urinary, kidney disease, ophthalmics and obesity. 
Each alliance may have several purposes, for example, one agreement many included both co-
development and license. During the I 990s, 73 per cent agreements were about research, 
development, and licensing; this is similar as the level of 72 per cent agreements about research, 
development, and license during 1980s. 
7.8.3. After 2000 
There was a dramatic increase in the total number of alliances, together with large scale mergers 
and acquisitions since 1999. However, by 2002 this trend was broken when the alliance number 
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decreased for three years: the number of alliances in 2004 was 56 per cent as many as that in 200 I. 
Then in 2005 and 2006, the number of alliances started growing rapidly again (Chart 44). The 
agreements signed in 2006 were only two fewer than that of 2001 . 
Chart 44 Agreements signed between 1983 and 2006 
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However, the decrease in numbers in 2002/2004 did not indicate inactive networking; rather this 
indicated an important consolidation of this subsector, because there were large scale mergers and 
acquisitions which replaced the normal co-research and co-development (Table 32). Besides 
consolidation within the UK biotechnology sector, this industry consolidation also included foreign 
companies, in particular large pharmaceutical companies, from North America, Europe, and Asia. 
The overall increase pattern of alliances was not only because of the growing number of firms 
(Chart 45). The growing size of firms, which accumulated large number patents and experience, is 
an important factor attracting partners. 
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Table 32 Selection of Acquisitions (Over £100 milHon) 
UK DD+D company Company which acquired 
which has been UK DD+D company 
acquired 
Cambridge Antibody AstraZeneca (UK-Sweden) 
Technology 
Arakis Limited Sosei Co. Ltd (JAPAN) 
CeJltech UCB (Belgium) 
PowderJect Chiron (US) 
Cbart 45 Number of Firms vs Number of Agreements 
Number of Firms vs Number of 
Agreements 
Value 
£702million 
£106.5 
million 
£1.53 billion 
£542 million 
81 
before 1992 1992-1996 1997-2001 2002-2006 
-Number of Firms in Business -Number of Agreements 
1 
Other research on European biopharmaceuticaJ industry between 1980 and 2000 also showed 
intensive and increasing networking (Ahrweiler, Gilbert, & Pyka 2006). AhrweiJer suggested that 
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"networks persist as the main structuring principle of the biotech industry despite firms changing 
their components, attachment strategies and structural properties. For example, in the UK and 
German biopharrnaceutical industries, collaborative activity can be observed as a permanent 
feature" (Ahrweiler, Gilbert, & Pyka 2006). 
Similar as 199Os, cancer, central nervous system diseases, and inflammatory diseases were still the 
main indications of alliances. 15 per cent of all alliances after 2000 were about cancer treatment. 
Infections also became a major indication after 2000. The major technologies concerned in 
agreements were synthetics, screening and drug delivery, followed by monoclonals, gene 
expression and bioinformatics. The technology involved in alliances also expended to cell therapy. 
Both biological and chemical technologies increased in use in the alliances after 2000; however, 
biological technologies grew faster than chemical technologies. 
7.9. Summary 
In this chapter, alliances of the drug discovery and development subsector have been reviewed and 
discussed. Previous researches indicated that the motivation of drug discovery and development 
companies to form alliances included learning from alliances, gaining access to complementary 
assets and novel technologies; reducing cost, market uncertainty and firm specific uncertainty; and 
building competitive advantages. 
This project found that the evolution of networking of the UK drug discovery and development 
subsector began with collaborating with US companies, in particular large pharmaceutical 
companies, and then moved to collaborate with small and medium sized companies from the US 
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and the EU. The role which drug discovery and development finns played in alliances since the 
1980s moved from solely R&D providers to buyers, reflecting the continuous growth and 
development of the drug development subsector since the I 980s. They have been generating, 
learning and diffusing knowledge through networking, and this has enabled their development and 
strength. 
As Senker suggested, the histories, resources and capacity of companies determined its strategy 
(Senker 1996). Companies with more R&D capacity are inclined to choose a research oriented 
strategy, and gain returns mainly from licensing out and contracting, while companies with more 
experience of downstream development are inclined to choose licensing in and marketing. The fast 
growth in licensing, steady growth of research and slower growth in development may suggest that 
many UK drug discovery and development companies have started discovery and development 
internally. Although these companies have been exploring new product pipelines, due to the 
constraint of financial support, they licensed out products in early stages rather than continued to 
development stage. This also indicated their relative maturity in early stage product discovery and 
development. Their maturity in early stage product discovery could be the main reason why many 
companies which were developing platform technologies and early stage products were acquired 
by large pharmaceutical companies. 
Form a perspective of the drug discovery and development subsector. these companies learnt from 
networking, and the growth of the subsector accompanied the increase of networking, in terms of 
both sheer numbers and density. The tradition of networking in this subsector enables 
accumulation of alliance experiences and further facilitates the performance of alliances. In the 
next two chapters, data on alliances and data from other chapters will be integrated and discussed. 
ImpUcations for poUcy: 
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The continuously exceptional intensive investment of the drug discovery and development sector 
produced large numbers of patents and drug candidates, but these patents and compound 
candidates need to be rapidly converted into successful products, otherwise these companies would 
be affected by financial problems and acquired by large pharmaceutical companies. This raises 
important questions about the long-term benefit of the industry to the UK economy, as it would 
appear that the benefits of the very successful knowledge production of these firms do not remain 
in the UK. Although the connections of this subsector with the domestic industry have been 
expanding, it still only accounts for a small fraction of the total alliances. It therefore appears that 
foreign countries are benefitting significantly from the activities of the UK drug discovery and 
development industry. Policies should respond to the "harvest" of successful UK knowledge and 
firms by foreign companies or large international pharmaceutical companies, and enable the 
healthy growth of the UK drug discovery and development sector. 
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Chapter Eight: Integration of Data 
Considering the pharmaceutical and biotechnology industry as a Sectoral Systems of Innovation, 
this study investigated the emergence of new actors in this system of innovation - the drug 
discovery and development companies established after the 1980s, when biotechnology first started 
to be applied to the drug innovation process. Malerba suggests four key challenges that are 
required for a better understanding of the relationship between innovation and the evolution of 
industries: the analyses of demand, knowledge, networks and co-evolution (Malerba 2006). This 
study investigated the knowledge base, technology domain and networks of UK the drug discovery 
and development companies. Using the conceptual framework of Sectoral Systems of Innovation, 
four issues were examined in this study: 
I) The drug discovery and development subsector's structure, the size and age of firms, 
their clustering and concentration; 
2) The knowledge contribution of the drugs discovery and development subsector and 
how this has developed over time; 
3) Their networking and collaboration with other actors and how this has changed over 
time; 
4) The development of different company strategies. 
From a historical and industry dynamics perspective, this study aimed to understand the co-
evolution of knowledge and network, and to stress the policy implications of these developments. 
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This study began with a historical introduction of the drug discovery and development activities of 
the phannaceutical and biotechnology industry, and how policy and regulations were used to shape 
this sector. This historical background was mainly focused on the period before the emergence of 
the focal companies, followed by a discussion of the contemporary pharmaceutical and 
biotechnology industry. Within this context, the focal subsectors' nature, technology domain, 
knowledge contribution, and networking were studied from a perspective of dynamics. 
This chapter will first look at the structure, clustering and concentration of the drug discovery and 
development subsector. Then it will discuss knowledge production and networking, and its impact 
on the wider phannaceutical and biotechnology industry. Finally it will categorize the 81 
companies according to their operations and activities and further analyze strategies, alliances and 
knowledge production. The third section is a preparation for answering research questions in the 
conclusion chapter. 
8.1. Mapping the drug discovery and development subsector 
8.1.1. Clustering, concentration and globalization 
One important feature of the UK drug discovery and development subsector was its hierarchical 
structure comprised of a few mature firms and a large number of young small firms: 80 per cent of 
companies have been established for less than ten years and 63 per cent of companies employed 
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less than 50 staff. This is similar to Bagchi-Sen's study on US biopharmaceutical industry (Bagchi-
Sen 2007). 
The UK pharmaceutical and biotechnology industry is clustered in the southeast of England, with 
the drug discovery and development subsector located mainly in Cambridge, London and Oxford. 
However, the larger drug discovery and development companies who survived and matured, either 
established operations outside the UK or were acquired, in particular by foreign pharmaceutical 
companies or large international pharmaceutical companies. Only a minority of firms retained a 
sole UK focus. This suggests that it is difficult to survive in a global industry with a purely national 
focus. The main reason for this is the importance of international markets, in particular, the need to 
have an operational base in the US. 
Based on the analysis of scientific publications, this subsector was highly geographically 
concentrated in terms of knowledge generation. Within the UK, Cambridge, Oxford and London 
were active centres in publishing. Total publishing and co-publishing were both highly 
concentrated in the Southeast of England, which was correlated with company clustering in these 
three places. Publication was even more concentrated than the number of companies in these areas, 
suggesting the most productive firms were mainly in this area. 
Analysis of scientific publications also highlighted the heavy international networking of this 
sector. These forms colIaborated widely with other countries, with the US and EU dominating co-
publishing within this subsector. The result of citation analysis also indicated an important impact 
of American institutions upon this subsector's research. Together with results from co-publishing, 
research in the US strongly influenced the UK drug discovery and development companies in a 
direct way through co-publishing and an indirect way through citation. Therefore, basic knowledge, 
as measured by publications output, was generated within a global network, but UK based authors 
were geographically concentrated. 
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In contrast to the global network of the co-publication of scientific papers, patents were mainly 
published by UK inventors. There were only 14 per cent of patents co-published with inventors 
from other countries, mainly in the EU, with the majority of patents published by local inventors. 
However, the analysis of alliances agreements indicated that licensing was globalized. In other 
words, patenting mainly happened locally, but commercialization was globalized. 
In short, this subsector shows a hierarchical structure in term of being dominated by a small 
number of very productive firms and these companies were highly clustered in Cambridge, London 
and Oxford. Basic knowledge production, which was generated through global cooperation, was 
also concentrated in these areas. However, patenting mainly happened locally, while 
commercialization was globalized. 
8.1.2. R&D outputs 
Another feature of this subsector was that companies were very R&D active. The top drug 
discovery and development companies ranked very high in terms of R&D investments. Compared 
with other companies of the pharmaceutical and biotechnology industry, this sector is very R&D 
intensive. Many companies invested more than 80 per cent of their sales in R&D. This exceptional 
intensive investment was a risk for the long term business development of this group of firms, as it 
made them vulnerable to acquisition from larger companies wishing to access new knowledge. In 
this sense, these highly productive firms can be thought of as 'knowledge rich', but had not 
managed to get commercial benefit from this due to the long time required for product 
development. 
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The drug discovery and development subsector is a major producer of knowledge, with the 
subsector's publications and citations data indicating a high level of productivity and a very 
hierarchical structure; a few companies dominated the publications produced by the subsector, in 
terms of both quantity and impact. One possible reason is that many of these high-end companies 
were established in the 1980s and may be the first movers in their fields, which enable them to 
accumulate larger numbers of publications and citations, as well as research experience. It is clear 
that the output of these companies is highly innovative and important, as seen by the high h-factors 
and number of citations. Although the total output of this subsector only accounted for a small 
proportion of all UK biomedical publications, the growth rate and impact of publications were far 
above average. An important finding was that the impact of the leading companies' publication 
was strongly correlated with its number of publications. This also supports the idea that the leading 
firms are very important producers of knowledge, both in terms of quality and quantity. 
Similar to the pattern of SCI publications, the patent publications pattern also indicated a 
hierarchical structure, with a small number of companies publishing the majority of patents. The 
top company, Celltech, published as many patent as many large pharmaceutical companies. This 
high output of patents was mainly the result of the large amount of R&D investment of this sector. 
The drug discovery and development sector has played a very important role in constructing 
product pipelines, in particular, in the early stages of drug discovery and development. The output 
of drug candidates was concentrated in well established firms, with late stage product development 
controlled by a handful of companies. 
It is also important to notice that this industry has a large number of young small companies, and 
they only have limited scientific publications, patents and product pipelines. Considering most 
firms examined in this study have already formed product pipelines, therefore, for these young 
small firms, to survive and continue their product development is more difficult, because their 
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portfolios are less attractive to venture capitals and large pharmaceutical companies (Baum & 
Silvennan 2004). 
8.2. Networking and Collaboration 
8.2.1. The dynamics of networking and collaboration 
Alliance activities had different characteristics during different time periods: not only has the 
technologies changed over time, but also the number of alliances, purpose, disease indications have 
changed. This section will describe the alliances from a perspective of dynamics. 
Small scale alliances focused mainly on R&D contracting occurred during the I 980s. Their 
partners were mainly from the US. Major indications were cardiovascular diseases and cancer. 
Alliances number grew steadily during the 1990s, in particular collaboration within the UK 
discovery and development sector became more and more common, but the major partners were 
from the US and the EU. UK drug discovery and development firms were not only active R&D 
providers, but also became active buyers both from the foreign countries and internally. Cancer, 
central nervous system diseases and anti-inflammatory diseases became the most important 
indications of alliances during the 1990s. 
There were dramatic increases in the total numbers of alliances, together with large scale mergers 
and acquisitions since 1999. Cancer, central nervous system diseases, and inflammatory diseases 
were still the main indications of alliances. 
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The purpose of alliances changed over time. 50 per cent of total alliances in the 1980s were 
concerned with clinical development. This number decreased to 39 per cent in 1990s, and fell 
further to 22 per cent after 2000. The percentage of alliances concerned with research has been 
stable at one fifth since 1980s. A major growth area of alliances was licensing: from 34 per cent of 
total alliances in the 1980s, increasing to 57 per cent in the 1990s, and to 64 per cent after 2000: 
this was partly due to the dramatic growth of patents. This fast growth in licensing, steady growth 
of research and slower growth in development suggested that many UK drug discovery and 
development companies started discovery and development internaIly, as shown by their product 
pipelines. 
It is important to notice that, although the alliances between the drug discovery and development 
subsector and domestic companies grew rapidly since 1990s, the number of these alliances only 
accounted for a smaIl fraction of the total number. The subsector's partners were mainly from the 
US and the EU. Therefore, much of the knowledge produced by this sector was going abroad 
through commercial licensing and M&As. 
The co-evolution of knowledge production and networking were due to many factors, one major 
reason was the growing size of this subsector, which accumulated large number of patents and 
experience in drug development. This was an important factor in attracting partners. These are all 
features of the industry maturing. 
8.2.2. Nodes of network 
241 
The three major disease categories of scientific publication and patents were similar: cancer, 
immune and immune mediated inflammation, and inflection. Scientific papers and patents were 
both published on biological and chemical knowledge, but with a greater emphasis on molecular 
biology and biotechnology. When compared with other studies of the research focus of public 
institutes (Webster 2(05), this sector followed a similar research route and directions to the public 
sector. Considering the clustering of this subsector and global cooperation in scientific publications, 
these firms focused on learning and producing knowledge at the same time: learning from public 
institutions globalIy and locally, and producing large number of scientific papers and patents. 
The three major disease categories of marketed drugs and pipeline drugs were cancer, central 
nervous system disease and infection. This result was similar to the analysis of alliances 
agreements. It is not supervising because over 70 per cent of alliances were concerned with 
licensing, research collaboration, and co-development. 
The major difference between indications of product pipelines and alliances, and indications of 
scientific publications and patents publications, was the fraction of central nervous system diseases: 
this was very significant in product pipelines and alliances. Therefore, there were two patterns of 
focus in this subsector: it had a shared knowledge and technology domain with universities and 
public institutions in publishing scientific papers and patents; while the subsector's drugs and 
pipeline products had a similar focuses to their partners in the pharmaceutical and biotechnology 
industry. 
The findings of this study suggested that there were different focuses on basic knowledge 
production and product development, and this was mainly due to their interaction with their 
partners. The focuses of knowledge production of this subsector were changed when partners 
changed. 
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In other words, this subsector worked as a node of the network of knowledge production, 
connecting both academic institutions and the established pharmaceutical industry. These firms 
served as both knowledge producers in their own right, but also as intermediaries in transferring 
knowledge from academia to the pharmaceutical industry. 
This result therefore give indirect evidence of the impact of technology push and market drive 
(Walsh, Niosi, & Mustar 1995). This subsector basic research and knowledge transfer might be 
"pushed" by technological advances of academic institution. Their product development might 
further "push" their partner's product development and also learn from partners. On the other hand, 
their product development might also be "driven" by the demand of al\iances partners and the 
wider market. From this perspective it is easier to understand why there has been more emphasis 
and success for chemistry based products, as these are a better fit with the dominant technology of 
the mainstream pharmaceutical industry. 
8.3. Companies performance 
8.3.1. Tiers of companies 
Based on the development stages of their product pipelines, the 81 companies were categorized 
into four tiers. The rational of this categorisation is based on the milestones of the drug discovery 
and development process. The major hurdles of drug discovery and development process are 
whether a compound could enter Phase 1111 clinical trials, whether a compound could enter Phase 
IIIIIV phase trials and whether a compound has reached the market. A compound entering Phase 
IIII clinical trials indicates that it can be test in human: healthy volunteers in Phase I and a small 
243 
group of patients in Phase II (Walsh 2003). A compound yielding positive results could enter 
Phases III clinical trials, the latter involves 1000-3000 patients and require strong financial support 
for the clinical trials. After clinical trials, onJy a small number of compounds reach the market. The 
resources required to reach Phase IIII are relatively modest. In contrast Phase III trials requires 
heavy investment and a high level of expertise. Lunching a drug on the market also requires further 
investment in marketing, regulatory affairs and distribution. 
Companies were therefore categorized into four tiers according to their most advanced programme 
(Figure 5). 
Figure 5 Operations of Companies 
1) Tier One - partially integrated biophannaceutical companies: there are 16 companies in 
this tier, and the major character of these companies is that they all have products on the 
market. These companies included Acambis, Alliance phanna, Ark Therapertics, 
Cambridge Antibody, Celltech, Controlled Therapeutics, Cyclacel, GW pharmaceuticals, 
Phytopharm, PowderJect, ProStrakan, Protherics, Shire Phannaceuticals, SkyePharma, 
Vectura, and Vernalis (Table 33). 
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Table 33 Tier One Companies 
Pipeline Year 
Company name SCI Patents s Alliance founded 
Acambis (1992-1999 Peptide Therapeutics; acquired 
Ora Vax US and changed name in 1999, acquired by Sanofi 
Pasteur in 2008 ) 51 9 14 31 1992 
Alliance Phanna pIc 0 0 2 17 1996 
Ark Therapeutics ( Eurogene Limited acquired the Oy 
Quattrogene Limited FINLAND in January 2001) 10 32 3 8 1997 
Cambridge Antibody (Acquired by AstraZeneca in 2006; 
ACQUIRED Aptein US in 1998) 91 71 8 57 1990 
Celltech Group pic (acquried by UCB Belgium in 2005; 
Acquired Chiroscience in 1999;merged with Medeva in 
1999; acquried Cistron Biotechnology US in 2000; 
acquired Oxford Glycosciences in 2003) 794 879 19 157 1980 
Controlled Therapeutics (Scotland) Limited (acquired by 
PharmaSciences, Inc US in 1993;Merger of 
PhannaSciences US with Cytokine Networks US to form 
Cytokine PhannaSciences in 1999) 7 4 0 2 1986 
Cyc1acel Ltd (founded in the UK, headquarter in US, 
primary research facility is located in The UK) 78 91 11 12 1996 
GW Pharmaceuticals 13 7 5 I 1998 
Phytopharrn pic 7 35 6 7 1990 
PowderJect (Acquired by Chiron in 2003; acquired SBL 
vaccin AB Sweden in 2001 ) 16 I 3 19 1993 
ProStrakan (formed after merger of Strakan <Scotland>and 
Proskelia<France> in 2004) 7 18 1 16 1995 
Protherics PLC (formed from the merger of Proteus 
International Pic <UK>and Therapeutic Antibodies 
Inc.<US>in 1999, acquired bv BTG in 2008) 47 9 4 20 1987 
Shire Pharmaceuticals Group pic 19 4 18 66 1986 
SkyePharrna (acquired Jago Pbarrna Switzerland in 1996; 
acquried DepoTech US in 1998; acquired Hyal 
Pharmaceutical Canada in 1999; acquired RTP Canada in 
2002) 0 I 17 18 1996 
Vectura(Acquired Innovata in 2006; Innovata was formed 
in July 2005 when ML Laboratories PLC acquired 
Quadrant) 68 210 22 20 1987 
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Vernalis (acquired by British Biotech and name change to 
Vernalis in 2003; British Biotech merged with RiboTargets 
in 2003; acquired Ionix Pharmaceuticals in 2005; acquired 
Cita NeuroPhannaceuticals Canada in 2005) 451 306 10 79 1986 
2) Tier Two - Late stage development companies: there are nine companies in this Tier, and 
the major character of these companies is that they have at least one drug development 
programme in phase III, but they do not have any drugs on the market (Table 34). 
Table 34 Tier Two companies 
Year of 
Company name SCI Patents Pipelines Alliance founded 
Xenova (acquired by Celtic Pharma 
Development BERMUDA in 2005; acquired KS 
Biomedix in 2003; acquired Cantab 
Phannaceuticals in 20011 181 136 20 42 1992 
Oxford BioMedica pic (acquired Qxxon 
Therapeutics in 2007 - Qxxon Therapeutics was 
recorded sej>erately) 81 108 12 16 1995 
A1izyme 2 16 4 4 1995 
CeNes Phannaceuticals (mergered with Core 
Group pic in 1999; acquired Cambridge 
NeuroScience US in 20oo;acquired Excyte in 
2000; acquried Management Dynamics 
Cambridge in 2oo1;acquired TheraSci in 2003; 
acquired by Paion AG in 2 0 0 ~ ~ 16 32 9 42 1997 
NeuTec (acquired by Novartis Pharma AG 
Switzerland in 2 o o ~ ~ 12 20 2 1 1997 
Plethora Solutions 1 2 0 5 2003 
Summit pic (V ASTox changed name to Summit 
pic in 2007; V ASTox acquired MNL pharma in 
2006;acquired DanioLabs Ltd and Dextra 
Laboratories Ltd in 2007) 3 13 5 6 2001 
Antisoma pic (ac--'luired Aptamera US in 2005) 32 21 6 14 1988 
Amarin (Acquired Laxdale Scotland in 2004) 60 32 7 45 1989 
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3) Tier Three - Early stage development firms: there are 24 companies in this Tier, and the 
major character of these companies is that they have at least one compound in clinical 
trials, but they don't have compounds in phase III (Table 35). 
Table 35 Tier Three companies 
Year of 
Company name SCI Patents Pipelines Alliance founded 
Adprotech Ltd (ACQUIRED BY Inflazyme 
Canada in 2004) 20 17 I 6 1997 
Arakis Limited ( acquired by Sosei Japan in 
2005) I 50 I 9 2000 
Argenta (2004 
- Argenta Discovery and 
Etiologics <FOUNDED IN 2 0 0 2 > m e ~ ~ 19 16 7 20 2000 
Arrow Therapeutics Ltd (acquired by 
AstraZeneca in February 20072 18 21 6 8 1998 
Astex Therapeutics (merged with metaGen 
Gennany in 2(03) 64 58 8 18 1999 
Cambridge Biotechnology (acquired by 
Biovitrum AB Sweden in 20051 0 9 2 1 2001 
Chroma Therapeutics 2 16 5 1 2000 
Hunter-Fleming Ltd (acquired Aegis in 2000; 
joint venture to fonn Trident Pbannaceuticals Inc 
US with Advent International in 2006; acquired 
by Newron Pharmaceuticals S.p.A. Itlll}' in 20081 2 9 5 1 1999 
KuDOS Phannaceuticals Ltd (acquired by 
AstraZeneca in 2(05) 29 40 3 4 1997 
Lipoxen Technologies Ltd 9 20 14 4 2000 
Microscience Ltd (Acquired by Emergent Europe 
US in 2(05) 18 31 2 4 1997 
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NovaBiotics Ltd 0 I 4 0 2004 
Onyvax Limited 15 10 6 4 1998 
Oxagen 66 20 3 17 1997 
Oxxon Therapeutics ( Ouon Phannaccines Ltd) 10 20 I 2 1999 
Phannagene (acquired by Asterand US 2006) 21 26 0 29 1996 
PowderMed (fonned in 2004 as a spin-off from 
PowderJect acquired by Chiron in 2003, then 
acquired by Pfizer in 2006) 2 4 6 4 2004 
PPL Therapeutics pIc (Acquired by QED In 
2004) 55 41 5 8 1994 
ReGen (acuqired Sciencom in 2006; acquired 
Guildford Clinical Pharmacology Unit Limited in 
2004) 5 9 I 0 1998 
ReNeuron (Acquired AmCvte US in 2007) 34 15 5 II 1997 
Spirogen Ltd 3 22 6 I 2000 
SR Phanna ( fonned Silence Therapeutics AG 
after acquired by Atugen AG, Germany in 2005 ) 6 I 7 4 1999 
Trigen (In 2005 Trigen Holdings pIc and 
ProCorde GmbH merged to fonn Trigen 
Holdings AG) 3 31 5 2 1997 
Xention Discovery Ltd 3 II 4 I 2002 
4) Tier Four - Early stage finns: there are 32 companies in this tier, and the major character 
of these companies is that they have a drug discovery programme, but they do not have 
any compounds in clinical trials (Table 36). 
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Table 36 Tier Four companies 
YEAR 
Company name SCI Patents Pipelines Alliance FOUNDED 
Amura (Amura 1 Proteom 05/06 Merger to form 
Amura Holdings) 17 20 I 5 1996 
Aquapharm Bio-Discovery Ltd 0 2 2 0 2000 
Avidex Ltd (acquired by Medigene, Gemany in 
2006) 26 41 I 12 1999 
Biotica Technology Ltd 26 24 4 3 1997 
Cambridge Microbial Technologies Ltd (eMT) 0 I 0 0 1999 
Crusade Laboratories Ltd 10 5 0 0 2000 
Curidium (Cielo 1 Curidium 06/06 Acq. for equity 
to form Curidium Medica) 0 3 0 I 2001 
De Novo Pharmaceuticals 40 10 0 10 2000 
Discema Ltd I 3 0 0 2001 
Domainex (merged with NCE Discovery Ltd in 
2007) I 0 0 0 2001 
Domantis Ltd (Acquired by GSK in 2007) 6 43 I 10 2002 
Drug Discovery Ltd (DDL) 0 0 0 2 1998 
Endocrine Pharmaceuticals Ltd 0 2 I 0 1995 
GeneMedix (acquired by Reliance Life Sciences 
Pvt Ltd India in 2007; set subs in Ireland and 
China) 0 6 0 7 1997 
Glycoform Ltd 0 0 2 I 2002 
Haptogen Ltd_<acquired by Wyeth in 2007) 4 4 I 3 2002 
Inpharmatica Ltd (acquired by Biofocus DPI of 
Galapagos, Netherlands in 2006; acquired ArQule 
(UK) Limited in 2003) 43 45 I 30 1998 
Isogenica Ltd 2 3 0 11 2001 
Lamellar Therapeutics Ltd 0 3 0 0 1999 
Lectus Therapeutics (Acquired NeuroServe in 
2006) 0 0 I 1 2003 
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Lorantis (acquried by ceJldex US in 2005) 14 43 0 3 1998 
Muscagen Ltd 0 3 0 0 2001 
NeuroTargets Ltd (joint venture between Bristol 
University and ANGLE) I 4 I 1 1999 
Novacta Biosvstems Ltd 3 1 5 0 2001 
Oxford Genome Sciences (UK) Ltd (Changed its 
Name to Oxford BioTherapeutics in Dec 2008) 1 I 0 5 2004 
Phico Therapeutics Ltd 4 I 0 0 2000 
Piramed (acquired by roach in 20081 I 2 2 I 2003 
Prolysis 3 2 2 4 1999 
Sareum 3 0 5 10 2003 
Scottish Biomedical 7 I 7 2 1999 
Senexis Ltd 2 3 4 2 2001 
TheRyte Ltd 1 8 1 0 1997 
Summarizing the four tables above (Table 33-36), there are three indicators that can be used to 
describe and compare these four tiers: company age, R&D output and alliances (Table 37, 38 & 
chart 46). 
Table 37 R&D Output and Alliances Agreements of Each Tier 
SCI publications Patents Pipelines AIliance 
Agreements 
Total Average Total Average Total Average Total Averae:e 
Tier One 1659 103.7 1677 104.8 143 8.9 530 33.1 
Tier Two 388 43.1 380 42.2 65 7.2 175 19.4 
Tier Three 405 16.9 498 20.8 107 4.4 159 6.6 
Tier Four 216 6.8 284 8.9 42 1.3 124 3.9 
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Table 38 Age Groups and Alliances with Top SO Pharmaceutical Companies 
NO. average 
of age 
firms 
TIer 16 14.06 
one 
TIer 9 9.78 
two 
TIer 24 6.12 
three 
TIer 32 5.12 
four 
20 
18 
16 
14 
12 
10 
8 
6 
4 
2 
0 
21-25 
Total average M Licens- average Co"abora 
NO. agree- & ing licensing -tlon 
of ments A 
allian 
ces 
92 5.75 4 58 3.63 22 
37 4.11 1 27 3.00 3 
46 1.92 3 34 1.42 16 
25 0.78 1 23 0.72 8 
Chart 46 Age group of companies 
16-20 11-15 6-10 1-5 
average Manufact 
co"abora -urlng 
-tlon 
1.38 5 
0.33 1 
0.67 1 
0.25 0 
.Tierone 
• Tier two 
• Tier three 
.Tier four 
One important feature of Tier one companies is that they started operating before 1998, with the 
earliest in business being Celltech, which was established in 1980. Tier two companies have an 
average ten years of age. In contrast, Tier three six years in business and Tier four, five years. As 
the first entrants of the industry, Tier one companies have accumulated greater numbers of SCI 
publications, patents, pipelines and alliance agreements than other tiers. 
25] 
Market 
-Ing 
8 
4 
1 
0 
Further investigation into the alliance agreements signed with the large pharmaceutical companies 
reveals that each tier has different characteristics. The major purposes of alliance agreements 
signed with Top 50 pharmaceutical companies are concerned with licensing, collaboration, M&A, 
manufacturing and marketing, with licensing being the most important purpose of agreements. 
Companies of Tier one are very active in all areas of alliances with top pharmaceutical companies: 
the total number and average number of agreements signed by Tier one companies are more than 
the other tiers. One reason may be that the average age of a Tier one company is 14 years, which is 
much greater than that of other tiers. Because of the number of agreements accumulated over time, 
the Tier one companies have the largest total number of agreements of each type (licensing, 
collaboration, manufacturing and marketing), as well as average number of agreements. In 
particular, this tier of companies has higher numbers of M&A with top pharmaceutical companies, 
which suggested that Tier one companies are acquisition targets of large pharmaceutical companies. 
At the same time, Tier one companies also rely heavily on top pharmaceutical companies to 
manufacture and market their products. Therefore the companies in Tier one can be seen to be 
highly integrated into the pharmaceutical industry. 
Companies of Tier two are very active in licensing. Although these companies do not have 
products on the market, they have a few agreements concerning future manufacturing and 
marketing. They have relatively high levels of licensing, but low levels of research collaboration 
with big pharmaceutical companies. This indicated that Tier two companies, which have the 
potential for product sales have adopted a more independent strategy than Tier one and Tier three 
companies. 
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Different from Tier two companies, companies of Tier three are more active In research 
collaboration with big pharmaceutical companies and less active in licensing. One interesting 
finding is that there are companies of Tier three established more than 10 years that did not 
continue downstream development. One explanation could be that these companies are focusing 
on licensing out rather than vertical integration, however, the data collected in this study indicated 
that the another possible reason is that these companies are acquired by big pharmaceutical 
companies or other biopharmaceutical companies, and this prevented them from further developing 
products. 
Companies of Tier four are less active than the other three groups. The main reason is likely their 
young age. 
8.3.2 Insight Into Tier One companies 
As shown above. the Tier one companies are the only group of companies which have products on 
the market, and they contributed the majority of SCI publications, patent publications and product 
pipelines. In other words. Tier one companies are the most successful companies of the drug 
discovery and development sector, therefore it is necessary to investigate this tier in more detail. 
Based on data from this project, the Tier one companies could be roughly categorized into two 
groups. The major criteria used are R&D investment, R&D intensity, R&D output and income. 
The rationale of this categorisation is that drug discovery and development is a long and expensive 
process with high risk, therefore R&D investment and R&D intensity indicate the commitment of a 
company to innovation, and it is also connected to its ability to raise capital. R&D output refers to 
SCI publications, patents publications and product pipelines, and it directly measures the company 
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performance and R&D productivity. Income refers to the commercialization of a company's 
products and services; it also includes the licensing fee and contract service. 
These most successful companies have been categorised into two groups (four companies were 
excluded from categorisation because data were unavailable due to M&A): Companies with high 
R&D investment, high R&D intensity, high R&D output and income are categorized into Group A; 
companies with high R&D investment, high R&D income, but relatively low R&D intensity are 
categorized into Group B. 
Group A: there are seven firms in this group, and they are characterized by heavy R&D 
investment, high R&D intensity, and very productive output in terms of patents and product 
pipelines. They are research orientated and the most innovative companies. Their income was 
ranked top of the drug discovery and development sector, and several of these firms had significant 
sales. Their R&D intensity was over 54 per cent, with most of these companies' R&D intensity 
being over lOOper cent. 
This group included companies such as CelItech, Vectura, Phytopharm, ProStrakan, Ark 
Therapeutics, GW Pharmaceuticals and Vernalis. Five of these companies have more than 30 
patents, four of these companies' R&D investment is over 10 million pounds each year. For 
example, Celltech, which is the top company of this group, has 879 patents, an average R&D 
investment per year of 56 million pounds, average income of 60 million pounds and R&D intensity 
of 93 per cent. Another typical company of Group A is Vectura: it has 68 scientific publications, 
210 patent publications, average R&D investment per year of 5.9 million pounds, average income 
of 4.2 million pounds and R&D intensity as high as 112 per cent. 
Interestingly, companies of Group A are very active in mergers and acquisitions. Five out of seven 
companies were involved in at least once merger or acquisition since 2000. Again using Vectura as 
254 
an example, it acquired Innovata in 2006, and Innovata was originally formed in July 2005 when 
ML Laboratories acquired Quadrant. 
Group 8: Group B consists of five finns (SkyePharma, Shire Pharmaceuticals, Protherics, 
Acambis and Alliance Pharma) and is characterized by heavy R&D investment and a large number 
of products in development. These companies' income is also ranked top of the subsector, however, 
their R&D intensity is below 45 per cent, and their patent publications are less than group A. Their 
major focus is on marketing. Examples of this group are Shire Pharmaceutical and SkyePharma. 
These companies mainly act as technology and product acquirers. They are less innovative than 
Group A companies but more commercially focused: these companies invested between £ I million 
and £ 131 million each year, and income generated is between £20 million and £780 million, 
however, none of them has more than 10 patents. Take Shire Pharmaceutical for example: it has 
only 19 scientific publications and four patent publications, however, its average R&D investment 
per year is as high as 131 million pounds, its average income is 781 million pounds and R&D 
intensity is 17 per cent. 
The different R&D investment patterns of these two groups are mainly a reflection of companies' 
strategy, which is in part determined by resources. Hall & Bagchi-Sen suggest that more R&D 
intensive companies tend to adopt research focused strategies such as a means of strengthening 
their own research capabilities, entering into research collaborations with universities, industry 
leaders and other biotech finns, and licensing their technology; while less R&D intensive 
companies tend to adopt production based strategies such as gaining market access, maintaining 
connections with customers, and building a research base (Hall & Bagchi-Sen 2007). 
Further investigation into Group A and Group B companies indicates that they have different 
strategies, and this provided evidence for Hall & Bagchi-Sen's arguments. The first group of 
companies played a key role in knowledge generation and knowledge transfer. Their output 
accounted for the majority of the suhsector's patents and product pipelines: three companies had 
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more than ten products in development and more than 200 patents. The Group B companies did not 
generate as large a number of patents as those of Group A: none of them had more than 10 patents 
developed in house. However, their large number of drugs in development was partly from their 
original development, and partly through acquisitions. Their R&D intensity was below 45 per cent, 
but the average sale per company per year was around 200 million pounds and their focus was 
marketing. 
As Pisano (2006) has suggested, drug discovery and development companies are started with 
fragments of an innovation process and business practice, therefore, vertical integration is a major 
aim of a company's development: from project development to manufacturing and marketing. The 
different strategies of Group A and Group B companies indicate different routes of integration. 
Based on the data from this project, the first and second group companies all achieved a certain 
level of integration, however, there are two routes of integration: research orientated (Group A) 
and business orientated (Group B). The key determinant of vertical integration strategy is the 
availability of financing (Pisano 2006). For the Group A companies, they could generate cash flow 
from licensing and contract service. For Group B companies, they may generate income from value 
added downstream in development and marketing, alternatively, they can license in patents from 
other companies and then license out. The routes they choose are mainly determined by the 
resources and competencies of companies. The methods they use to generate cash flow may be 
hybrid. 
As Pisano suggests, because the number of successful companies is too smalI and the time of the 
company development still relatively short, and because different types of technology and product 
pipelines have different risks and potential (Pisano 2006), it is therefore difficult to identifY the 
best strategy for the whole industry. The next section will discuss how strategy development 
connects with companies' technology and products. 
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8.3.3. Convergence of technology: Chemical and biotech 
As discussed in the previous data chapters, the drug discovery and development companies adopt 
both new biotechnology and traditional chemical technologies. Scientific papers and patents were 
both published on biological and chemical knowledge, but with a greater emphasis on molecular 
biology and biotechnology. The technologies that formed the basis of company product pipelines 
were also focused on both biology and chemistry, but with a greater emphasis on chemical 
technologies, and the biological technologies were mainly applied in the early stages. However, it 
should be noted that the technological focus of alliances moved from chemical technology during 
the 1990s, to biotechnology and biologicals after 2000. Previous chapters suggested that very few 
biotechnology products entered the final stages of development in this subsector's pipelines: either 
because they had high failure rates or had been acquired/licensed out in late stage. The data from 
early stage pipelines and alIiances suggests that this may change in the future, with a greater 
number of biological drugs coming through the industry pipeline. 
Another finding from the data was that the pipelines of companies in Tier one and Tier two are 
mainly focused on smaIl molecules and drug delivery, which means the most successful companies 
did not focus on biologicals. Although the large number of small molecule related companies may 
be the results of the development of genomics, the large proportion of chemicals indicated the 
cooperation of this sector with large pharmaceutical companies is mainly focused on chemicals. 
Since large pharmaceutical companies were the largest partners of this sector most Tier one and 
Tier two companies had at least one alliance agreement with large pharmaceutical company. The 
average alIiance agreements with large pharmaceutical companies of Tier one and Tier two 
companies was as many as 5.8 and 4, and the major purposes were licensing and research. Celltech 
together with the companies it acquired (Chiroscience, Medeva and Oxford Glycosciences), has 
signed 26 major agreements with over 18 large pharmaceutical companies since 1984 (Table 39). 
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These agreements covered licensing, research, manufacture, supply, asset purchases, and 
acquisitions. These close connections with large pharmaceutical companies suggested that this 
sector has been influenced by their partners in the choice of technology and products. Tier three 
companies are also very active in licensing, take Astex Therapeutics for example, since 2000, it 
had licensing deals with Sanofi-Aventis, Schering, AstraZeneca, Boehringer Ingelheim, Novartis, 
Pfizer, GSK, and had research deals with Johnson & Johnson, AstraZeneca and Sanofi-Aventis. 
Table 39 Major agreements signed between CeUtech and large pharmaceutical companies 
Company history Year Large phannaceutical Content 
comJ!aIlY 
1986 Lilly Supply 
1988 Pfizer License 
1990 Boehringer Il!&elheim License 
1991 Roche License 
Celltech 1992 GSK Asset purchase, 
license 
Acquried by UCB Johnson Research (Belgium) in 2005; 1993 Roche SUQIJly 
acquired Chiroscience 1994 Astra Supply in 1999; Bristol-M'yers S..!luibb Manufacture 
merged with Medeva in 
Merck Asset purchase, 1999; acquried Cistron license Biotechnology (US) in 
GSK License 2000; acquired Oxford 
1995 Zeneca License supply Glycosciences in 2003 
Elan License 
Wyeth Asset purchase, 
supply 
Upjohn Research 
Janssen License 
1997 S c h e r i n ~ - P l o u g h h License 
1998 Bristol-Myers Squibb License 
Zeneca License 
Pfizer License 
1999 Merck License 
2000 Bayer License 
GSK License 
2001 Johnson License 
2002 Amgen License 
2005 UCB Acquisition 
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Moreover, the choice of technology and products had further impact on the company's strategy. 
Pisano (2006) suggests that biopharmaceutical companies may adopt different strategies because of 
their products. He suggested three types of companies: companies adopting novel research 
methods and tools, companies focusing on novel targets and mechanisms, and companies focusing 
on novel compounds, treatments and markets (Pisano 2006, P 167-172). He analyzed the degree of 
information asymmetry, the need for investments in specialized assets, the tacitness of the 
knowhow and the degree to which they have relevant intellectual property (Pisano 2006, P165-
166). He suggests that companies developing novel research methods and tools may adopt a 
strategy of contract service, companies focusing on novel targets and mechanisms may develop 
long-tenn collaborations with large pharmaceutical companies, and companies focusing on novel 
compounds may further integrate (Pisano 2006). 
However, the data of this project indicated a rather different picture. Most companies discussed in 
this project can be categorized as companies focusing on novel compounds. As showed in the 
previous section, these companies are not only moving towards integration, but also have forged 
long-tenn coIIaboration with large pharmaceutical companies, and provided contract service. Take 
the agreements of Celltech in Table 38 for example. The first Initial Public Offering year of 
CeIItech was 1993. Before 1995, shortly after it became public, Celltech's agreements were 
regarding contract research, licensing, supply, manufacturing and assets purchase. It depended on 
the contract research and licensing agreements with large pharmaceutical companies to generate 
cash flow to fund further research, while relying on the expertise and facilities of large 
pharmaceutical companies to conduct downstream activities, i.e. manufacturing. At the same time, 
they also prepared the firms for further integration through the purchase of necessary assets. After 
1995, and before the acquisitions by UCB in 2005, Celltech's agreements with large 
pharmaceutical companies were mainly about licensing. 
Therefore, the strategy of cooperation with large pharmaceutical companies has changed over time, 
and the major factors are not the innovation focus, but available financing, knowledge 
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accumulation and maturity of the company. Again take Celltech as an example, it had 15 alliance 
agreements and 109 patent publications during the 1980s, and it had 90 alliance agreements and 
502 patent publications during the 1 99Os. 
To conclude. as a company gains enough financing, expertise and experiences overtime, its 
strategies also change according to their resources and competencies. At the same time, it will rely 
less on its large pharmaceutical partners and forge connections with other actors. 
In short, Pisano's (2006) argument is generally support by data collected from this project; 
however, empirically there were some important differences, most notably the companies which 
move towards vertical integration also have forged long term col1aboration with large 
pharmaceutical companies, and licensing is still very important for their income. There are three 
main reasons to explain this: first, the returns on drug development are highly skewed -
downstream products will gain much more return than upstream products. A company wanting to 
gain a large proportion of return needs to conduct late stage development and marketing. However, 
the late stage development is time-consuming, costly and risky. Therefore, second, the company 
needs to generate income from various resources to finance drug development: R&D contracts and 
licensing. Third, companies that do not have experience in late stage development and marketing 
may need long term cooperation with other companies, in particular, large companies with 
complementary assets and funding to co-develop new drugs. Because these companies are 
dependent on large companies' funding, these three types of strategies are all more or less 
influenced by the behavior of large companies. Companies focusing on novel compounds may 
further conduct integration, as with the cases of companies in Group A and Group B, however, the 
processes are also influenced by other factors. In short, companies' strategies are also determined 
by network position and stage of company's life cycle. 
Based on the empirical data of this chapter, the next chapter will theoretically interpret the 
development of strategy, and its co-evolution with industry structure. 
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Chapter Nine: Discussion, Conclusion and Policy 
Implication 
The three main focuses of a sectoral systems framework are knowledge and technological domain, 
actors and networks, and institutions (Malerba 2005). In the previous chapters, data of knowledge 
production, technological domain, actors and networking have been investigated and analysed, and 
the institutions (policy and regulations) were also discussed (Introduction chapter and literature 
review chapter). This chapter will try to answer the research questions raised in the literature 
review chapters by looking at the findings using a theoretically interpreting based on the core 
concept of the sectoral systems framework - co-evolution. 
There are two issues to be addressed in this section: a) the co-evolution of strategy and networking, 
which covered two research questions: Is there a divergence of strategies existing in the drug 
discovery and development subsector? If so, what are the key factors which determine the 
divergence of strategy? The second issue is b) the co-evolution of industry structure and strategies, 
which also covered two research questions: From a perspective of industry, to what are extent the 
drug discovery and development companies integrated into the traditional pharmaceutical industry 
and how do divergent technological strategies influence industry structure? 
The third section of this chapter is about regulation and policy and will focus on discussing this 
issue from the perspective of co-evolution, and further elaborate the policy issues raised in this 
project. 
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9.1. Co-evolution of networking and technological strategy 
As discussed in the literature review chapter, there were different opinions on the shaping of the 
strategies of biopharmaceutical companies. Pisano had observed a trend towards vertical 
integration of new biotechnology companies from R&D activities to manufacturing and marketing 
during the 1980s and suggested that the ultimate strategy for biopharmaceutical companies was 
vertical integration along the lines of traditional large pharmaceutical companies (Pisano 1991). 
However. after the application of molecular genetics and recombinant DNA technology, the small 
biotech start-ups played an important role in innovation, and the large pharmaceutical firms that 
began to enter the field had to develop new strategies (Galambos & Sturchio 1998). Galambos & 
Sturchio's research raised the question of strategy development: is the supply of contract service a 
long term strategy or a temporary strategy? Will these companies continue to a create technology 
and collaborate with large pharmaceutical companies to finish the clinical and regulatory 
development processes? Their research indicated that the contracting service is a long term strategy, 
and biotech-pharmaceutical collaboration wiII likely remain for a long time, and the large 
pharmaceutical companies still dominate the innovation process (Galambos & Sturchio I 998b). 
However. since ten years has passed since Galambos & Sturchio published their paper, there are 
now companies that are divergent from a sole focus on R&D research or partnership with other 
companies. As discussed in section 8.3.2, companies may adopt multiple strategies rather than 
solely contracting R&D or long-term partnership. Kollmer and Dowling (Kollmer & Dowling 2004) 
suggested that "being not-fully integrated is not a transitional state, but a sustainable business 
strategy" (Kollmer & Dowling 2004, P1l48) and their findings indicated that licensing is a 
commercialisation strategy for both fully and not-fully integrated firms. 
In this study, the divergence of companies' strategy was also observed. As shown in the previous 
chapter, companies of different tiers have adopted different strategies. The stage of a company's 
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development is an important factor for the selection of strategy, e.g. different companies with 
different product pipeline stages have different strategies. For example, the Tier three companies, 
which have compounds in clinical phase VII but not in phase III, are mainly focusing on research 
collaboration with large pharmaceutical companies, while Tier two companies, which already have 
compounds in phases III, are mainly focusing on licensing out to large pharmaceutical companies. 
For some Tier one companies, which have a clear "evolving path" from Tier four to Tier Three, 
Tier two then Tier one, their strategies have been changing overtime. This is also closely connected 
to their product development stages. 
Furthermore. companies which have similar development stages may also have a different 
combination of strategies. The typical examples are Tier one companies which have been in 
operation for a long time and already have products on the market. There are generally two types 
of strategies adopted by Tier one companies: research orientated (Group A) and business orientated 
(Group B). Another interesting finding is that strategies of both Group A and Group B companies 
were influenced by their previous strategies and the accumulation process of experience and 
competency. For example. a typical research orientated company, like Celltech, uses a main 
strategy of expanding its patent portfolio and licensing out patents while conducting in-house R&D. 
Further. its previous M&A targets are also mainly research orientated companies. While a typical 
business orientated company, like Shire pharmaceutical, has a main strategy of licensing in and 
marketing. and its previous M&A targets are mainly companies which could help it expand its 
market. For both types of companies, their accumulated or acquired experience and competency 
were also important factors for strategy making. 
Another important factor which influenced the divergence of strategies was the financial condition 
of companies. There are two sets of evidence relating to this: first of all, companies that wanted to 
"push" their product into higher clinical stages needed much more funding than it previously, 
therefore. strategy development of each tier of firms was partly determined by their financial cap. 
Moreover, the R&D intensity of different companies, which was determined by its nature of 
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business, further influenced the company's strategy, in particular, the M&A decisions. Companies 
with high R&D intensity are more active in M&A with large pharmaceutical companies. 
There is a notable factor connected to those discussed above - networking. Companies 
continuously collaborate with other actors during their development: selling knowledge while 
acquired funding, experience and competencies. Although networking can be seen as a part of a 
company's strategy, networking also has a profound impact on a company's overall strategy 
because it involved other actors of the innovation system, in particular, those large pharmaceutical 
companies which have more control and power over alliance agreements. 
There are two perspectives on firm's strategy development connected to networking: one is from 
capability and learning (Koput, Smith-Doerr, & Powell 1997), which focuses on how finn strategy 
changes while the firm develops in competition. Another perspective is from risk management, 
which focuses on how firms minimise the innovation risk by networking (Hopkins & Nightingale 
2006). 
Learning from networking, in particular, from networking with large pharmaceutical companies, is 
an important factor influencing a company's strategy making. This is different from the driving 
factor of financing need and push factor of knowledge accumulation, rather this is an external 
factor, because this process involves interactions with other actors. Powell, Koput, Smith-Doerr 
and Owen-Smith suggested that a model of industry evolution could be understood as a learning 
race from networking, moreover, there are limits to a firm's learning from networking because 
there is a decrease of return to the networking (Powell, Koput, Smith-Doerr and Owen-Smith, 
1999). 
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Another perspective on the strategic alliances of drug discovery and development companies is risk 
management. Companies adopt different strategies to minimise the risk of innovation and secure 
cash flow and investment via networking. 
"Given the diversity of types of risk, ways of managing them, and differing organizational 
capabilities, certain organizational structures based on configurations of firms, markets, 
government bodies and NGOs will be better able to transform and transfer specific types 
of risk than others. Consequently, firms that can position themselves within these 
networks and can cost-effectively disaggregate and disappropriate some of the uncertain 
or undesirable consequences of innovation onto third parties (that are better able to 
manage these risks) can potentially be at a competitive advantage. " 
(Hopkins & Nightingale 2006, P361) 
Both perspectives of minimising risk and gaining competency have an emphasis on how to create 
competitive advantages within the network with other parties. As shown in this study, the alliance 
contents, purpose and partners changed significantly overtime. The changing positions of 
companies within evolving networks and the accumulation of experience further influence the 
development of company strategy. Gulati, Nohria, & Zaheer have suggested that "an understanding 
of the consequences of the ubiquitous growth of strategic networks emphasizes that finns are more 
properly viewed as connected to each other in multiple networks of resource and other flows" 
(Gulati, Nohria, & Zaheer 2000). In particular. there are two important dimensions of 
biopharmaceutical company alliances: the number of alliances and internationalization. 
Koput etc. suggested that "older and larger finns have deeper and more extensive portfolios of 
collaboration" (Koput, Smith-Doerr, & Powell 1997, P251). This result is supported by the data 
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collected in this project. However, based on the analysis of Tier one companies, this thesis further 
suggested the speed of firm growth is faster than the speed of its network expansion. The indicator 
used is the ratio of number of patents publications and number of alIiance agreements. One 
possible reason is that the companies move from R&D cooperation to in-house development when 
they have enough funds to conduct their own research, therefore, the number of alliance 
agreements may decrease while the patents number may increase. Another reason might be that 
finns are less dependent on acquiring certain recourses from networking when they have 
accumulated a certain level of experience, however, these companies may rely on networking if 
they need new resources. 
Moreover, the position within networks also connected with a company's technological strategy. 
Companies need networks to access resources and manage risk, because they do not have the 
capability to handle certain risks and uncertainties themselves. However, this brings pressure to 
develop products that 'fit' with their partners, in particular, large pharmaceutical companies. This 
is supported by findings of this study (As discussed in 8.2). There were different focuses on basic 
knowledge production and product development, and this was mainly due to their interaction with 
their partners. The focuses of knowledge production of this subsector were changed when partners 
changed. Many companies started as biologically focused companies, and then moved to both 
chemical and biological focus after cooperating with large pharmaceutical companies. In other 
words, this subsector worked as a node of the network of knowledge production, connecting both 
academic institutions and the established pharmaceutical industry. As discussed in 8.2.2 these 
finns served as both knowledge producers in their own right, but also as intennediaries in 
transferring knowledge from academia to the pharmaceutical industry. This result was also indirect 
evidence of the impact of technology push and market drive (Walsh, Niosi, & Mustar 1995). This 
subsector's basic research and knowledge transfer might be ''pushed'' by technological advances of 
academic institution. Their product development might further ''push'' their partner's product 
development and also they might learn from partners. On the other hand, their product 
development might also be "driven" by the demand of alliance partners and the wider market. 
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From this perspective it is easier to understand why there has been more emphasis and success for 
chemistry based products, as these are a better fit with the dominant technology of the mainstream 
pharmaceutical industry. This finding also supports the conceptualization of actors and networking 
in the Sectoral Systems of innovation: the actors and linkages are not simply co-existing, but 
dynamically interact with each other (McKelvey & Orsenigo 2001). 
To summarize, the divergence of strategies could be explained by the levels of financing ability, 
experience, competency of different tiers, and their positions within the network. For individual 
companies, it is important for biotechnology finns to know when to vertically 
integrate, when to license and when to collaborate (Pisano 1991). 
9.2. Co-evolution of industry structure and strategy 
Many researchers have argued that the reality of the drug discovery and development sector has 
not met the promise of biotechnology (Hopkins, Martin, Nightingale, Kraft, & Mahdi 2007 ;Pisano 
2006). Pisano (2006) suggested that the main problem was the result of industry structure and 
strategies, as well as outside factors such as government policies, regulations and capital market: 
"whereas the effective development application of the technology requires integration. the 
business of biotech is dn"ven by specialization and fragmentation; whereas the uncertainty 
and novelty of the science requires rapid diffosion of 'high fidelity' information, the 
business strategies of biotech firms impede information flow; whereas the science 
requires long-term cumulative learning, the biotech firms face market pressure to 
optimize short-term perceptions of value" 
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(Pisano 2006, P159). 
One important issue concerning the difference is the measurement of performance: in Pisano's 
study, the major indicator is the cost per new molecular entity (NMEs) by biotech, as well as 
financial returns. However, as Kollmer & Dowling's study indicated, patents should also be 
considered as an important measurement of R&D performance. It is also important to notice that 
Pisano's study of the biotechnology industry indicated that the emphasis on intellectual property 
actually impeded the activity of networking; moreover, the industry structure does not deal very 
well with risk management, learning and integration (Pisano 2006). In this project, patents are 
considered an important part of the performance of this sector, since most companies do not have 
products on the market. 
Orsenigo et al (2001) have analyzed the structural evolution of the network of collaborative 
agreements in pharmaceutical R&D in the last 20 years (Orsenigo, Parnmolli, & Riccaboni 2001). 
They suggest that both the growth of knowledge and the structural evolution of the network have 
been characterized by fast expansion, proliferation of research trajectories and techniques, and 
hierarchization (Orsenigo, Parnmolli, & Riccaboni 2001). Their argument is supported by the 
findings of this study, the fast growing numbers of patents and alliance agreements are 
concentrated in a small group of companies. During the early I 980s, the sector only consisted of a 
few companies and the industry structure was simple, and company strategy was largely based on 
R&D contracting. While many new companies entered this industry, product pipelines were 
growing, networking was expanding, the older companies appear to have repositioned themselves 
within the industry: with experience accumulating and capacity growing, a few successful 
companies and a large number of young companies formed the hierarchical structure (as discussed 
in chapter four) of this industry. The established companies adopted different strategies to the 
young firms during this period of expansion and transition. 
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The first divergence of strategy is mainly determined by stage of companies' life cycle: mature 
finns adopted different strategies from young finns. At the same time, collaborating with large 
pharmaceutical companies and exposure to international competition and collaboration also 
required that companies adjust their strategy from time to time. For the established companies, the 
second divergence of strategy was determined by many factors including the company's 
development history, resources and knowledge bases (Senker 1996). Companies with more R&D 
capacity are inclined to choose a research oriented strategy, and gain return mainly from licensing 
out and contracting, while companies with more experience of downstream development are 
inclined to choose licensing in and marketing. 
As discussed earlier, a significant proportion of companies in Group A have been acquired by large 
pharmaceutical companies in the past few years and so the structure of this sector is changing again: 
there are less companies on the top of the pyramid. Although companies may face less competition 
within this sector, however, both established companies and young companies will face 
competition from large pharmaceutical companies which have acquired new innovation 
competency and retain development capacity. From the perspective of the drug discovery and 
development industry, the data from the project supports Galambos & Sturchio's research: biotech-
pharmaceutical collaboration will likely remain for a long time, (discussion of CeJltech in 8.3.2) 
and large pharmaceutical companies will continue to dominate the innovation process. However, 
from the view of individual companies in Tier one, the argument that contracting service is a long 
term strategy may not be supported. Contracting service was the major business in the early stage 
for many companies, however, for the most successful companies, although contacting services 
may still exist, companies' focus may move to in house R&D. Many companies are moving from 
developers to buyers, e.g. Shire Pharmaceutical discussed in Chapter seven. Although small 
companies may survive from solely contracting service, considering the return of drug discovery 
and development is highly skewed, many companies are driven to conduct downstream drug 
discovery and development. 
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Therefore, there are a group of companies which have been largely integrated into pharmaceutical 
sector (some companies of Tier one), a group of companies specialized in order to avoid direct 
competition with established players (some companies of Tier three) Another group of companies 
chose a more independent route as they started to sell (license) knowledge to other companies as a 
key element of their commercialisation strategy while continuing to conduct in-house R&D. Since 
many companies of the last type have been established more than ten years, this would fit with 
them reaching a 'ceiling' on their activities due to difficulties in raising the large amount of finance 
required to move into late stage clinical trials. In other words, it might be seen as an important shift 
in strategy from being fully integrated companies to being suppliers of early stage product 
candidates. This fits with broader changes in the strategies of large pharmaceutical companies who 
are increasingly interested in filing their empty pipelines. Therefore, the divergence of companies' 
strategy may form part of a more general 'vertical disintegration' of the pharmaceutical and 
biotechnology R&D function. 
Since the returns on drug discovery and development are highly skewed, is it the case that 
biotechnology firms are become more traditional as the biotechnology interorganizational field 
matures and consolidates as suggested by some researchers? In other words, is it more beneficial 
for biotechnology companies' survival if they adopt the strategies of traditional pharmaceutical 
companies? 
The findings from this project suggest that firms with a more traditional strategy are less likely to 
be acquired by large pharmaceutical companies, because the R&D intensity is lower, and the 
company is less dependent on partners' funding. Moreover, these companies also have better 
performance according to research (Patel, Arundel, & Hopkins 2008). The top companies of the 
pharmaceutical and biotechnology industry were identified by correlation of three variables. If 
considering the links between R&D expenditure and patent applications, SkyePharma, Shire 
Pharmaceuticals, AstraZeneca and GlaxoSmithKline have the highest ratio of performance 
measurement. Comparing the patent applications and economic performance it is clear that 
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AstraZeneca and GlaxoSmithKIine have the highest ratios. The third link in consideration is R&D 
expenditure and profits where Acambis, AstraZeneca and GlaxoSmithKline have the highest ratios 
(Patel, Arundel, & Hopkins 2008). Interestingly, except big pharmaceutical companies 
(AstraZeneca and GlaxoSmithKIine), Skyepharma, Shire Pharmaceuticals and Acambis are all 
Group B of Tier one identified in this thesis. This suggests that biopharmaceutical companies 
which have lower R&D intensities have higher survival rates. 
The differences of R&D intensity are important in understanding the merger and acquisitions 
record since 2000, where exceptional intensive R&D investment could be a possible reason to 
explain why the output of Tier one, Group A was easily harvested by large pharmaceutical 
companies and other foreign companies. Due to five years of high R&D intensity, more than ten 
firms of Group A experienced M&A, and four of them were acquired by large pharmaceutical 
companies. The exceptional intensive investment was therefore a risk for the long term business 
development of these firms. Temporary shortage of R&D funding would cause problems for the 
whole company. The continuously exceptional intensive investment of the firms produced a large 
number of patents and drug candidates, but unless this was rapidly converted into successful 
products the companies were vulnerable to acquisition. 
While the strategy of transforming the business into a more traditional company model is a way to 
minimize innovation risk, however, a question is raised: will firms lose innovation advantages at 
the same time? If so, will the risk to innovation impede the further development of this innovation 
intensive industry? Or wiII the industry be more flexible and adopt technology innovation from 
learning? 
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9.3. Policy 
9.3.1. Questions for policy 
One important feature of the UK drug discovery and development sector is that this sector is highly 
internationalized: it could not survive if it collaborates solely with local companies. There are 
many reasons for collaboration, and national strength is one of the most important external factors. 
The national strengths of the UK biotechnology industry include biopharmaceuticals, clinical trials, 
venture capital, strategic aIliances, revenue per employee, and biotech publications (Patel 2008). 
Amongst the key ingredients of UK success, the most important factors are a pre-existing strong 
pharmaceuticals sector, effective capital markets and knowledge base (McMeekin & Green 
2002b;Van Reenen 2004). These factors played a very important role in decisions of strategic 
alliances and facilitate the development of this sector. However, how these advantages can be 
effectively transferred into productivity and at the same time retained in the UK are important 
issues for policy raised in this thesis. 
Both well established firms and young small finns in the drug discovery and development 
subsector face intense competition from local clusters of fIrms and international rivals. For smaJl 
startups, their major problems are how to survive in local clusters while attracting investors to 
fInance their product pipelines. For large and well established fIrms their major problems are how 
to quickly develop and market new products while minimizing the fInancial risk. These large and 
well established finns are, by far the most important, in terms of their intellectual capital, alliances 
and market presence. These companies (mainly from Group A and B) dominate the output of this 
subs ector, and this sector's output is far greater than the average of the European industry. 
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It is therefore worth asking if policy should be focused on supporting these larger biotech finns and 
trying to secure their leading role in biophannaceutical research in Europe? Furthennore, if these 
larger finns are supported, will this further concentrate the industry in the Southeast of England? 
This may broaden the difference in knowledge production between clusters and other areas. 
Therefore, how should policy be designed to avoid underutilization of technologies developed by 
universities and public research institutions outside the Southeast? 
On the other hand, should policy be focused on supporting the creation of small start-ups with the 
aim of creating the next generation of larger successful companies? If so, should policy pay more 
attention to supporting small start-ups in areas other than the established clusters with the aim of 
building other successful 'bioregions'? 
Moreover, is it realistic to construct an integrated policy framework and to promote the companies 
at different stages of their life cycles? If so, should policy be designed to enhance the perfonnance 
at the sector level, industry level, or national level? What is required is recognition of the need for 
a policy response that recognises the different groups of companies and the different stages of a 
company life cycle. 
As addressed previously, much of the knowledge produced by this subsector is going abroad, as 
illustrated by the pattern of licensing and commercialization. Furthennore, the acquisition of major 
Group A companies such as Celltech raises important questions about the long-tenn benefit of the 
industry to the UK economy, as it would appear that the benefits of the very successful knowledge 
production of these finns does not remain in the UK. Although the connections of this subsector 
with the domestic pharmaceutical industry have been expanding, it still only accounted for a small 
fraction of total alliances. It therefore appears that foreign countries are benefitting significantly 
from the activities of the UK drug discovery and development industry. 
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How should policy respond to the "harvest" of successful UK firms by foreign companies or large 
international pharmaceutical companies? Is it possible to prevent this subsector from being 
absorbed by foreign industry? To solve the problems outlined above should policy start by aiming 
to strengthen domestic networking or begin with enhancing companies' competitiveness through 
financial support? 
9.3.2 Future studies 
From a methodological perspective, further studies could benchmark the new indicators used in the 
citation analysis and compare these to companies' performance. Further analysis of the co-
publishing of scientific papers and patents could give more information on networking and 
collaboration. Attention may also be paid to the analysis of citations of scientific publications in 
patents, to better understand how and to what extent scientific improvements are transformed into 
technology innovation in this industry. Similarly, studies of how patent publications cite other 
patents would facilitate the understanding of knowledge diffusion. Moreover, interviews with 
company managers could provide subjective information of firms' innovation strategies and help 
validate the findings of this study concerning the relationship between innovation, knowledge 
production and company strategy. 
From an industry perspective, future studies may pay more attention to the convergence between 
the biotechnology sector and the pharmaceutical industry, since the biotechnology industry is 
heavily involved in discovering, developing and producing chemical drugs. Moreover, further 
studies could also address the impact of globalization on the dynamics of this subsector, e.g. the 
net benefit of industry from networking and knowledge sharing in the global economy. 
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Appendix 1 R&D investment of the top 35 companies (2002-
2006) 
(Data source: DTI) 
Total R&D 
2006 R&D 2005 R&D 2004 R&D 2003 R&D 2002 R&D 2002-2006 
Company J£M) (£M) (£M) (£Ml . (£M) (£M1 
Shire 154.4 146.71 107.78 128.38 119.34 656.61 
Celltech R&D 52.6 90.1 59.7 48.6 31.5 282.50 
Vernalis 38.89 26.49 21.42 31.28 23.47 141.55 
Acambis 37 34.5 28.9 19.9 16.3 136.60 
~ k y e P h a r m a a 31.6 26 27.96 25.06 15.07 125.69 
Celtic Phanna 4.36 14.28 15.07 17.66 15.37 66.74 
Alizyme 18.33 15.75 6.27 11.4 9.69 6l.44 
GW Phannaceuticals 13.1 10.28 13.94 12.68 10.75 60.75 
Oxford Biomedica 19.52 9.33 9.19 10.77 10.83 59.64 
ProStrakan 10.7 22.43 10.26 5.12 9.26 57.77 
Astex Therapeutics 14.69 12.59 11.38 8.67 6.64 53.97 
Innovata 8.26 10.37 12.9 10.91 10.85 53.29 
Ark Therapeutics 13.02 13.94 9.15 5.37 5.02 46.50 
Phytopharm 6.54 6.86 6.35 7.23 6 32.98 
Renovo 11.32 7.72 6.12 4.2 3.4 32.76 
Antisoma 14.94 6.19 0 1.2 9.73 32.06 
Protherics 13.98 6.75 4.58 3.67 1.59 30.57 
Arakis 10.35 9 6.39 3.09 1.29 30.12 
Vectura 8.03 5.73 5.87 3.84 - 23.47 
CeNeS Pharmaceuticals 7.28 4.89 3.48 2.94 3.54 22.13 
Amarin 8.41 4.25 1.78 2.78 3.86 21.08 
Chroma Therapeutics 8.3 6.69 4.44 0.83 0.69 20.95 
Lorantis 4.42 4.53 3.86 3.75 2.69 19.25 
ReNeuron 4.37 4.3 2.4 2.11 3.21 16.39 
NeuTec Pharma 2.68 5.14 3.29 2.97 1.86 15.94 
SRPharma 3.19 1.66 1.7 3.01 2.46 12.02 
Plethora Solutions 5.4 4.55 1.81 - - 11.76 
GeneMedix 2.33 2.21 3.23 2.01 0.78 10.56 
Cambridge Biotechnology 2.29 2.88 2.37 0.97 0.11 8.62 
Biotica Technology 2.29 1.71 1.25 0.91 0.73 6.89 
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Alliance Pharma 1.94 2.22 0.86 0.49 - 5.51 
Vastox (now Summit) 2.94 1.03 0.27 - - 4.24 
ReGen Therapeutics 0.83 0.75 0.46 0.33 0.58 2.95 
Sareum 1.11 0.7 
- -
- 1.81 
L ~ o x e n n 1.72 - - - - 1.72 
Total R&D (£M) 541.13 522.53 394.43 382.13 326.61 2166.83 
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Appendix 2 European Classification and publications 
I\. Human necessities 
1\.01 AOIK 32 
A.griculture; New breeds of animals 
forestry; animal AOIN 4 
husbandry; Preservation of bodies of humans or animals or plants or parts thereof; biocides, e.g. as disinfectants, as pesticides, as herbicides 
hunting; 
raping; fishing 
A23 A23L 7 
Foods or food Foods or food stuffs, their preparation or treatment 
stuffs, their 
preparation or 
treatment 
A61B 2 
Diagnosis; surgery; Identification 
A61F 3 
Filters implantable into blood vessels; prostheses; orthopaedic, nursing or contraceptive devices; fomentation; treatment or protection of eyes or ears; bandages, 
dressiDJts or absorbent pads; first-aid kits 
A61H 1 
A61 Physical t h ~ y y apparatus 
Medical or A611 5 
veterinary Devices or methods specially adapted for bring pharmaceutical products into particular physical or administering fonns; devices for administering medicines orally 
science; A61K A61K8 2 
hygiene Preparations for Cosmetic or similar toilet preparations 
medical, dental, or toilet A61K9 89 
purposes Medicinal preparations characterised by special physical form 
A61K31 315 
Medicinal preparations containing organic active ingredients 
A61K33 7 
Medicinal preparations containing inorganic active ingredients 
A61K35 16 
Medicinal preparations containing material or reaction products thereof with undetermined constitution 
A61K36 2 642 
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives 
thereof, e.g. traditional herbal medicines 
-- - ------ -
--
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A61K38 75 
Medicinal preparations containing peptides 
A61K39 83 
Medicinal preparations containing antigens or antibodies 
A61K41 4 
Medicinal preparations obtained by treating materials with wave energy or particle radiation 
A61K45 35 
Medicinal preparations containing active ingredients not provided for in groups A61 K31 to A61 K41 
A61K47 110 
M e d i c i n a l p ~ a r a t i o n s s characterised \)y non-active inRredients used 
A61K48 25 
Medicinal preparations containing generic material which is inserted into cells of the living body to treat genetic diseases; gene 
therapy 
A61K49 16 
Preparations for testing in vivo 
A61K51 31 
Preparations containing radioactive substances for use in theraI>Y or t e s t i n ~ ~in vivo 
A61L 10 
Methods or apparatus for sterilising materials or objects in general; disinfection, sterilisation, or deodorisation of air, chemical aspects of bandages, dressings, 
absorbent pads, or surRical articles; material for bandages, dressings, absorbent pads or surgical articles 
A61M A61Ml 4 72 
Devices for introducing Suction or pumping devices for medical purposes; devices for canying-off, for treatment of, or for carrying-over, body-liquids; 
media into, or onto, the drainage systems 
body A61Mll 2 
Sprayers or atomisers specially adapted for therapeutic purposes 
A61MI5 64 
Inhalators 
A61M16 I 
Devices for influencing the respiratory system of patients by gas treatment 
2 
A61M35 
Devices for allying media, e.g. remedies, on the human body; into human body by diffusion through the skin 
A61M39 2 
Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use 
A61Q 2 
Use of cosmetics or similar toilet preparations 
B Performing operations; transporting 
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BOI 8 
Physical or 
chemical BOlD 
processes or Separation 
apparatus in 
general BOU 4 
Chemical or physical processes, e.g. catalysis, colloid chemistry; their relevant apparatus 
BOIL 3 
Chemical or Physical laboratory apparatus for general use 
B05 B05B 3 
Spraying or Spraying apparatus; atomising apparatus; nozzles 
atomising in 
general 
B28 B28B I 
Working Methods or machines specially adapted for the product of tubular articles 
cement, clay, or 
stone 
B29 B29C 2 
Working of Injection moulding; i.e. blowing a perform or parison to a desired shape within a mould; apparatus there of 
plastics 
B65 B65B 2 
Conveying; Machines, apparatus or devices for, or methods of, packaging articles or materials; unpacking 
packing; 3 
storing; B65D 
handling thin or Containers for storage or transport of articles or materials; accessories, closures, or fittings therefore; packaging elements, packages 
filamentary 
material 
B67 B67B 1 
Liquid Hand or power-operated devices for opening closed containers 
handling B67C 1 
Funnels 
C Chemistry; Metallurgy 
C07 C07B 9 
Organic General methods of organic chemistry; apparatus thereof 
chemistry C07C 194 
Acyclic or carbocyclic compounds 
C07D 645 
Heterocyclic compounds 
C07F 31 
---- --
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Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulphur, selenium or tellurium 
C07H 34 
Sugars; derivatives thereof 
C07} 26 
Steroids 
C07K C07KI 31 716 
Peptides General methods for the preparation of peptides 
C07K2 1 
Peptides of undefined number of amino acids; derivatives thereof 
C07KS 42 
Peptides c o n t a i n i n ~ ~up to four amino acids in a full defined sequence; derivatives thereof 
C07K7 14 
Peptides h a v i n ~ ~S to 20 amino acids in a full defined sequence; derivatives thereof 
C07K9 2 
Peptides having up to 20 amino acids, containing saccharids radicals and having a fully defined sequence; derivatives thereof 
C07K14 395 
Peptides having more than 20 amino acids; gastrins; somatostatins; melanotropins; derivatives thereof 
C07K16 319 
Immunoglobulins, e.g. monoclonal or polyclonal antibodies 
C07K17 I 
Carrier-bound or immobilised peptides 
C07K19 S 
Hybrid peptides 
COS COSB 10 
Polysaccharides; derivatives thereof 
Organic C08F 4 
macromolecula Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bounds 
r compounds; COSG 6 
their Macromolecular c o m ~ u n d s s obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bounds 
preparation or COS} 2 
chemical Processes of t r e a t i n ~ ~ or cOJllll<>unds macromolecular substances 
working-up; 4 
compositions C08L 
based thereon Compositions of macromolecular compounds 
C09 C09D 2 
Coating, C o a t i n ~ ~ c o m ~ s i t i o n s s based on macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain 
adhesives C09} 2 
Adhesives; adhesive ~ r o c e s s e s s in general 
Cll CllB 
- --- ---- - -- ----- ---- ------- -- - -
,---1-
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Animal and Essential oils; perfumes 
vegetable oil, 
fats 
CI2 CI2M 13 
Biochemistry; Apparatus for e n z y m o l o ~ ~ or microbiology 
beer-, spirits; Cl2N Cl2NI II 488 
wine; vinegar; M i c r ~ o r g a n i s m s s or M i c r ~ o r g a n i s m s ; ; compositions there of 
microbiology; enzymes; compositions CI2N5 34 
enzymology; thereof Undifferentiated human, animal or plan cells, e.g. cell lines; tissues; cultivation or maintenance thereof; culture media therefore 
mutation or Cl2N7 19 
genetic Viruses; bacteriophages; compositions thereof; preparation or purification thereof 
engineering CI2N9 175 
Enzymes; proenzymes; compositions thereof 
Cl2Nl5 331 
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, 
preparation or purification; use of hosts therefor 
Cl2P 52 
Fermentation or enzymes-usin&PTocesses to ~ t h e s i z e e a desired chemical cof!lPOund or composition or to separated optical isomers from a racemic mixture 
C12Q 77 
Measuring or testing processes involving enzytnes or micro-organisms 
Cl2R 11 
Processes using micro-organisms 
C13 C13K I 
Sugar or starch Glucose 
industry 
C40 C40B30 11 35 
Combinational C40B Methods of screening libraries 
chemistry Combinational C40B40 27 
chernistry;libraries Libraries }>C:f se, e.g. a r r a ~ , , mixtures 
G Physics 
GOl GOlF 5 
Measuring Measuring volume; volume flow; mass flow or liquid level; metering b)'_ volume 
GOIN 170 
Investigating or analysing materials by deterring their chemical o r ~ h y s i c a l l properties 
GOIP I 
Measuring linear or angular speed, acceleration, deceleration, or shock; indicating presence, absence, or direction, of movement 
G06 G06F 9 
Computing; Electrical digital data P!ocessing 
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calculating; G06M 6 
counting C o u n t i n ~ ~mechanisms 
G06T 2 
Image data processing or generation 
G07 G07C I 
. Checking- Digital computers in which all the computation is effected mechanically 
devices 
Y General t a g g i n ~ ~ of new technological developments 
YOl YOIN YOIN2 9 I3 
Broad technical Nanobiotechnology_ 
fields Nanotechnology YOIN6 5 
characterised Nanotechnology for materials and surface science 
by dimensional 
aspects 
(Because many pUblications have more than one classification number, the total are not a simple add up of all numbers, duplicates have been removed) 
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Appendix 3 Classification of immunoglobulins (C07K16) 
& Classification of genetic engineering (C12N1S) 
C07K16/06 
Aialnst matlrill from sirum 
.--
C07K16/08 ~ ~ C07K16/10 J Aia,nst material I-- from viruses From RNA viru,., 
C07K16/22 J C07K16/12 Ai.,ns! ,rowth factors Aia,nst m a t ~ n a l l/ 
- from b a c t ~ n a aC07K16/00 C07K16/24 ImmunOllobulins ( Aia'nst 'ytokin ••. Ivmphok'ne. or ,nterferon. 
C07K16/14 
Aia,nst matenal U C07K16/26 J r- trom tunei. Aga,nst h o r m o n ~ 5 5algae or lichl!'ns 
C07K16/18 C07K16/28 C07K16/30 
Aia,n.t matenal I-- AI.,nst receptors. cell From tumour 
r- from an,mal or surfl" Intl,lns or cIIi ellis 
human. 
~ ~
surflce determinants 
C07K16/40 H C07K16/32 J Ailinlt enzymes ~ ~ Ala,nst translat,on products 01 
C07K16/42 H C07K16/34 
Alainst Aiainst blood ,roup ant'lens 
r- Immuno,lobulin 
C07K16/36 ] Ata,nst blood coalJulat,on tactors 
r- C07K16/44 
Alainst mlterill 
not provided for 
elsewhere 
'--
C07K16/46 
HVbrid 
,mmuno,lobulin 
1 ------, C12N15!02 C J 2 N l ~ / j 4 4
Pr,p,fltlon of n.,brld c.lft by ·\.1110" of two : ) ~ ~ mer. cell. l :unl' 
1I1NIVIO 
,........j ~ r t · : : ( ' t l " £ £ I'tf I.4IIf\.U,l'lne nurl,.., .l(11t1t f-nm " ' I 1 n 1 ~ l n l l umpl,.o;.; I ~ o l l h n e e In mtiI'll111.)1 
don" bv \LIWnine libr .. ri",: t DNA \ y ' l t h . - . . i ~ . . ,ubh.K ,"d t[)NA lih, .. v (o,n.tl.l( 11011 
( I l N I ~ / ~ l l
-{ Cl2N15/11 }-O 1m IIIJYI It" llf ._Ut"II'1ItIt" DNA or RNA fr'lIITIents C12N15IG2 
tor tuslor prott'"" 
r OlN15/00 C12N15/6-4 
,........j rUI ~ r t " p , . r i l i ( ( Un. \t,'\tJl, fv IlItrOJUlill)ll it utu "t'll'lI..H , ..... 
Mutat'tI"'II'I ..,. ~ 1 C ' \ l . ~ ~ t t l ~ ~ l ~ l t l J l l ll.-'Ldllllllt, hv>!. 
•• ..,.hc 
.." lnoot'"in •. ~ ~ C l 2 N 1 5 I : I ~ I I ; " U < I I < ; n ( u . ' < . , , , , J vecton, ~ . .their I ~ . b o n . .
prtpaflltlM 
C12N1S/67 ( 1 } " I I 1 · 1 / t . ~ ~
or f- £""""01"1 the 
ffi 
!>t.lbifh.ltioll ,Jt ttMl' V\*l\:), 
jX.I'iftc.tiufI, C12Nl _ l t J " l r _ ~ < < nn 
use ~ . . hon, 5/09 C12N15/6J ( IJ'41Vtlil 
th .. ,_tu IllII'"J'liUIo' IlwUJ!rv 1Il.lul ..... u"u ... , , ~ ~ IIII 
Kt'tV'II' I n t r c d u c t l ~ ' ' C12N15/70 
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